Core-shell microcapsules, method of manufacture and use

Core-shell microcapsules with a polysaccharide-based hydrogel shell address the challenge of maintaining encapsulated integrity during degradation and processing, enabling efficient multi-step reactions without dilution, thus improving the compatibility and efficiency of biomolecule processing.

JP2024545437APending Publication Date: 2024-12-06ドロップレット ゲノミクス ユーエービー
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024533234
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-11-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing methods for compartmentalizing biomolecules in liquid environments face challenges in maintaining the integrity of encapsulated contents during degradation and processing, particularly when subjected to mutually incompatible reactions, often requiring serial dilution and complex microfluidic manipulation.

Method used

The development of core-shell microcapsules with a polysaccharide-based hydrogel shell that is semi-permeable and degradable under mild conditions, allowing for sequential, incompatible reactions to be performed without dilution, using enzymatic or mechanical means to release contents while preserving their integrity.

Benefits of technology

Enables efficient, multi-step processing of biomolecules and nucleic acids within microcapsules, facilitating predictable reagent exchange and release without volume expansion, thereby enhancing the compatibility and efficiency of downstream reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545437000001_ABST
    Figure 2024545437000001_ABST
Patent Text Reader

Abstract

Provided herein are core-shell microcapsules useful for compartmentalizing biomolecules in solution. Also provided are processes for producing the core-shell microcapsules and methods of using the core-shell microcapsules for compartmentalizing and optionally processing biological entities and biomolecules.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 284,770, filed December 1, 2021, the entire contents of which are incorporated herein by reference. Field The present technology relates, in part, to core-shell microcapsules useful for compartmentalizing biomolecules in solution. The present technology relates, in part, to processes for making core-shell microcapsules and methods of using core-shell microcapsules to compartmentalize and optionally process biological entities and biomolecules. [Background technology]

[0002] Core-shell microcapsules comprise a core surrounded by a shell and can serve as microcompartments in a liquid environment for containing biological entities and biomolecules. The shell may be a hydrogel and is typically permeable to relatively small biomolecules, such as peptides, proteins, enzymes, nucleotides, and shorter oligonucleotides (e.g., less than 50 consecutive nucleotides in length). The core is typically liquid or semi-liquid and can hold larger biological entities, such as eukaryotic or prokaryotic cells, and / or larger biomolecules, such as nucleic acids (e.g., more than 100 consecutive nucleotides in length). Core-shell microcapsules are structurally distinct from other types of microcompartments. For example, core-shell microcapsules differ from hydrogel beads because the latter do not have a liquid or semi-liquid core surrounded by a permeable shell. They also differ from liquid droplets because the latter do not have a shell. Summary of the Invention

[0003] Core-shell microcapsules are provided containing a shell polymer comprising a polysaccharide modified by a crosslinking moiety, optionally modified by a hydrophilic / hydrophobic modifying moiety, and a core polymer comprising a polysaccharide unmodified by a crosslinking moiety and a hydrophilic / hydrophobic modifying moiety that modifies the first polymer. Such core-shell microcapsules are useful for encapsulating and thereby compartmentalizing biological entities and biomolecules in a liquid environment, and are particularly useful for processing the encapsulated biomolecules. Such core-shell microcapsules are also degradable under relatively mild degradation conditions, maintaining the integrity of the encapsulated contents during degradation. Degradation is achieved by contact with enzymes such as glycosylases or thermal or mechanical degradation conditions such as heating, sonication, or shearing. For example, encapsulated contents, such as biological entities and biomolecules, are at risk of degradation under the more destructive microcapsule degradation conditions required by the shell and / or core degradation of microcapsules used in the art. Core-shell microcapsules are also referred to herein as "microcapsules."

[0004] Similarly, provided herein are methods for degrading core-shell microcapsules, such as those described herein or otherwise known in the art, such that the core-shell microcapsule contents are not negatively affected. To degrade core-shell microcapsules under biologically relevant or biologically suitable conditions, degradation is often achieved by enzymes, such as enzymes that degrade monomer precursors or other components of the core-shell microcapsules. An example of such an enzyme described herein is a glycosidase, which degrades the microcapsules without chemically affecting the composition of the reaction products carried by the microcapsules.

[0005] Also provided herein are methods for processing nucleic acids in intact core-shell microcapsules. Some such methods allow iterative reactions to be performed on the microcapsule contents. In exemplary embodiments, sequential reactions are mutually incompatible with each other, yet are accomplished without substantial dilution of the microcapsule contents. This is achieved by replacing incompatible reaction reagents and / or buffers by washing or diffusing them out of the microcapsules. In contrast, iterative reactions in emulsions are primarily achieved by sequential dilution of a first reaction droplet with a second, substantially larger volume droplet, etc., to dilute the contents of the first reaction. This process in emulsions is difficult to repeat serially beyond the second reaction, because the volumes required to dilute the incompatible reaction conditions become difficult to manipulate and deliver. Using the methods and compositions disclosed herein, multiple iterative reactions, such as incompatible reactions, can be performed on the contents of a single microcapsule without sequential orders of magnitude increases in volume. The product can then be easily released from the microcapsules to facilitate downstream analysis.

[0006] Also provided herein are compositions for fabricating microcapsules and for co-embedding reaction product precursors or analyte targets within the microcapsules to facilitate downstream repetitive reactions, such as incompatible reactions and subsequent biocompatible release. The compositions include polymerized monomers, such as those described above, elsewhere herein, or known in the art, distributed in one or both aqueous shell phases. The compositions are mixed in emulsified droplets to form microcapsules with a uniform outer hydrogel and an aqueous interior. The interior may carry the analyte or reaction product, while the uniform outer hydrogel facilitates regular, predictable timing of reagent replacement. This predictable timing of reagent replacement allows for more specific and efficient replacement of one set of buffers, reagents, or reaction conditions with a second set of buffers, reagents, or reaction conditions, e.g., replacing incompatible ones with the first set. Variability in shell thickness leads to variability in reagent set replacement efficiency, which can negatively impact reaction efficiency, especially if subsequent reactions are incompatible.

[0007] Certain implementations are further described in the following description, examples and claims, and drawings. The drawings described herein are illustrative of certain implementations of the present technology, but are not limiting. For clarity and ease of illustration, the drawings are not drawn to scale, and in some instances, various aspects may be exaggerated or enlarged to facilitate understanding of certain implementations. In the drawings, "NA" refers to nucleic acid, and "SPC" refers to microcapsules. [Brief explanation of the drawings]

[0008] [Figure 1] FIG. 1 presents a schematic diagram of the workflow herein from assembly of analyte-containing microparticles for sequential reaction performance to analyte product release. [Figures 2A-2E]Figures depicting microcapsule formation: Figure 2A is a schematic of a microcapsule generation device; Figure 2B presents the emulsification of microcapsule precursor reagents; Figure 2C presents mixed microcapsule precursors without the hydrogel shell yet formed; Figure 2D presents a population of microcapsules with a hydrogel outer layer present; and Figure 2E presents individual microcapsules with visually distinct hydrogel shells and aqueous cores. [Figure 3] FIG. 1 depicts the chemical synthesis for the microcapsule precursor Dex-MAB. [Figure 4] FIG. 1 shows 1H-NMR analysis demonstrating successful synthesis of Dex-MAB. [Figure 5] FIG. 1 depicts a microcapsule nucleic acid ligation workflow that yields ligated nucleic acids from common sources. [Figure 6] FIG. 1 illustrates a split-pool nucleic acid barcoding workflow culminating in the release of barcoded nucleic acids for bulk sequencing. [Figure 7] Figure 1 shows the barcode addition efficiency (x-axis) and the number of PCR cycles performed before barcoding (y-axis) for a range of single barcode efficiencies after three barcode additions, illustrating a very high barcode success rate and a very low percentage of unique transcripts that were irrecoverably lost. [Figure 8A] FIG. 1 shows a eukaryotic scRNAseq workflow involving a series of mutually incompatible reaction steps performed on the contents of a single microcapsule. [Figure 8B] FIG. 1 shows a workflow for microbial cell scDNAseq involving a series of mutually incompatible reaction steps performed on the contents of a single microcapsule. [Figure 9A] FIG. 1 shows a sequencing library consistent with the disclosure herein. [Figure 9B] FIG. 1 shows a sequencing library consistent with the disclosure herein. [Figure 10]FIG. 1 shows library assembly for single-cell DNA sequencing, focusing on the steps from barcoding A-tailed amplified DNA fragments in microcapsules for release of barcoded material to final library construction as a bulk reaction. [Figure 11] FIG. 1 shows the sequence of steps involved in library preparation, including RT with U+ polymerase, PCR, U excision, and barcode ligation (x3), performed in microcapsules, followed by library assembly for single-cell sequencing of eukaryotic mRNA, including release of the reaction products and fragmentation, A-tailing, ligation, and PCR performed on the bulk reaction products. [Figure 12] FIG. 1 shows the microcapsule workflow for scRNAseq, which involves mutually incompatible reactions carried out sequentially within a single microcapsule volume, including the steps of cell encapsulation and lysis, reverse transcription, cDNA enrichment PCR, proteinase K treatment, USER treatment, split-and-pool barcoding, library preparation, and sequencing. [Figure 13A] FIG. 1 depicts the delivery of barcodes to microcapsules with low analyte loading ratio (1 / 5) by one-to-one loading of microcapsules with barcoded beads, followed by introduction of the barcode inside the microcapsules. [Figure 13B] FIG. 1 depicts the delivery of barcodes to pre-sorted microcapsules with high analyte loading ratio (5 / 5) by one-to-one loading of microcapsules with barcoded beads followed by introduction of the barcodes inside the microcapsules. [Figure 14A] FIG. 1 depicts fixation and permeabilization of cell lysis for nucleic acid labeling. [Figure 14B]FIG. 1 depicts cell lysis and nucleic acid labeling of cells distributed in microcapsules, where the cell lysate is subjected to nucleic acid amplification prior to labeling such that the number of target nucleic acids and target-bound signals are amplified in the microcapsules, and the microcapsules prevent mixing of the amplified nucleic acids. [Figure 15A] FIG. 1 shows the protocol and results for the determination of microcapsule nucleic acid size retention. [Figure 15B] FIG. 1 shows the protocol and results for the determination of microcapsule nucleic acid size retention. [Figure 16] FIG. 1 shows a population of microcapsules with a Ficoll-based shell before and after dextranase treatment of the core polymer. [Figure 17] FIG. 1 shows a population of microcapsules with a Ficoll-based shell before and after dextranase treatment of the core polymer. [Figure 18] FIG. 1 presents a workflow for preparing nucleic acids for sequencing. [Figure 19] FIG. 1 illustrates an example workflow compatible with the technology herein. [Figure 20] FIG. 1 illustrates an example workflow compatible with the technology herein. [Figure 21] FIG. 1 presents a schematic diagram of long-read sequencing library preparation of B cell receptor heavy and light chain concatemers formed in microcapsules. [Figure 22] FIG. 1 shows the workflow and specific nucleotide sequences for ligation and sequencing of heavy and light chains. [Figure 23] FIG. 1 shows detection of MDA-amplified nucleic acids as indicated by fluorescence in DNA-containing microcapsules. [Figure 24] FIG. 1 presents the UMI / concatenation workflow and the "1 UMI set = 1 cell" principle. [Figure 25] FIG. 1 presents a tagging workflow compatible with the technology herein. [Figure 26]FIG. 1 provides a schematic of an exemplary workflow for target amplification, UMI tagging, and ligation. [Figure 27A] FIG. 1 provides the workflow and expected results based on two in silico simulations of the "1 UMI set = 1 cell" principle. [Figure 27B] FIG. 1 provides the workflow and expected results based on two in silico simulations of the "1 UMI set = 1 cell" principle. [Figure 28] FIG. 1 shows the workflow for USER-mediated ligation of bacterial amplicons. [Figure 29] FIG. 29 illustrates a more detailed implementation of the workflow in FIG. 28. [Figure 30] FIG. 29 shows coverage for a sample of 100 reads identified as containing all three of the loci identified in FIG. 29. [Figure 31] FIG. 1 shows the split-pool synthesis workflow for scDNAseq. [Figure 32] 13A-13C present successful results obtained from the use of the techniques of FIGS. 8A, 11 and 12. [Figure 33] FIG. 13 presents a graphical representation of the results from the techniques of FIGS. 8A, 11 and 12. [Figure 34] FIG. 13 presents another graphical representation of the success of the techniques of FIGS. 8A, 11 and 12. [Figure 35] FIG. 13 presents another graphical representation of the success of the techniques of FIGS. 8A, 11 and 12. [Figure 36] 1 is a DNA-stained image of genome-amplified DNA encapsulated in microcapsules. [Figure 37] FIG. 32 depicts the barcoding specificity of the approach of FIG. 31 for encapsulated nucleic acids. [Figure 38] FIG. 32 presents results from a mixed species experiment using the approach of FIG. 31 . [Figure 39]FIG. 32 shows the scattering of barcodes from the approach of FIG. 31 on a plot of percent coverage versus depth. [Figure 40] FIG. 1 presents a workflow for efficient genome amplification and barcoding in droplets using barcoded beads, followed by whole genome or targeted sequencing. [Figure 41A] FIG. 41 shows experimental results from the application of the approach detailed in FIG. 40 for whole microbial genome sequencing. [Figure 41B] FIG. 41 shows experimental results from the application of the approach detailed in FIG. 40 for whole microbial genome sequencing. [Figure 41C] FIG. 41 shows experimental results from the application of the approach detailed in FIG. 40 for whole microbial genome sequencing. [Figure 41D] FIG. 41 shows experimental results from the application of the approach detailed in FIG. 40 for whole microbial genome sequencing. [Figure 41E] FIG. 41 shows experimental results from the application of the approach detailed in FIG. 40 for whole microbial genome sequencing. [Figure 42A] FIG. 1 shows the results of bacterial lysis optimization. [Figure 42B] FIG. 1 shows the results of bacterial lysis optimization. [Figure 42C] FIG. 1 shows the results of bacterial lysis optimization. [Figure 42D] FIG. 1 shows the results of bacterial lysis optimization. [Figure 43] FIG. 1 depicts the results as bright field microscopy images of SPC suspensions in aqueous buffer after chemically induced shell polymerization. [Figure 44] FIG. 1 shows the results of ultrasonic treatment on microcapsules under a first treatment regimen. [Figure 45] FIG. 1 shows the results of ultrasonic treatment on microcapsules under a second treatment regimen. [Figure 46] FIG. 1 shows the results of ultrasonic treatment on microcapsules under a third treatment regimen. [Figure 47]FIG. 1 presents an analysis of the effect of sonication on reaction products. [Figure 48] Figure 1 shows successful microcapsule formation using methacryloyl-arabinoxylan (AxylMA10) as the shell polymer and under varying starting material composition. [Figure 49] FIG. 1 presents fluorescence microscopy images of FITC-avidin stained SPC with (left) or without (center and right) shell biotin modification. [Figure 50] FIG. 1 presents fluorescence microscopy images of SPC with (left) and without (right) biotin modification of the shell stained with FITC-biotin via an avidin bridge. [Figure 51] FIG. 1 presents the appearance and enzymatic dissolution of SPC with a 2-hydroxyethyl cellulose (HEC) based shell. [Figure 52] FIG. 1 depicts a bright field microscope image of an SPC formed using a shell polymer modified with acryloyl crosslinking moieties. [Figure 53] FIG. 1 shows an electrophoretic analysis of microcapsule content retention for two shell polymers. [Figure 54] Figure 1 presents bright-field microscopy images of shell-patterned SPCs using 2-3 μm magnetic beads. [Figure 55] FIG. 1 shows that DexMAC21090 polymer can be used to generate SPCs, using acetyl groups as the hydrophilic / hydrophobic modifying moiety. [Figure 56] FIG. 1 shows the formation of emulsions followed by the formation of capsules with diameters less than 20 μm. [Figure 57] Figure 1 shows the formation of capsules with diameters less than 20 μm. [Figure 58] FIG. 1 shows the formation of emulsions followed by the formation of capsules with diameters greater than 100 μm. [Figure 59] FIG. 1 shows the formation of capsules with diameters greater than 100 μm. [Figure 60]FIG. 1 shows the formation of emulsions according to triple co-current aqueous phase capsule production. [Figure 61] FIG. 1 presents a bright-field microscopy image montage of a single pre-SPC droplet traveling along a microfluidic channel immediately after formation in a triple parallel flow chip. [Figure 62] FIG. 1 shows bright field microscopy images of aqueous suspensions of SPC produced using a triple parallel flow chip. [Figure 63] FIG. 1 shows that SPCs are successfully formed when various dextrans with average molecular weights ranging from 10 kDa to 2 MDa are used as core polymers. [Figure 64] FIG. 1 shows that SPC is successfully formed when using a blend of two shell-forming polymers with different cross-linking moieties, DexMAB1090 and DexAB50100. DETAILED DESCRIPTION OF THE INVENTION

[0009] Core-shell microcapsules and processes for making them, such as processes for making core-shell microcapsules containing encapsulated biological entities and / or biomolecules, are described hereinafter. Also described are methods for using core-shell microcapsules (e.g., those described herein), such as (i) methods in which the core-shell microcapsules described herein are degraded under biocompatible conditions, such as enzymatic degradation with enzymes such as glycosidases (see, e.g., Examples 4-10, 12, and 19); (ii) methods in which encapsulated nucleic acids derived from biological entities are linked in intact microcapsules and then released (see, e.g., Examples 7-9); (iii) methods in which encapsulated nucleic acids derived from biological entities are amplified, barcoded in intact microcapsules, and then released (see, e.g., Examples 9, 10, and 12); and (iv) methods in which microcapsules containing encapsulated nucleic acids derived from biological entities are mixed with particles to which barcode polynucleotides are bound in droplets and the nucleic acids barcode in the droplets (e.g., Example 10). The term "nucleic acid" generally refers to a nucleic acid molecule.

[0010] The compositions and methods disclosed herein allow analytes to be contained within core-shell microparticles. Once contained, analytes, such as cells, proteins, nucleic acids, or other biomolecules or non-biomolecules, can be subjected to sequential, mutually incompatible reactions without serial dilution of each previous reaction condition or environment in the reaction volume. Thus, for example, cells can be lysed, the lysate treated with protease and DNase, followed by reverse transcription, RNase treatment, barcoding or other oligoadapter addition, PCR amplification, and delivery of microcapsules to locations on a reaction surface, followed by lysis of the microcapsules to locally release the PCR products. This series of reactions may, in some cases, be mutually incompatible (e.g., protease treatment is incompatible with a later enzymatic manipulation, while DNase treatment is incompatible with a later DNA synthesis step). Using emulsion-based techniques, sequential reactions are achieved by serially diluting the previous reaction environment with a substantial excess (e.g., 10-fold volume) of the subsequent reaction environment to dilute out any reagents that are detrimental to the subsequent reaction. Such approaches limit the effectiveness of downstream reactions and restrict the number of subsequent reactions that can be performed, both due to the inability to remove previous reagents and buffers and the necessary substantial increase in emulsion droplet volume required for each successive step. In contrast, using the approaches herein, reagents and buffers can be diffused to the exterior of the microcapsules and replaced by the buffers and reagents required for subsequent manipulations without adding substantial excess volume to the microcapsules. This is achieved by manipulating the aqueous environments in which the microcapsules are sequentially incubated to efficiently replace one reaction environment with another without dilution and loss of analyte or reaction product. Microcapsules are sometimes produced with a uniform hydrogel exterior so that the time to complete reagent exchange is uniform throughout the population. Once the reaction is complete, the products are readily released under in vivo conditions to minimize damage to the reaction products and maximize compatibility with reagents or materials in the environment in which release occurs.As a result, a substantially wider range of operations can be performed by practicing the present disclosure compared to those of the current art.

[0011] Core-shell microcapsules Core-shell microcapsules suitable for carrying a series of, sometimes mutually incompatible, reactions to be performed on contained analytes are provided. The microcapsules are often of uniform shell thickness such that the reagents are exchanged with the aqueous carrier environment at a predictable rate. The microcapsules are readily degraded, such as under in vivo conditions, to release the reaction products without further reaction and without damage to the environment in which the release occurs.

[0012] In one exemplary set of embodiments, the microcapsules contain a shell polymer comprising a polysaccharide modified with a cross-linking moiety (see, e.g., Examples 1, 4, 14-23, 27, 28). The microcapsules, in some cases, comprise a core polymer comprising a cross-linking moiety or polysaccharide that has been modified with a hydrophilic / hydrophobic modifying moiety, and a polysaccharide that has not been modified with a cross-linking moiety and a hydrophilic / hydrophobic modifying moiety that modifies the first polymer. Such core-shell microcapsules are useful for encapsulating and thereby compartmentalizing biological entities and biomolecules in a liquid environment, and are particularly useful for processing the encapsulated biomolecules.

[0013] The shells of the core-shell microcapsules described herein are generally porous and semi-permeable. The shells of intact microcapsules generally allow the passage of reagents such as nucleic acid primers, nucleotides, buffers, and enzymes, but prevent nucleic acids (e.g., released from encapsulated biological entities) and processed nucleic acids (e.g., processed nucleic acids transcribed and / or amplified from the released nucleic acids) from escaping from the intact microcapsules (see, e.g., Examples 3, 24, and 25). The porous, semi-permeable shells generally remain intact when exposed to nucleic acid-releasing conditions that release nucleic acids from the biological entities within the microcapsules. Additionally, the porous, semi-permeable shell generally remains intact when exposed to nucleic acid processing conditions, such as, for example, (i) strand displacement conditions, (ii) ligation conditions, (iii) oligonucleotide annealing conditions, (iv) conditions that disrupt double-stranded nucleic acid structures, (v) RNA reverse transcription conditions, (vi) isothermal amplification conditions, (vii) thermal cycling amplification conditions (e.g., polymerase chain reaction conditions), and (viii) nucleic acid fragmentation conditions (e.g., when the microcapsules are exposed to nucleases). The porous, semi-permeable shell generally remains intact under nucleic acid conditions that release nucleic acids from encapsulated cells and under nucleic acid processing conditions until the microcapsules are exposed to reagent-releasing conditions (see, e.g., Examples 6, 8, 9, 10, 12). Examples of biocompatible reagent release conditions include contacting the microcapsules with an enzyme (e.g., a hexose or pentose sugar-degrading enzyme, such as a glycosidase (see, e.g., Examples 4 and 19)) under degradation conditions that are typically specific and relatively mild compared to certain nucleic acid release and processing conditions. The aqueous core or microcapsule generally allows the biological entity and / or nucleic acid contained therein to interact with an agent introduced to the exterior of the shell and diffuse into the core. The aqueous core is sometimes liquid or semi-liquid and, in certain implementations, has a higher viscosity than water.

[0014] Figure 1 illustrates a specific implementation for the formation of semipermeable compartments encapsulating biological entities, their processing, and eventual biocompatible release. The semisynthetic shell material can be based on a polysaccharide backbone, which can be biocompatible and dissolved to release living cells, double-stranded DNA, or other biological entities. Polysaccharide modifications allow for crosslinking in the shell hydrogel and controlled phase separation of the core / shell polymer solution during microcapsule formation. The microcapsules are subjected to a series of biochemical entity processing steps to form reaction products derived from the encapsulated analyte. The processing steps can be mutually incompatible when performed simultaneously on a single microcapsule. Finally, the analyte reaction products are released into aqueous solution to make them available for downstream reactions, such as nucleic acid sequencing.

[0015] Figures 2A-E show actual images of the microcapsule generation process. The emulsion generation microfluidic device, seen in Figures 2A and 2B and detailed in Example 2, produces droplets containing a mixture of core and hydrogel shell precursor reagents. The result is a non-polymerized emulsion population, Figure 2C, which is allowed to polymerize from the microparticles, Figure 2D. A close-up of the microparticles clearly shows that the shell has a uniform thickness and is distinct from the aqueous core.

[0016] Core-shell microcapsules may comprise a hydrogel shell that is generally semipermeable in a size-selective manner. The pores in the shell can be characterized by the size of the macromolecules that the microcapsules can hold. For example, the microcapsules described herein can hold double-stranded DNA that is 100, 500, or 1000 or more consecutive nucleotides in length.

[0017] Several approaches for modulating microcapsule porosity are disclosed herein. Some approaches include one or more of varying the shell thickness, varying the level of substitution with crosslinking moieties, and varying the backbone polysaccharide forming the shell (see, e.g., Example 4). Alternatively, or in conjunction, microcapsule porosity can be modulated by the ionic strength of the solution in which the capsules reside, as ionic strength can cause the microcapsule hydrogel to expand or contract, affecting porosity. Similarly, selective degradation of components of the hydrogel, such as by enzymatic treatment to digest a portion of the shell, can affect the porosity of the hydrogel as a whole to increase permeability while maintaining the capsule, for example, if a shell composed of a blend of dextran and cellulose-based polymers is subjected to digestion of only the dextran. Similarly, microcapsules containing nanoparticles within their hydrogel can be subjected to partial or total selective nanoparticle degradation to alter microcapsule permeability.

[0018] Alternatively, the surface charge of a microcapsule, or reactions that alter the surface charge of a microcapsule, can also affect its permeability, particularly to molecules with a charge similar to that of the surface charge. For example, alkaline treatment, used for cell lysis, hydrolyzes the ester bonds that link the crosslinking moieties to dextran in the shell polymer of some hydrogel microcapsules. Interestingly, the integrity of the capsules is maintained. At typically used near-neutral pH, the resulting -COOH group formed after ester hydrolysis is -COO-, resulting in negatively charged capsules. The presence of this charge can affect the permeability of the shell to negatively charged molecules, such as nucleic acids.

[0019] While the semipermeability of microcapsules is similar to that of hydrogel beads, the advantage of capsules is that they contain a liquid or semiliquid core. This liquid or semiliquid core allows the analyte to be contained within the aqueous liquid environment within the microparticle as a whole. At the same time, the hydrogel shell allows the retention of the analyte or its reaction products, while the reaction buffer and reagents within the microcapsules are changed by incubating or washing the microcapsules in an aqueous environment containing new reaction buffer and new reagents. In addition to retaining the analyte or analyte reaction products while exchanging reaction environments, this process allows repeated, and in some cases incompatible, reactions to be performed on a common analyte without repeatedly diluting the completed reaction environment with a new reaction environment by droplet fusion or other techniques known in the art, which result in a substantial volume increase with each new reaction step. These volume increases in industry techniques can reach 5- to 10-fold or more per reaction, posing challenges for fluidic droplet manipulation. Using the semi-permeable nature and aqueous liquid core volume of the microcapsules disclosed herein, one skilled in the art can perform a substantially larger number of sequential reactions without having a substantial impact on the volume of the reaction site.

[0020] Furthermore, molecular biological reactions are often carried out more efficiently in an aqueous liquid environment than in solid or semi-solid hydrogel beads. Reagents and analytes diffuse freely within the aqueous environment, allowing for faster, more efficient reactions. For example, nucleic acid processing is much more efficient in a liquid environment such as that disclosed herein, because nucleic acids would otherwise become entangled within the bulk of hydrogel beads and interact with each other only slowly, if at all. In particular, reactions proceed much faster in an aqueous environment compared to a hydrogel environment. This timing has practical implications, as reagents can diffuse beyond the hydrogel shell of the microcapsules.

[0021] When using the microcapsules described herein, diffusion within the aqueous core is faster and more favorable than diffusion across the hydrogel shell. As a result, the rate of analyte loss is lower compared to the rate of reaction in the microcapsules disclosed herein. In contrast, the rate of diffusion within the bead core of hydrogel beads is comparable to the rate of analyte loss from the beads to the environment. This further hinders the ability of those skilled in the art to perform sequential reactions in hydrogel beads compared to the microcapsules disclosed herein. Furthermore, because reagents such as buffers and enzymes are generally smaller than nucleic acids, such as nucleic acids of 100-500 bases or more, and are often neutrally or positively charged, the reagents are likely to diffuse in and out of the microcapsules at a higher rate than that of nucleic acid analytes.

[0022] Diffusion across the microcapsule membrane by reagents smaller than the size of the target analyte, such as nucleic acids of 100-500 bases or more, is often efficient enough that encapsulated analytes in microcapsules can be processed using protocols and timing parameters designed or optimized for unpartitioned analytes in solution, i.e., no additional time needs to be added to incubation or washing steps to allow reagent diffusion across the microcapsule shell. Furthermore, the liquid or semi-liquid core also allows for the cultivation of live, intact cells within the core, yet another advantage over hydrogel beads or water-in-oil emulsions.

[0023] Core-shell microcapsules can be produced by forming water-in-oil droplets containing an aqueous solution of two immiscible polymers that form an aqueous two-phase system (ATPS). Biological entities (e.g., molecules, cells, virus particles) can be entrapped within the microcapsules during droplet formation and polymer phase separation into core and shell layers. The shell polymer can be converted into a hydrogel by crosslinking it or by solidifying it. Upon shell polymerization, the microcapsules are released from the water-in-oil emulsion and further manipulated as water-in-water microcapsule "droplets" that can be used for the compartmentalization of cells or molecules. An advantage of microcapsules is that they can enable multi-step workflows: components of an earlier reaction can be washed out of the microcapsule interior before continuing with the subsequent reaction. This feature contrasts with regular water-in-oil droplets, which cannot remove molecules without adding reagents, which lose compartmentalization and require difficult droplet manipulation.

[0024] A similar advantage of the microcapsules disclosed herein is that reagent buffer exchange is often rapid. As a result, analytes encapsulated within microcapsules can be subjected to molecular biology protocols under conditions and parameters comparable to those of analytes in free solution. That is, in some cases, it is not necessary to delay reactions or extend incubation steps to accommodate diffusion steps. Certain features and advantages of particular core-shell microcapsule implementations are described below. 1. The shell polymer may sometimes be a semi-synthetic polysaccharide comprising a natural polysaccharide backbone with backbone groups (e.g., hydroxyl groups, and / or amino and / or carboxyl groups, where applicable) modified by conjugating chemical groups that provide additional functionality (see, e.g., Examples 1, 14, 16, 18, 20, 22, 27).

[0025] 2. The polysaccharide backbone is sometimes a nonionic backbone with a neutral charge. This characteristic contrasts with ionic (charge-carrying) polymers or polyampholytes (which carry a charge but have an overall charge that can be neutral). The neutrality of the shell polymer can minimize binding of polyelectrolytes, such as nucleic acids or proteins, which have a net surface charge. Unbound encapsulated entities and molecules allow the encapsulated entities to move freely within the core and interact freely with external reagents (e.g., for nucleic acid processing) that enter the microcapsule. Alternatively, modifying the microcapsule surface charge can affect the effective porosity of the hydrogel to generally limit the diffusion of charged molecules across the hydrogel. For example, modifying a hydrogel to apply a negative charge can hinder the diffusion of negative molecules, such as nucleic acids, across the hydrogel, effectively reducing microcapsule porosity with respect to nucleic acids while allowing more efficient movement of neutral or positively charged reagents. 3. Cross-linking moieties (e.g., acryloyl or methacryloyl groups) in the shell polymer allow cross-linking of the shell polymer and formation of a semi-porous hydrogel shell within the microcapsules (Figure 1), allowing external reagents to enter the microcapsules while simultaneously retaining biological entities and biomolecules, thereby enabling, for example, processing of the biological entities and biomolecules.

[0026] 4. The degree of polysaccharide modification with crosslinking moieties is controlled by adjusting the stoichiometry of the polysaccharide functionalization reaction (see, e.g., Example 4). A higher degree of substitution results in more crosslinking and decreased microcapsule shell permeability. Starting with a naturally occurring polysaccharide and chemically modifying it allows for fine-tuning of shell permeability, hydrogel stiffness (e.g., deformable microcapsules), and shell resistance to high temperatures and extreme pH (e.g., shell compositions that survive thermal cycling). The ability to fine-tune shell permeability is useful. For example, various shell polymers are available to form microcapsules that hold DNA with lengths of more than 100, 200, 500, or 1000 consecutive nucleotides. Microcapsules containing other types of polymer backbones do not easily allow for fine-tuning of the degree of modification using crosslinking moieties and other substituents. For example, PEG diacrylate (PEGDA), used as a shell polymer, cannot be easily modified with functional groups throughout its length due to its inert chemical composition. It is difficult to adjust pore size or add additional desired functionality, such as fluorescence or protein binding. Control of shell permeability when using PEGDA has not been demonstrated. Additional PEGDA only allows for pore size reduction, not pore size enhancement.

[0027] 5. When hydrophilic / hydrophobic modifiers modify the polysaccharide in the shell polymer, they can facilitate the formation of an aqueous two-phase system (ATPS) with the core polymer, facilitating core / shell separation within the droplets to form microcapsules. For example, methacryloyl-modified dextran with a degree of modification of less than 20% does not form an ATPS with naturally occurring dextran. However, when naturally occurring dextran is further modified with butyryl moieties (which are inactive in crosslinking), even 2% methacryloyl substitution is sufficient for the doubly modified polysaccharide to form an ATPS and be crosslinked into a hydrogel (see, for example, Example 4). 6. Modification of naturally occurring polysaccharides, for example, expands the choice of phase-separating microcapsule shell and core polymer pairs. For example, methacryloyl- and / or butyryl-modified dextrans form ATPS with unmodified dextrans. 7. Additional functional groups can be introduced that perform a primary function other than ATPS formation or cross-linking. For example, fluorescent dyes can be incorporated into the shell polymer to allow for fluorescent microcapsule detection. Similarly, biotin can be introduced to immobilize proteins bearing avidin tags (see, e.g., Examples 16 and 17).

[0028] 8. Crosslinked shell hydrogels can be degraded, for example, enzymatically hydrolyzed using hydrolases specific for the backbone polysaccharide under relatively mild conditions (e.g., pH 6-8; temperatures below 40°C). For example, microcapsules containing dextran-based core and shell polymers can be degraded by dextranase under relatively mild enzymatic conditions that do not degrade the encapsulated biological entities and / or molecules released from the microcapsules upon microcapsule degradation (see, e.g., Example 4). Similarly, microcapsules can be subjected to sonication or shearing. In some cases, this allows the release of reaction products without harm to the products or the environment into which they are delivered (see, e.g., Example 13). In contrast, degradation of microcapsules containing PEGDA shells requires extreme pH and high temperatures. Specifically, release of PCR amplicons from microcapsules containing PEGDA shells may require treatment with 1 M NaOH at 50°C for 10 minutes. Such a relatively harsh treatment prevents the release of viable cells from microcapsules containing PEGDA shells without killing the cells. When working with RNA, such alkaline conditions result in RNA degradation by hydrolysis. Such conditions also denature double-stranded DNA (dsDNA) to single-stranded DNA (ssDNA), which is undesirable for many workflows involving DNA manipulation within microcapsules.

[0029] 9. Microcapsules maintain the analyte in its aqueous liquid core while allowing diffusion of reagents through the hydrogel shell. This allows reaction buffers and reagents to be washed in and out by incubating the microcapsules in one reaction mix or another without repeatedly diluting the reaction buffer, while maintaining a favorable reaction environment inside. Thus, multiple mutually incompatible reactions can be performed in succession on the analyte without the need for repeatedly diluting the reaction volume. 10. Microcapsules exhibit a uniform minimum thickness. As a result, diffusion times for buffers or reactants are predictable, while analytes are unlikely to "leak" through localized thin spots in the shell. Consistent with microcapsules having one or more of the above improvements, disclosed herein are compositions, methods of use, compositions beneficially or exclusively made by use of the disclosures herein, methods of making, systems for making, and compositions for making said microcapsules.

[0030] In certain embodiments, provided herein are compositions comprising a plurality of microcapsules, each comprising a core surrounded by a shell. The shell may be a hydrogel comprising a first polymer. The first polymer may comprise a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety. Molecules of the cross-linking moiety of the first polymer are often cross-linked in the hydrogel. The core may be a liquid or semi-liquid core. The core may comprise a second polymer containing a polysaccharide that does not comprise a cross-linking moiety and does not comprise a hydrophilic / hydrophobic modifying moiety.

[0031] Polysaccharides are generally polymers comprising multiple covalently linked sugar monomers or units (e.g., disaccharide units). Polysaccharides may be linear or branched. Polysaccharides may (i) comprise sugar monomers linked by glycosidic bonds; (ii) be a glucan; (iii) comprise pentose and / or hexose monomers (see, e.g., Examples 14 and 15); (iv) comprise glucose monomers; (v) comprise fructose monomers (see, e.g., Example 4); or (vi) a combination of two or more of (i), (ii), (iii), (iv), and (v). Non-limiting examples of polysaccharides include glucans, dextran (see, e.g., Example 1), alginate, hyaluronic acid, glycogen, starch (e.g., amylose, amylopectin), agarose, agar, heparin, pectin, cellulose and modified celluloses (e.g., methyl-, ethyl-, hydroxyethyl-, hydroxypropyl-modified cellulose; Examples 18 and 19), hemicelluloses (e.g., xyloglucan, xylan, mannan and glucomannan, and beta-(1-->3,1-->4)-glucan), chitosan, chitin, xanthan gum, gum arabic, galactomannan, and pectin. Polysaccharides may be naturally occurring (e.g., dextran, cellulose), non-naturally occurring, or synthetic (e.g., ficoll and modified celluloses (e.g., methyl-, ethyl-, hydroxyethyl-, hydroxypropyl-modified cellulose)). Polysaccharides are sometimes neutrally charged, non-ionic polysaccharides, non-limiting examples of which include glucan, dextran, starch, agarose, galactomannan, hemicellulose, cellulose and modified celluloses (methyl-, ethyl-, hydroxyethyl-, hydroxypropyl-modified cellulose) and chitin; polysaccharides are sometimes neutrally charged and non-ionic at pH 7. Polysaccharides are sometimes ionic polysaccharides (e.g., pectin, alginate, chitosan).The polysaccharide may be of any suitable molecular mass for forming microcapsules, including, but not limited to, a molecular mass of about 5,000 g / mol to about 50,000,000 g / mol, or a molecular mass of about 50,000 g / mol to about 2,000,000 g / mol, or a molecular mass of about 500,000 g / mol (see, e.g., Examples 1, 14, 18, 32).

[0032] The microcapsules disclosed herein often exhibit a uniform hydrogel shell thickness. The shell, in some cases, exhibits a thickness of about at least 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, 16 μm, 17 μm, 18 μm, 19 μm, 20 μm, 25 μm, 30 μm, 40 μm, or 50 μm or less. Shell thickness often varies by 50% or less within a population or microparticle. Exemplary shell thicknesses are in some cases 1-6 μm, 10-20 μm, or 15-30 μm. Some microcapsules exhibit shell thicknesses of about 3 μm or 3 μm + or - 50%. Another shell thickness observed is about 14 μm, or 14 μm + or - 50%.

[0033] Microcapsules, or portions thereof, are often degradable, for example, under chemical or biological conditions. Some microcapsules are degradable at pH ranges of 3-11, 4-10, 5-9, 6-8, or equivalent ranges having a previously listed high endpoint with a previously listed low endpoint. Similarly, some microcapsules are degradable at temperatures of about, at least, or at most 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 75° C. (See, e.g., Examples 4 and 19). Some microcapsules are degradable under mechanical conditions, such as shearing or sonication. Sonication at levels lower than those sufficient to shear nucleic acids is sufficient to disrupt the hydrogel microcapsule shell. In particular, mechanical degradation, such as sonication, is suitable when the analyte is expected to be 1 kb or less, e.g., 900 pb or less, 800 pb or less, 700 pb or less, 600 pb or less, 500 pb or less, or less than 500 pb. Alternatively, under analytical conditions where some disruption of the analyte or reaction product is acceptable, analytes up to 1 kb in size may be released by mechanical degradation, such as shearing or sonication (see, e.g., Example 13).

[0034] Some microcapsules are degradable under temperature conditions, such as by heating. Hydrogels generally exhibit melting points below the temperature at which the analytes or reaction products contained within the microcapsules decompose. Heating can involve a single incubation at the melting temperature or, alternatively, repeated thermal cycling to the melting temperature. Some hydrogel compositions disclosed herein or contemplated in the art are resistant to thermal cycling, for example, so that polymerase chain reaction can be performed on the microcapsules to amplify the contents of certain microcapsules. In contrast, other compositions are vulnerable to some thermal cycling reactions at higher temperatures, such that the analytes or reaction contents are released at higher temperatures. Various compositions disclosed herein or contemplated in the art are vulnerable to degradation at temperatures of at least 65, 70, 75, 80, 85, 90, 95, 100°C, or above 100°C. Alternatively, other compositions disclosed herein or contemplated in the art are resistant to decomposition at temperatures of at least 65, 70, 75, 80, 85, 90, 95, 100°C or greater (see, e.g., Examples 3 and 4). Biological degradation is often achieved by enzymatic treatment, such as using enzymes to degrade the monomer or polymerized monomer components of the hydrogel polymer. Exemplary targets are hexose or pentose sugar monomer or polymer components, although any component for which a degradative enzyme is available can be used as a target.

[0035] In certain implementations, the microcapsules are glycosidase-degradable (see, e.g., Examples 4 and 19). In certain examples, (i) the first polymer is glycosidase-degradable, or (ii) the second polymer is glycosidase-degradable, or (iii) the first polymer and the second polymer are each glycosidase-degradable. In examples where the microcapsules or portions thereof are degradable under enzymatic conditions that allow the glycosidase enzyme to degrade the microcapsules, the microcapsules are glycosidase-degradable. The microcapsules described herein can be degraded by glycosidases under relatively mild conditions to release encapsulated biological entities (e.g., cells, molecules) that may be contained in the microcapsules. The extent of degradation can be determined, for example, by the presence or amount of entities (e.g., dye-labeled particles, fluorescently labeled particles, nucleic acids) released from the microcapsules as determined by light microscopy or a suitable method (e.g., microscopy, electrophoresis). Microcapsule degradation conditions are generally enzymatic microcapsule degradation conditions in which the polymer in the shell, and sometimes the core, is enzymatically degraded by one glycosidase type or two or more types of glycosidase. Microcapsule degradation conditions may include contacting the microcapsules with the glycosidase at a temperature of about 80°C or less and a pH of about 3 to about 11, and in certain instances, may include contacting the microcapsules with the glycosidase at a temperature of about 40°C or less and a pH of about 6 to about 8. Glycosidase degradation conditions may include any suitable glycosidase, including, but not limited to, glycosidases that degrade polysaccharides as described herein, such as, for example, dextranase (e.g., suitable for degrading dextran; Example 4), agarase (e.g., suitable for degrading agarose), amylase (e.g., suitable for degrading starch), and cellulase (e.g., suitable for degrading cellulose; Example 19).Glycosidase degradation conditions may include any suitable amount of glycosidase that degrades the microcapsules in a reasonable amount of time (e.g., within 1 hour; within 30 minutes; within 15 minutes, or any of 1 hour, 45 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 2 minutes, 1 minute, 30 seconds or less) and does not significantly degrade the contents of the biological entity within the microcapsules.

[0036] In some cases, microcapsules are glycosidase-degradable if contacting the microcapsules with 200 enzyme units (U; micromoles / min) of glycosidase per gram of shell polymer under in vivo conditions, in this case including pH 7.0 and a temperature of 25° C., results in the release of nucleic acid encapsulated in the microcapsule core in 15 minutes or less, as determined by electrophoresis of a solution containing the microcapsules. Certain microcapsules, such as microcapsules containing cross-linked polyethylene glycol or polyacrylamide shells, are not glycosidase-degradable under such conditions.

[0037] If the glycosidase used degrades the polysaccharide that is the main component of the shell and the polysaccharide that is the main component of the core, for example, if the polysaccharide in the core and the shell is the same, the shell and the core of the microcapsule can be degraded under glycosidase degradation conditions. If the polysaccharide in the core is not the same as the polysaccharide in the shell, and if the glycosidase used degrades the polysaccharide that is the main component of the shell but not the polysaccharide that is the main component of the core, the shell but not the core of the microcapsule can be degraded under glycosidase degradation conditions. If the polysaccharide in the core is not the same as the polysaccharide in the shell, and if the glycosidase used does not degrade the polysaccharide that is the main component of the shell but degrades the polysaccharide that is the main component of the core, the core but not the shell of the microcapsule can be degraded under glycosidase degradation conditions (see, for example, Example 4).

[0038] In certain implementations, the microcapsules or portions thereof are enzymatically degradable, such as by glycosidase degradation. This degradation occurs at a pH of about 3 to about 11 and at a temperature of about 80°C or less. The microcapsules or portions thereof are sometimes enzymatically degradable, such as by glycosidase, at a pH of about 6 to about 8 and at a temperature of about 40°C or less. Sometimes, the enzyme, such as glycosidase, used for the degradation conditions is selected from dextranase and cellulase (see, e.g., Examples 4 and 19). The extent of microcapsule degradation can be determined by the amount of entity (e.g., dye-labeled particles, dye-labeled nucleic acids) released from and / or retained within the microcapsule core, as determined by a suitable method (e.g., optical and / or fluorescence microscopy, electrophoresis).

[0039] Glycosidases are just one example of enzymatic degradation of microcapsules under biological conditions, which can gently release reaction products from the microcapsules, even after multiple sequential reaction processes, without harm to the reaction products or to the local environment into which they are released.

[0040] Microcapsule compositions often include a first polymer and a second polymer, and in certain implementations, the first polymer is the major component of the shell and the second polymer is the major component of the core. In certain examples, (i) the amount of the first polymer in the microcapsules is enriched in the shell and the amount of the second polymer in the microcapsules is enriched in the core; (ii) the ratio of the amount of the first polymer to the amount of the second polymer is significantly higher in the shell compared to that in the core; (iii) the ratio of the amount of the second polymer to the amount of the first polymer is significantly higher in the core compared to that in the shell; (iv) when the aqueous two-phase system comprises a solution comprising the first polymer as a first aqueous phase and a solution comprising the second polymer as a second aqueous phase, and the droplets containing the two-phase aqueous system are in an oil environment (e.g., an oil composition), the enrichment of the first polymer in the shell and the second polymer in the core is the result of separation of the aqueous two-phase system in the droplets; (v) the first polymer is greater than 50% of the dry shell weight and the second polymer is greater than 50% of the dry core weight; or (vi) a combination of two or more of (i), (ii), (iii), (iv), and (v).

[0041] The first polymer and the second polymer sometimes comprise different polysaccharides; in certain instances, the first polymer and the second polymer comprise the same polysaccharide. In certain implementations, the first polymer, or the first polymer and the second polymer, comprise a neutrally charged nonionic polysaccharide. In certain implementations, the first polymer and / or the second polymer comprise a polysaccharide containing monomers linked by glycosidic bonds. The first polymer and / or the second polymer sometimes comprise a glucan polysaccharide, and / or sometimes comprise a polysaccharide containing pentose and / or hexose monomers, and / or sometimes comprise a polysaccharide containing glucose and / or fructose monomers. The first polymer and / or the second polymer sometimes comprise a naturally occurring polysaccharide, and sometimes comprise a polysaccharide selected from dextran and cellulose. The first polymer and / or the second polymer sometimes comprise a non-naturally occurring polysaccharide, and sometimes comprise ficoll. The first polymer and / or the second polymer sometimes comprise a polysaccharide having a molecular mass of about 5,000 g / mol to about 50,000,000 g / mol, or about 50,000 g / mol to about 2,000,000 g / mol, or about 500,000 g / mol (see, e.g., Examples 4, 19, and 32).

[0042] The first polymer sometimes includes one type of crosslinking moiety, and in certain instances, two or more types of crosslinking moieties (see, e.g., Examples 1, 20, and 33). Any suitable crosslinking moiety can be selected for modification in the first polymer, and the crosslinking moiety or moieties included in the first polymer are sometimes selected from photoactivated, chemically activated, or thermally activated crosslinking moieties (see, e.g., Examples 2 and 11). Non-limiting examples of crosslinking moieties include thiomers (e.g., thiolated polysaccharides crosslinked via their thiol substructures (e.g., Summonte et al., J. Controlled Release 330:470-482 (2021)); acryloyl or substituted acryloyl groups; copper-catalyzed azide / alkyne cycloaddition (CuAAC) groups and other "click chemistry" groups (e.g., Elchinger et al., Polymers 3(4):1607-1651). (2011)). In certain implementations, the cross-linking moiety or moieties in the first polymer are independently selected from acryloyl groups or substituted acryloyl groups, and sometimes the cross-linking moiety or moieties in the first polymer are independently selected from acryloyl, methacryloyl, or acryloyl and methacryloyl groups (see, e.g., Examples 1, 20, and 33). Varying the density, type, and / or monomer amount of the cross-linking moieties in the first polymer allows for tuning of the mechanical properties (e.g., elasticity, porosity) of the microcapsules (see, e.g., Example 4). The second polymer sometimes does not include cross-linking moieties, and in certain instances, the second polymer is not cross-linked.

[0043] In certain instances, the first polymer comprises a hydrophilic / hydrophobic modifying moiety, which often modifies the water solubility of the first polymer compared to a first polymer that does not contain the hydrophilic / hydrophobic modifying moiety (see, e.g., Examples 1, 4, and 27). The hydrophilic / hydrophobic modifying moiety generally modifies the hydrophobic and / or hydrophilic properties of the first polymer compared to a first polymer that does not contain the hydrophilic / hydrophobic modifying moiety. Without being limited by theory, the inclusion of the hydrophilic / hydrophobic modifying moiety in the first polymer facilitates liquid-liquid phase separation between the first polymer and the second polymer compared to a first polymer that does not contain the hydrophilic / hydrophobic modifying moiety. Any suitable hydrophilic / hydrophobic modifying moiety can be selected for modification in the first polymer, including, but not limited to, fatty acyl groups such as C2-C8 fatty acyl groups (e.g., acetyl (see, e.g., Example 27), propionyl, butyryl (see, e.g., Example 1), isobutyryl, valeryl, isovaleryl, caproyl, heptanoyl, and octanoyl groups). The first polymer may contain one type of hydrophilic / hydrophobic modifying moiety, and in certain instances, may contain two or more types of hydrophilic / hydrophobic modifying moieties. The bridging moiety can act as a hydrophilic / hydrophobic modifying moiety. In certain implementations, the second polymer does not contain a hydrophilic / hydrophobic modifying moiety, and in certain instances, the second polymer does not contain a hydrophilic / hydrophobic modifying moiety that modifies the first polymer (when the first polymer contains a hydrophilic / hydrophobic modifying moiety).

[0044] The polysaccharide in the first polymer can be modified with crosslinking moieties and / or hydrophilic / hydrophobic modifying moieties by any suitable conjugation method. The crosslinking moieties and / or hydrophilic / hydrophobic modifying moieties are often covalently attached (i.e., covalently bonded) to the polysaccharide, particularly in the case of polysaccharides having a neutrally charged, nonionic backbone, to primary and / or secondary hydroxyl groups of the polysaccharide backbone (see, e.g., Examples 1, 14, 16, 18, 20, and 27). In the case of dextran, for example, the glucose monomers in the polysaccharide backbone are linked by primary hydroxyl groups, so the crosslinking moieties and / or hydrophilic / hydrophobic modifying moieties can be covalently attached via secondary hydroxyl groups of the polysaccharide backbone. In implementations in which the polysaccharide backbone is ionic, the crosslinking moieties and / or hydrophilic / hydrophobic modifying moieties can be covalently attached via hydroxyl groups, amino groups, or acid groups (e.g., carboxylic acid groups).

[0045] In certain implementations, the polysaccharide of the first polymer contains monomers (e.g., pentose and / or hexose monomers) and the molar ratio of (i) the crosslinking moiety to (ii) the monomer is about 0.01 to about 2.0, or about 0.01 or more, or about 0.20 or less, or about 0.01 to about 0.20 (e.g., a ratio of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0; see, e.g., Example 4). In certain implementations, the polysaccharide of the first polymer contains monomers (e.g., pentose and / or hexose monomers) and the molar ratio of (i) the hydrophilic / hydrophobic modifying moiety to (ii) the monomer is about 0.05 to about 1.0, or about 0.10 or more, or about 0.80 or less, or about 0.20 to about 0.80, or about 0.25 to about 0.65 (e.g., a ratio of about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0). In certain implementations, the polysaccharide of the first polymer is modified with a crosslinking moiety and modified with a hydrophilic / hydrophobic modifying moiety, the crosslinking moiety is methacryloyl and the hydrophilic / hydrophobic modifying moiety is butyryl, and in certain examples, the molar ratio of (i) the methacryloyl moiety to (ii) the first monomer is the ratio or range of ratios described above, and the molar ratio of (i) the butyryl moiety to the monomer is the ratio or range of ratios described above (see, e.g., Examples 1 and 4).

[0046] In certain examples, the first polymer and / or the second polymer comprises a detectable label (see, e.g., Example 17). Any suitable detectable label can be used, including, but not limited to, fluorescent labels, such as organic fluorophores, lanthanide fluorophores (chelated lanthanides; dipicolinate-based terbium(III) chelators), transition metal-ligand complex fluorophores (e.g., ruthenium, rhenium, or osmium complexes); quantum dot fluorophores, isothiocyanate fluorophore derivatives (e.g., FITC, TRITC), succinimidyl ester fluorophores (e.g., NHS-fluorescein), maleimide-activated fluorophores (e.g., fluorescein-5-maleimide), and amidite fluorophores (e.g., 6-FAM phosphoramidite); radioactive isotopes (e.g., I-125, I-131, S-35, P-31, P-32, C-14, H-3, Be-7, Mg-28, Co-57, Zn-65, Cu-67, Ge-68, Sr-82, Rb-83, Tc-95m, Tc-96, Pd-103, Cd-109, and Xe-127); light scattering or light diffracting labels (e.g., light scattering gold nanorods, resonant light scattering particles); enzyme or protein labels (e.g., green fluorescent protein (GFP), peroxidase); or other chromogenic labels or dyes (e.g., cyanines).Non-limiting examples of organic fluorophores include xanthene derivatives (e.g., fluorescein, rhodamine, Oregon Green, eosin, Texas Red); cyanine derivatives (e.g., cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine); naphthalene derivatives (dansyl, prodan derivatives); coumarin derivatives; oxadiazole derivatives (e.g., pyridyloxazole, nitrobenzoxadiazole, benzoxadiazole); pyrene derivatives (e.g., cascade blue); oxazine derivatives (e.g., Nile red, Nile blue, cresyl violet, oxazine 170); acridine derivatives (e.g., proflavine, acridine orange, acridine yellow); arylmethine derivatives (e.g., auramine, crystal violet, malachite green); and tetrapyrrole derivatives (e.g., porphine, phthalocyanine, bilirubin). Detectable labels sometimes comprise fluorophores or dyes.

[0047] In certain implementations, the first polymer and / or the second polymer comprise a binding partner moiety to which the binding partner counterpart moiety can bind (see, e.g., Examples 16 and 17). Non-limiting examples of binding partner / binding partner counterpart pairs include antibody / antigen, antibody / antibody, antibody / antibody fragment, antibody / antibody receptor, antibody / protein A or protein G, hapten / antihapten, biotin / avidin, biotin / streptavidin, folate / folate binding protein, vitamin B12 / intrinsic factor, nucleic acid / complementary nucleic acid (e.g., DNA, RNA, PNA), etc. In certain implementations, the binding partner moiety is biotin and the binding partner counterpart moiety is avidin, or the binding partner counterpart moiety is biotin and the binding partner moiety is avidin (see, e.g., Examples 16 and 17).

[0048] When included, the detectable label and / or binding partner moiety are often conjugated to the polymer backbone, sometimes directly, sometimes via an intermediate moiety. In certain instances, the detectable label and / or binding partner moiety is covalently attached to the polymer (e.g., covalently attached to the polysaccharide backbone of the polymer). In certain implementations, the microcapsules remain intact (i) at a pH range of about 2 to about 12, at 37°C for 2 hours or more, and / or (ii) under polymerase chain reaction thermocycling conditions. Polymerase chain reaction (PCR) thermocycling conditions are known and sometimes include, for example, denaturing conditions at about 95°C for about 1 minute, annealing conditions at about 55°C for about 2 minutes, and extension conditions at about 70 to about 75°C for about 3 minutes (see, e.g., Example 3).

[0049] In certain implementations, the microcapsules are microspheroids. Microcapsules are sometimes defined by a diameter of about 1 micrometer to about 10,000 micrometers, or sometimes a diameter of about 10 micrometers to about 100 micrometers (e.g., about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 micrometers; Examples 2, 29, and 30). The microcapsules in the composition are generally uniform and often monodisperse, and the microcapsules in the composition generally have a high degree of circularity and concentricity. Circularity and concentricity can be determined at the individual microcapsule level, and the average can be reported at the microcapsule population level. The microcapsules in the composition generally have a mean radius R, where R is the square root of √((S / π)), where S is the equatorial transverse surface of the capsule. In certain examples, the diameters of the microcapsules in the composition vary by a coefficient of variation of about 30% or less (e.g., the diameters of the microcapsules vary by a coefficient of variation of about 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less). Circularity C is the ratio of the minor axis (Rmin) to the major axis (Rmax) of an ellipse aligned to the outer edge of a projected equatorial cross section. In certain implementations, C is about 0.8 to about 1.0 for the microcapsules in the composition (e.g., C is about 0.85 or more, 0.90 or more, 0.95 or more, 0.99 or more, or 1.0). The concentricity O of the microcapsules in the composition is generally equal to (Wmin / Wmax) × 100% (where Wmin is the thinnest part of the shell and Wmax is the thickest part of the shell). In certain implementations, O is greater than or equal to 75% for the microcapsules in the composition.

[0050] In particular, the microparticle morphology of the hydrogel shell allows for precise control over reagent exchange without leakage of analytes from the aqueous liquid core. The uniform microparticle shell of minimal thickness allows for precise calculation and implementation of the incubation time required to remove reagent buffers, such as those incompatible with reactions subsequently performed on analytes carried within the microcapsules. Microparticles are durable, such that sequential buffer ionic strength or composition changes can cause some expansion or contraction of the overall microparticle volume, variously up to 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, or even up to 25%. However, this buffer-dependent expansion or contraction is very modest compared to the 2-, 3-, 5-, or even 10-fold dilutions often required when delivering dilution buffer to droplets where an incompatible reaction has previously occurred. Furthermore, while buffer-induced volume fluctuations in the microparticles herein are not additive from one reaction to another in a reaction sequence, buffer dilution delivered to droplets in an emulsion results in a constant increase in droplet volume proportional to the volume diluted. That is, droplet volume expansion is exponential and unlikely to be more manageable than one or two sets of reaction conditions.

[0051] Furthermore, reagent delivery is facilitated by washing the microcapsules in an aqueous carrier of fresh reaction buffer. Upon completion of each reaction, the microcapsules are washed in the next reaction buffer, which then diffuses across the hydrogel shell into the aqueous interior, "exchanging" for the previous buffer conditions. This process is relatively straightforward and does not require complex microfluidic manipulation. In contrast, reactions in emulsions require the fusion of new reaction buffer into the emulsion droplets and in a volume sufficient to dilute the previous reaction conditions. This often requires fine-tuned droplet fusion, resulting in substantially larger droplet sizes and thus complicating microfluidic manipulation.

[0052] Microcapsules produced according to the present disclosure may have a wide range of volumes. In some cases, volume variations may be observed between microcapsules, but are often roughly uniform for a given population of microcapsules. Microcapsule volume is often governed by the fluidics of the emulsification process and the relative proportions of shell and core components in the emulsification process that results in microcapsule production. In some cases, the volumes of microcapsules in a given population differ from each other by no more than 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, or 10-fold. Alternatively, the volumes of microcapsules in a given population differ by no more than 50%, 25%, 10%, 5%, or less than 5%.

[0053] A wide range of microcapsule volumes is consistent with the disclosure herein. Some microcapsule populations are sized to be less than 1 pL, 2 pL, 5 pL, 10 pL, 20 pL, 50 pL, 100 pL, 200 pL, 500 pL, 1 nL, 2 nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL. nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL or more, or about 1 pL, 2 pL, 5 pL, 10 pL, 20 pL, 50 pL, 100 pL, 200 pL, 500 pL, 1 nL, 2 nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL. Similarly, some individual microcapsules may have a volume of 1 pL, 2 pL, 5 pL, 10 pL, 20 pL, 50 pL, 100 pL, 200 pL, 500 pL, 1 nL, 2 nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL or less, 1 pL, 2 pL, 5 pL, 10 pL, 20 pL, 50 pL, 100 pL, 200 pL, 50

[0013] Microcapsules may exhibit volumes of 0 pL, 1 nL, 2 nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL or greater, or about 1 pL, 2 pL, 5 pL, 10 pL, 20 pL, 50 pL, 100 pL, 200 pL, 500 pL, 1 nL, 2 nL, 5 nL, 10 nL, 20 nL, 50 nL, 100 nL, 200 nL, or 500 nL. In some cases, the microcapsule population exhibits a size range having a lower endpoint of a range selected from a first volume previously listed and a higher endpoint of a range selected from a second, larger volume previously listed. Microcapsule volumes are in some cases selected to accommodate a particular analyte or reaction product, or to facilitate a particular reaction time, or to accommodate a particular reaction component.

[0054] The shells of the microcapsules in the composition sometimes contain pores, and the microcapsules retain nucleic acids greater than about 100 base pairs in size, greater than about 500 base pairs in size, or greater than about 1,000 base pairs in size (see, e.g., Examples 3, 4, and 24). The shells of the microcapsules in the composition sometimes contain pores of about 0.1 nanometers to about 500 nanometers, or about 10 nanometers to about 50 nanometers. The shells of the microcapsules in the composition may have pores of about 0.1 nm, 0.5 nm, 1 nm, 2 nm, 3 nm, 5 nm, 7 nm, 10 nm, 15 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, or 200 nm, where "nm" is nanometer. In some cases, the microcapsules may have pores of at least about 0.1 nm, 0.5 nm, 1 nm, 2 nm, 3 nm, 5 nm, 7 nm, 10 nm, 15 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, or 200 nm. In some cases, the pores may vary in size and may range from about 0.1 to 1 nm, 0.1 to 10 nm, 1 to 10 nm, 0.1 to 100 nm, 1 to 100 nm, 10 to 100 nm, 0.1 to 200 nm, 1 to 200 nm, or 10 to 200 nm.

[0055] In certain examples, (i) the microcapsules in the composition do not contain an intermediate layer between the shell and the core; (ii) the microcapsules in the composition do not have an intermediate layer between the shell and the core containing a polymer different from the first polymer and the second polymer; (iii) the microcapsules in the composition do not have a layer outside the shell; (iv) the microcapsules in the composition do not contain lipids and organic solvents; (v) the polymer of the microcapsules in the composition consists of the first polymer and the second polymer; (vi) the microcapsules in the composition consist of a core and a shell; (vii) the microcapsules in the composition do not contain a polyethylene glycol polymer or a modified polyethylene glycol polymer; or (viii) a combination of two or more of (i), (ii), (iii), (iv), (v), (vi) and (vii). In certain implementations, the composition containing the microcapsules is a liquid composition (e.g., an aqueous liquid composition). In certain instances, the composition containing the microcapsules is a solid composition, where the solid composition sometimes comprises a hydrogel.

[0056] In certain implementations, the microcapsules in the composition contain a biological entity encapsulated within some or all of the core of the microcapsule. Any suitable biological entity can be encapsulated within the microcapsule. The biological entity is sometimes a molecule or reagent, non-limiting examples of which include buffers, organic molecules, biomolecules, nucleotides, oligonucleotides, nucleic acids, detection agents, amino acids, enzymes (e.g., ligases, polymerases, transposases), and proteins (e.g., antibodies, biotin, avidin, streptavidin). The biological entity is sometimes a nucleic acid-containing entity, non-limiting examples of which include unicellular organisms, multicellular organisms, cells derived from multicellular organisms, eukaryotic cells, prokaryotic cells, microorganisms, bacteria, archaea, fungi, plants, viruses, organelles (e.g., mitochondria or chloroplasts), liposome vectors, and extracellular vesicles. The eukaryotic cell is sometimes derived from a unicellular organism or a multicellular organism, and sometimes derived from a human subject or a non-human subject. Non-human subjects are sometimes mammals, reptiles, birds, amphibians, fish, ungulates, ruminants, bovines (e.g., cows), equines (e.g., horses), caprines (e.g., sheep, goats), porcines (e.g., pigs), camelids (e.g., camels, llamas, alpacas), monkeys, apes (e.g., gorillas, chimpanzees), ursidae (e.g., bears), poultry, dogs, cats, mice, rats, fish, dolphins, whales, and sharks. The subject may be male or female (e.g., female, pregnant female). The subject may be of any age (e.g., embryo, fetus, infant, toddler, adult).

[0057] The present disclosure allows for the performance of repetitive or sequential reactions on analytes encapsulated in microcapsules. In some cases, two or more of these reactions are incompatible with one another, preventing them from being carried out simultaneously in a common volume, or one of them interferes with or inhibits the second. Nevertheless, the techniques disclosed herein allow for the performance of a first reaction, followed by the replacement of its reaction conditions with those of a second reaction, without substantial volume expansion or dilution, to perform sequential, incompatible reactions in a common microcapsule.

[0058] Examples of mutually incompatible reactions include: 1) proteinase treatment of the first reaction, followed by any enzymatic second reaction where the enzyme is susceptible to proteases; 2) primary antibody staining of the first reaction, followed by secondary antibody staining - if the primary antibody is in excess and not washed away, secondary antibody binding will occur, but will result in non-specific signals and suboptimal staining; 3) RNase treatment of the first reaction, followed by RNA synthesis of the second reaction - if RNase is not removed from the reaction volume, the synthesized RNA will be quickly degraded. In each of these cases, maintaining the first reaction conditions above a threshold will inhibit the second reaction. Additional incompatible scenarios can be easily envisioned by those skilled in the art.

[0059] In certain embodiments, methods are provided that include degrading microcapsules. Degradation is achieved by subjecting the microcapsules to degradation conditions or by contacting the microcapsules with a degradation reagent. Exemplary degradation reagents catalyze microcapsule degradation. In some cases, the catalyst includes a degrading enzyme, such as a glycosidase or other carbohydrate-degrading enzyme, under enzymatic microcapsule degradation conditions. Enzymatic microcapsule degradation conditions generally hydrolyze the microcapsules (e.g., hydrolyze all or part of the microcapsule shell). The microcapsule degradation conditions may degrade all or part of the microcapsules in the composition and may include one or more types of glycosidase enzymes. In certain implementations, the glycosidase can enzymatically degrade the polysaccharides in the first polymer and the second polymer of the microcapsules. In certain instances, the polysaccharide in the first polymer is the same as the polysaccharide in the second polymer. Under glycosidase degradation conditions, at least the shells of the majority of the microcapsules are often enzymatically degraded by the glycosidase. In certain implementations, the enzymatic microcapsule degradation conditions include a pH of about 3 to about 11 and a temperature of about 80° C. or less, or a pH of about 6 to 8 and a temperature of about 40° C. or less. The microcapsule degradation conditions sometimes include a glycosidase selected from dextranase and / or cellulase (see, e.g., Examples 4 and 19).

[0060] In certain aspects, methods are provided that include exposing a composition containing the microcapsules described herein to washing conditions. The washing conditions may change the composition of the solution in which the microcapsules are suspended, often changing the composition of the core and shell or the reaction buffer environment. The washing conditions often involve exposing the microcapsule population to a solution containing a buffer and, in some cases, reagents suitable for a reaction to be performed on the microcapsule contents, such as an analyte or product of a previous reaction step. For example, washing may change the pH, salt concentration, and reagent concentration in the microcapsule suspension. The washing conditions may (i) reduce and / or remove components present in the microcapsules and / or (ii) increase the concentration of components present in the solution used for washing. The washing conditions often replace a first set of buffer conditions compatible with a first reaction with reaction conditions and reagents compatible with a second reaction that, in some cases, is incompatible with the first reaction or the first reaction buffer conditions. Mutually incompatible reactions can be performed in a population of microcapsules by washing the population of microcapsules to replace one set of reaction conditions and reagents with a second, and in some cases, incompatible, set of reaction conditions and reagents. In various cases, the microcapsules are subjected to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 changes in washing conditions to facilitate performing successive reactions on the analytes or reaction products contained in the microcapsules (see, e.g., Examples 6, 8, 9, 10, 12).

[0061] Without being limited by theory, components can migrate into and out of the microcapsule interior through pores in the microcapsule shell when the microcapsule is exposed to washing conditions. In certain implementations, where processed nucleic acids are generally retained within the microcapsule and other molecules (e.g., reagents) migrate from the microcapsule interior to the exterior, the microcapsules containing the nucleic acids can be exposed to washing conditions after exposing the microcapsules to nucleic acid processing conditions (e.g., cell lysis conditions, nucleic acid fragmentation conditions, reverse transcription conditions, ligation conditions, MIP incorporation conditions, amplification conditions, barcode incorporation conditions, sequencing adapter incorporation conditions, etc.). The microcapsules can be exposed to washing conditions for implementation of a subsequent processing step. In non-limiting examples, microcapsules can be exposed to washing conditions after lysis (e.g., to remove certain lysate components), after amplification (e.g., to remove excess primers and exchange buffers), after barcode binding (e.g., to remove unbound barcodes), after fragmentation (e.g., to exchange buffers), and after multiple steps of nucleic acid library preparation for sequencing (see, e.g., Examples 6, 8, 9, 10, 12).

[0062] Those skilled in the art will appreciate that washing conditions can replace the buffer environment of the microcapsules without diluting the contents or conditions of the previous reaction or otherwise substantially diluting the microcapsule core volume. Thus, those skilled in the art will appreciate that changes in washing conditions can alter the reaction buffer environment without substantially changing the microcapsule core reaction volume. In some cases, changes in core reaction volume occur, such as those resulting from changes in osmotic pressure on the microcapsule hydrogel shell. These changes are likely to be no more than 20%, 15%, 10%, 5%, or less than 5%.

[0063] These changes are in stark contrast to the volume changes that result from dilution of reaction conditions due to droplet fusion in an emulsion droplet population, where the volume changes can be substantial, potentially by a factor of 5, 10, or more. Volume changes of this magnitude can create challenges for microfluidic operations, and droplet fusion, which affects them, is technically challenging. In contrast, with the techniques herein, reagent buffers and reagents are exchanged, in part, by a simple but technically sophisticated incubation of the microcapsules in an excess of new reagent buffer.

[0064] Reagent buffer exchange can be direct, i.e., one buffer for another. Alternatively, in some cases, reagent buffer exchange is performed by incubation in an intermediate buffer, such as PBS or water, to minimize contamination of the previous or first reaction conditions and buffer with the second reaction conditions and buffer. Alternatively, in some cases, direct exchange of a first reaction buffer with a second reaction buffer is unaffected by contacting the first reaction buffer with the second reaction buffer, e.g., where the second reaction buffer is provided in sufficient excess to dilute any effect of the first reaction buffer on subsequent reaction conditions.

[0065] In certain aspects, a process for producing a composition comprising a plurality of microcapsules, comprising: (a) a first polymer comprising a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; a second polymer comprising a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise the hydrophilic / hydrophobic modifying moiety; a first aqueous solution and / or a second aqueous solution comprising a biological entity; monodisperse water-in-oil droplets are produced containing the first polymer, the second polymer, and the biological entity; and a liquid core is formed into a liquid shell. A process is provided that includes emulsifying (i) a first aqueous solution containing a first polymer and (ii) a second aqueous solution containing a second polymer in oil in a droplet generating device, whereby an aqueous two-phase system is formed within water-in-oil droplets in which the core is completely surrounded by the first polymer and the biological species is preferentially distributed in the liquid core; and (b) exposing the microcapsules to cross-linking conditions that conjugate cross-linking moieties in the first polymer, thereby forming a hydrogel shell surrounding the core in a plurality of microcapsules (see, e.g., Example 2, as well as many of the other examples). Without being limited by theory, microcapsules comprising a core surrounded by a shell form in the droplets as a result of separation of a first phase comprising the first polymer and a second phase comprising the second polymer. In certain implementations, the polysaccharide of the second polymer does not contain cross-linking moieties and hydrophilic / hydrophobic modifying moieties, and sometimes the second polymer is an unmodified polysaccharide. In certain implementations, the first polymer is a modified polysaccharide and the second polymer is an unmodified polysaccharide, and in certain instances, the polysaccharide backbones of the first and second polymers are the same (e.g., the first polymer is a modified dextran and the second polymer is an unmodified dextran).

[0066] In certain implementations, the contacting includes, in part, (a) contacting the first and second aqueous solutions with a third aqueous solution contained in a water-in-oil droplet (see, e.g., Example 31). Without being limited by theory, the third aqueous solution in the water-in-oil droplet (i) separates the first and second aqueous solutions, (ii) mixes with the first and / or second aqueous solutions, (iii) forms a core within a core, (iv) forms a shell outside a shell, or (v) is a combination of two or more of (i), (ii), (iii), and (iv). In certain examples, the first aqueous solution, the second aqueous solution, the third aqueous solution, or a combination of two or three thereof independently comprises a biological entity.

[0067] The contacting can be performed, in part, by (a) injecting, pouring, delivering, and / or loading the first aqueous solution, the second aqueous solution, and optionally the third aqueous solution into a device that mixes the two solutions, such as a droplet-forming device (see, e.g., Examples 2 and 31). In certain implementations, the water-in-oil droplets are generated by a microfluidic device. Microfluidic devices often include channels that are sometimes in capillary assemblies, where the channels in the capillary assemblies have any suitable cross-sectional shape (e.g., oval, circular, rectangular, oblong, square). Channels in microfluidic devices sometimes have cross-sectional widths of about 1 micrometer to about 10,000 micrometers, about 10 micrometers to about 1000 micrometers, or about 20 micrometers to about 100 micrometers. The microfluidic device is sometimes a microfluidic chip. In certain implementations, the fluidic device includes a flow-focusing junction (e.g., a nozzle), and sometimes the water-in-oil droplets are generated by injecting the first aqueous solution, the second aqueous solution, optionally a third aqueous solution, and oil through the flow-focusing junction. In certain instances, the water-in-oil droplets and microcapsules are not atomized. The oil can be considered a carrier oil in the processes described herein.

[0068] The oils used herein are particularly preferably hydrophobic in order to allow the accumulation of the microcapsule hydrogel components on the periphery of the microdroplets. Any suitable oil can be used, non-limiting examples of which include FC40 oil (3M®), FC43 (3M®), FC77 oil (3M®), FC72 (3M®), FC84 (3M®), FC70 (3M®), HFE-7500 (3M®), HFE-7100 (3M®), perfluorohexane, perfluorooctane, perfluorodecane, Galden-HT135 oil (Solvay Solexis), Galden-HT170 oil (Solvay Solexis), Galden-HT110 oil (Solvay Solexis), Galden-HT90 oil (Solvay Solexis), Galden-HT70 oil (Solvay Solexis), Galden PFPE fluid, Galden® SV Fluid, or H-Galden® ZV. Fluorinated oils (fluids) such as fluororesin (Fluid); and hydrocarbon oils such as mineral oil, light mineral oil, adepsin oil, arbolene, cable oil, baby oil, dorechol, electrical insulating oil, heat treatment oil, hydraulic oil, lignite oil, liquid paraffin, mineral seal oil, paraffin oil, petroleum oil, technical oil, white oil, silicone oil, or vegetable oil. In certain implementations, the oil may contain a surfactant. Without being limited by theory, the surfactant may be a stabilizing surfactant capable of stabilizing the water-in-oil droplets formed in the processes described herein. Any suitable surfactant may be used, and the surfactant may be present in the carrier oil at a concentration ranging from about 0.05% to about 10% by weight, from about 0.1% to about 5% by weight, or from about 0.25% to about 2% by weight. Non-limiting examples of surfactants include emulsifying surfactants, nonionic surfactants (e.g., Triton X-100, Pluronic F127), anionic surfactants, hydrocarbon surfactants, and fluorosurfactants (e.g., perfluoropolyether-polyethylene glycol-perfluoropolyether (PFPE-PEG-PFPE) triblock copolymers; polyethylene glycol-perfluoropolyether (PEG-PFPE) diblock copolymers).In certain examples, the oil comprises a fluorinated fluid and a fluorosurfactant, and in certain implementations, the oil comprises an HFE-7500 fluid and a PFPE-PEG-PFPE triblock copolymer or a PEG-PFPE diblock copolymer fluorosurfactant. In certain examples, the oil (e.g., carrier oil) comprises a surfactant, and sometimes the oil (e.g., carrier oil) comprises a fluorinated fluid and a fluorosurfactant.

[0069] In certain implementations, the water-in-oil droplets are collected in the form of an emulsion, and sometimes the emulsion is collected outside the microfluidic device. In certain examples, after part (a) or after part (b), the process includes separating the microcapsules from the oil into an aqueous solution, which sometimes includes de-emulsification. De-emulsification is generally a process in which the water-in-oil droplets are broken down by chemical or physical means. A non-limiting example of chemical-type or de-emulsification includes bursting the water-in-oil droplets with perfluorooctanol. In the microcapsules formed by the processes described herein, the first polymer is often the predominant component of the shell and the second polymer is often the predominant component of the core, the predominant component being the component having a dry mass greater than 50% of the total dry microcapsule mass in the composition containing the microcapsules.

[0070] In certain aspects, provided herein is a process for producing a composition comprising a plurality of microcapsules, the process comprising: (a) contacting (i) a first aqueous solution comprising the first polymer, (ii) a second aqueous solution comprising the second polymer, and (iii) oil under droplet-forming conditions such that: (a) a first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety and optionally modified with a hydrophilic / hydrophobic modifying moiety; the core comprises a second polymer comprising a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise the hydrophilic / hydrophobic modifying moiety; monodisperse water-in-oil droplets containing the first polymer and the second polymer are generated; and an aqueous two-phase system is formed within the water-in-oil droplets in which the liquid core is completely surrounded by the liquid shell; and (b) cross-linking the cross-linking moieties in the first polymer to form a hydrogel shell surrounding the core in a plurality of microcapsules encapsulating a biological entity; and (c) disrupting the water-in-oil droplets, releasing the microcapsules encapsulating the biological entity into an aqueous solution (see, e.g., Examples 2 and 31). In certain aspects, provided herein is a composition comprising a plurality of microcapsules obtainable by the processes described herein.

[0071] Connection method The present invention provides a method for releasing encapsulated nucleic acids from biological entities after linking them in intact microcapsules. Linking can, for example, allow nucleic acids from a common source to be linked by a common phosphodiester bond, facilitating the identification of their common origin. Nucleic acid linking in microcapsules in combination with long-read sequencing technology opens the possibility of single-cell sequencing without the use of additional cell barcodes. Non-limiting examples of long-read sequencing technology include nanopore sequencing and real-time DNA sequencing from a single polymerase molecule. Highly efficient methods for single-cell nucleic acid (NA) analysis often rely on the "one barcode = one cell" paradigm, in which all nucleic acids of interest from a given cell are tagged with the same barcode, which varies between cells. The barcoding step must occur on NAs from individual cells in separate compartments (e.g., wells, droplets, fixed cells, or nuclear scaffolds). After barcoding, nucleic acids from multiple cells are pooled and sequenced as a single sequencing library. Reads that share the same barcode are considered to originate from the same cell.

[0072] Here, two different principles are provided for single-cell sequencing: "1 read = 1 cell" (see, e.g., Examples 6 and 8) and "1 unique molecular signature (UMI) set = 1 cell" (see, e.g., Example 7). The "1 read = 1 cell" principle is based in part on an approach where nucleic acids of interest from individual cells in separate microcapsule compartments can be ligated into long concatemers (shown as an example in Figure 5). The concatemers from individual cells can then be pooled and sequenced as a single library using long-read sequencing (LRS; e.g., Oxford Nanopore, PacBio sequencing instruments). The information from a single read originates from the same cell. Such a method can be used for sequencing BCR heavy and light chain pairs, an example of coupling two targets by ligation (see, e.g., Example 6). The "1 read = 1 cell" principle is useful for simultaneous testing of fewer than 10 genomes per transcriptome target of similar abundance.

[0073] The "one UMI set = one cell" principle is an extension of the "one read = one cell" principle (see, e.g., Example 7). For the "one UMI set = one cell" principle, targets derived from a single cell can be tagged with a unique set of UMIs (i.e., one UMI per target). The unique set of UMIs is often composed of random sequences sampled from a pool of poly-N oligos (Figure 5). Given a sufficiently large pool of poly-N oligos, each sample of UMI is essentially unique, equivalent to a molecular "barcode." The UMI-tagged targets can then be amplified (e.g., by PCR) and then linked in microcapsules. Concatameric reads originating from the same cell share one or more UMIs, but the information derived from a given read originates from the same cell. The "one UMI set = one cell" principle can be useful for several targets in the range of thousands of targets.

[0074] Droplet-based techniques have been proven to handle over one million cells in a single experiment. However, droplet-based techniques are expensive and technically complex for purposes of testing fewer than 1,000 targets per cell, especially fewer than 10. Droplet-based methods typically rely on the "one barcode = one cell" principle, with the notable exception of some demonstrations of two-target pairing by emulsion overlap extension RT-PCR for BCR sequencing. Certain droplet-based methods rely on the delivery of cell barcodes bound to beads (e.g., Drops, 10x genomics solution in DropSeq). The production of such beads is technically challenging and expensive, and coupling of cells to beads requires sophisticated microfluidic manipulation. Droplet-based techniques also typically rely on water-in-oil droplets, which cannot completely remove reagents and do not allow multi-step processing without loss of compartmentalization. Because of this limitation, the ligation-based methods described herein cannot be readily applied to droplets and are instead typically performed in core-shell microcapsules.

[0075] Water-in-oil droplet-based approaches for single-cell sequencing rely on early barcoding and are limited in the amount of nucleic acid preprocessing allowed before barcoding. Because multistep processing is not possible within such compartments, only a limited number of preprocessing steps can be performed on nucleic acids from individual cells before barcodes are introduced. For example, a wide range of droplet-based single-cell RNA sequencing (scRNAseq) methods often rely on cell lysis (i.e., making RNA accessible) and barcoding by reverse transcription, which occurs as a single step in the same droplet. However, if nucleic acid preprocessing is not separated from the barcoding step, the breadth of application is limited. For example, the harsh lysis required to make microbial nucleic acids accessible cannot be combined with enzymatic barcoding. Multistep approaches based on core-shell microcapsules do not suffer from this limitation (see, for example, Example 8).

[0076] Certain core-shell microcapsule concatemer methods described herein are based in part on the "one read = one cell" and "one UMI set = one cell" principles described herein and benefit from at least the following advantages: Core-shell microcapsules benefit from the highly efficient nature of droplet microfluidics. In contrast to water-in-oil droplets, microcapsules enable true multi-step nucleic acid processing, including uncompromised lysis, nucleic acid amplification, and ligation, without loss of compartmentalization. The method is relatively simple because it avoids the use of multiple wells or sophisticated microfluidic manipulations (e.g., co-encapsulation of cells and barcoded beads). Cells are often encapsulated in microcapsules using basic microfluidic water-in-oil droplet formation, followed by shell polymerization and emulsion breaking to transfer the microcapsules into an aqueous solution. Once this is done, all steps are generally performed simultaneously on up to millions of microcapsules as a single-tube reaction, without split-and-pool steps and without steps required, for example, for re-encapsulation into droplets. The core-shell microcapsule concatemer methods described herein generally implement microcapsule-enabled multi-step processing of nucleic acids from individual cells and long-read sequencing techniques that allow for sufficient read lengths (up to megabases, 10,000 and 100,000 contiguous nucleotides routinely sequenced in a single read).

[0077] Figure 5, shown below, illustrates the "one read = one cell" principle. The schematic shows the example of three targets, but many more targets can be tested using this method. DNA-containing entities (e.g., eukaryotic cells, prokaryotic cells, viruses, liposome vectors, extracellular vesicles, organelles (e.g., mitochondria, chloroplasts)) are encapsulated in microcapsules (1), followed by cell lysis and a molecular biology reaction to obtain amplicons of the desired DNA or RNA targets. The amplicons are then ligated within the microcapsules (3). The ligated DNA is further prepared for nanopore sequencing (4). Identical concatemers, and therefore amplicons on the same read, originate from the same cell.

[0078] The "one read = one cell" principle of the core-shell microcapsule-based concatemer method described herein is particularly applicable to B cell receptor (BCR) sequencing, a non-limiting application (see, e.g., Example 6). BCR sequencing is relevant to antibody-based drug screening, among other applications. BCR sequencing is challenging because it requires sequencing both the heavy and light chain subunits of an antibody and performing this at the single-cell level to determine whether the heavy and light chain pair forms a functional antibody. Along with long-read sequencing (LRS) readouts, microcapsules enable sequencing of BCR heavy and light chain pairs originating from the same cell. This sequencing is achieved by linking heavy and light chain cDNA molecules originating from the same B cell within the microcapsule. After linkage, concatemers (linked single cDNA molecules) from individual microcapsules can be pooled together in bulk solution after microcapsule shell disassembly. Information from the same long read, and therefore the same concatemer, originates from the same cell. The workflow is detailed in Figures 5 and 20 above.

[0079] The workflow described above and in Figure 5 can be generalized to any two or more target DNA or RNA molecules (e.g., about 10 target molecules) that can be linked by ligation or Gibson assembly. Multiple gene targets can be sequenced at the single-cell level using their linkage within the microcapsule. Long-read sequencing can be used to sequence and identify concatemers generated within the same microcapsule and for a single cell. For the "1 UMI set = 1 cell" principle, nucleic acids in individual microcapsules can be tagged with a unique molecular identifier (UMI), for example, by ligation. The UMI-tagged NAs can then be amplified and linked within the microcapsules. The UMI-containing concatemers can then be pooled into a bulk solution, prepared for sequencing, and sequenced using standard protocols. The resulting reads can be demultiplexed using the shared UMI information in the long reads. Figures 27A and 27B provided later in this specification show a specific example for demultiplexing long reads using the "1 UMI set = 1 cell" principle.

[0080] Thus, in certain embodiments, there is provided a method for preparing a plurality of nucleic acids for sequencing, the method comprising: (a) generating a plurality of microcapsules containing biological entities, each of which contains at least one nucleic acid molecule, wherein the microcapsules are suspended in an aqueous environment; (b) after part (a), contacting the intact microcapsules with release conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to nucleic acid amplification conditions that generate amplicons corresponding to target portions of the released nucleic acids in the intact microcapsules; and (d) after part (c), generating one or more concatemers within certain intact microcapsules by exposing the intact microcapsules to ligation conditions that link the plurality of amplicons end-to-end within the intact microcapsules. An amplicon is generally multiple copies of a portion of the encapsulated nucleic acid, sometimes including a target portion.

[0081] In certain implementations, (i) each microcapsule comprises a shell surrounding a core; (ii) each microcapsule comprises a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core; (iii) the microcapsule shell sometimes comprises a polysaccharide and is glycosidase degradable; (iv) the shell allows the passage of primers, enzymes, and assay reagents and prevents nucleic acids from escaping the microcapsule and being released from the biological entity; or (v) a combination of two or more of (i), (ii), (iii), and (iv). The microcapsules produced in part (a) are sometimes microcapsules described herein that comprise a core surrounded by a shell, where the shell is a hydrogel comprising a first polymer; the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; molecules of the cross-linking moiety of the first polymer are cross-linked in the hydrogel; and the core comprises a second polymer that does not comprise the cross-linking moiety of the first polymer and that comprises a polysaccharide that does not comprise a hydrophilic / hydrophobic modifying moiety.

[0082] In certain implementations, the plurality of microcapsules produced in part (a) includes microcapsules that do not contain a biological entity and microcapsules that contain a biological entity. Of the microcapsules that contain a biological entity, the majority of microcapsules generally contain a single biological entity. Of the total microcapsules in the population, sometimes about 1% to about 37% contain a single biological entity, and in certain instances, about 10% to about 30% contain a single biological entity. Of the microcapsules in the population that contain a biological entity, sometimes about 58% to about 99.5% of the microcapsules contain a single biological entity, and in certain instances, about 77% to about 95% of the microcapsules contain a single biological entity.

[0083] In certain examples, the method includes, after part (d), part (e), which includes exposing the intact microcapsules to microcapsule-disrupting conditions that release concatemers from the microcapsules. In certain examples, parts (b), (c), and (d) are performed in a single vessel, or parts (b), (c), (d), and (e) are performed in a single vessel. Sometimes, one or more of parts (b), (c), (d), and (e) are sometimes performed in different vessels.

[0084] In certain implementations, the method includes sequencing the concatemers, or portions thereof, or processed products of the concatemers or portions thereof. The sequencing device may be a separate component from the sequencing apparatus that sequences the concatemers, or portions thereof, or processed products of the concatemers or portions thereof, or may be the sequencing apparatus. In certain examples, the method includes placing the microcapsules, or portions thereof, into a sequencing device, followed by releasing the concatemers from the microcapsules in the sequencing device. In certain examples, the method includes releasing the concatemers from the microcapsules, followed by placing the concatemers, or portions thereof, or processed products of the concatemers or portions thereof into a sequencing device. The processed products of the concatemers may result from implementation part (c) and other steps. For example, before placing the resulting processed concatemers, or a portion thereof, into a sequencing device, the concatemers released from the microcapsules may be exposed to further amplification conditions, and optionally, purification conditions may be performed before and / or after performing the further amplification conditions. The method sometimes includes contacting the nucleic acid with library preparation conditions. Any suitable library preparation conditions can be used, such as those including contacting the nucleic acid with an adapter under adapter incorporation conditions. The adapter sometimes includes a tether, motor, or hairpin. In certain implementations, sequencing generates reads greater than 50 base pairs in length, or greater than 100 base pairs in length, or greater than 500 base pairs in length, or greater than 2,000 base pairs in length, or greater than 3,000 base pairs in length, or greater than 4,000 base pairs in length, or greater than 5,000 base pairs in length. Each read generally corresponds to a nucleic acid derived from a single biological entity.

[0085] The nucleic acids released from the biological entities in the microcapsules may include RNA, and the RNA can be reverse transcribed into complementary DNA (cDNA) using reverse transcription conditions known in the art. The resulting cDNA is sometimes amplified before part (c). In certain implementations, the method includes amplifying and / or reverse transcribing the nucleic acids released from the biological entities in the intact microcapsules after part (b) and before part (c). The method sometimes includes tagging the nucleic acids released in part (b), or tagging nucleic acids amplified and / or reverse transcribed from the nucleic acids released in part (b), before part (c) with molecular beacon polynucleotides (MIPs) derived from a plurality of different MIPs, where the concatemers in one microcapsule include a set of MIPs that differs from the set of MIPs in other microcapsules. In certain instances, the amplification conditions of part (c) incorporate molecular beacon polynucleotides (MIPs) from multiple different MIPs into each amplicon, such that the amplicon in one microcapsule contains a set of MIPs that is different from the set of MIPs in other microcapsules.

[0086] MIPs are sometimes referred to as unique molecular beacons (UMIs). The MIPs incorporated into nucleic acids often originate from multiple MIPs that have been contacted with intact microcapsules. The MIPs in the multiple MIPs are often random polynucleotides, sometimes ranging in length from about 4 contiguous nucleotides to about 50 contiguous nucleotides. Tagging nucleic acids with MIPs generally results in covalent attachment of the MIPs to nucleic acids contained in intact microcapsules. In certain implementations, nucleic acids within microcapsules can be tagged with MIPs by, for example, exposing the nucleic acid in intact microcapsules to multiple MIPs under ligation, primer extension with DNA or RNA polymerase, Gibson assembly, and / or template switching conditions that result in binding of the MIPs to the nucleic acid in the intact microcapsules. The MIPs can be incorporated into individual cDNAs prior to part (c), or the MIPs can be incorporated into amplicons in part (c). Tagging n nucleic acid molecules per cell in m cells is sometimes achieved by covalent attachment of the MIPs to nucleic acids contained in intact microcapsules. * n * It is carried out using a pool of m unique MIPs, sometimes at least 100 * n * Sequencing is performed using a pool of m unique MIPs. Sequencing can generate reads that each contain one or more MIPs and a portion of the genome sequence, where individual reads that share one or more MIPs are attributed to a single biological entity.

[0087] In certain implementations, the biological entities in the plurality of microcapsules are from a group of about 10 million or less biological entities, about 100,000 or less biological entities, or about 1,000 or less biological entities. Each biological entity may contain about 300,000 transcripts (RNA molecules) or about 1,000 DNA molecules (e.g., representing 48 chromosomes and tens or hundreds of mitochondrial DNAs in the case of a human cell). The biological entity is sometimes an entity that contains nucleic acid, non-limiting examples of which include unicellular organisms, multicellular organisms, cells derived from multicellular organisms, eukaryotic cells, prokaryotic cells, microorganisms, algae, protozoa, bacteria, archaea, fungi, plants, viruses, organelles (e.g., mitochondria or chloroplasts), liposome vectors, and extracellular vesicles. The biological entity is sometimes an antibody-producing cell (e.g., a B cell or a hybridoma), and sometimes the nucleic acid targeting moieties released into the intact microcapsules in part (c) are variable heavy (VH) and variable light (VL) domain targeting moieties (see, e.g., Example 6). Sometimes the biological entity is a prokaryotic cell (e.g., a gram-positive bacterium, a gram-negative bacterium, an archaea; Example 8), and sometimes a yeast cell.

[0088] In certain examples, the method includes, after part (b), exposing the intact microcapsules to washing conditions. The washing conditions may include contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. The washing conditions sometimes include contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of the amplification conditions present in the microcapsules. In certain examples, the aqueous solution includes a buffer.

[0089] In certain implementations, the method includes, after part (b) and before part (c), purifying one or more of: (i) the nucleic acid released into the intact microcapsules, (ii) the nucleic acid amplified before part (c), and (iii) the amplicon produced in part (c). In certain examples, the amplification conditions of part (c) or other amplification performed include contacting the nucleic acid with a DNA polymerase, an RNA polymerase, or a combination thereof.

[0090] In certain implementations, (i) the particles containing the barcode nucleic acid are not contacted with a microcapsule as part of the linking methods described herein; (ii) the biological entity and the nucleic acid of the biological entity are not immobilized on a solid support or in a matrix and are not contacted with a barcode polynucleotide as part of the linking methods described herein; and (iii) the nucleic acid is not exposed to precipitation conditions that produce precipitated nucleic acid as part of the linking methods described herein; (iv) the nucleic acid is not exposed to rehydration conditions that rehydrate precipitated nucleic acid as part of the linking methods described herein; or (v) a combination of two or more of (i), (ii), (iii), and (iv).

[0091] Microcapsule barcoding method Methods are provided in which encapsulated nucleic acids from biological entities are amplified in intact microcapsules, barcoded, and then released (see, e.g., Examples 9 and 12). In the methods described herein, after encapsulation in microcapsules, the biological entities, such as cells, are typically lysed to release the nucleic acids (NAs) into the microcapsule core. The core volume is often in the range of 0.25-250 pL. Because the nucleic acids are uniformly dissolved within this volume, barcode assembly reactions using split-and-pool techniques can occur in a uniform 0.25-250 pL solution, as opposed to on a surface, resulting in enhanced barcoding efficiency.

[0092] In the methods described herein, NAs in microcapsules are generally amplified prior to split-and-pool barcoding. After amplification, inefficiencies in the barcoding step can be tolerated: many NAs have copies after amplification, so the loss of some NAs due to incomplete barcoding can be tolerated. In contrast, when using other methods based on NAs captured on immobilized cell scaffolds, for example, a pre-amplification step is not generally possible because the amplified material diffuses outside the cell scaffold. The above advantages of the microcapsule-based method provided herein enable more efficient whole genome single-cell DNA sequencing. This advantage is particularly evident for de novo genome assembly, where high coverage of the genome derived from a single cell is a prerequisite. For single-cell RNA sequencing (scRNAseq), pre-amplification of cDNA using the method provided herein can dramatically increase transcriptome capture rate, which is a performance indicator for scRNAseq protocols.

[0093] The methods described herein solve problems associated with other barcoding methods. One problem arises from the requirement for other methods to fix cells or nuclei before split-and-pool barcoding. Without being limited by theory, the uniform reactions obtained by the methods of the present invention, which do not require fixation of cells or other biological entities before split-and-pool barcoding, are more efficient than those involving surface-bound substrates. Another problem is the inevitable inefficiency of enzymatic reactions that propagate through multiple barcoding steps in a multiplicative manner. For example, during the in-droplet barcoding approach, as part of barcode synthesis, hydrogel beads bearing DNA barcodes undergo a purification step to remove barcoding oligonucleotides with incomplete barcodes. Such incomplete oligonucleotides may account for more than 50% of the oligonucleotides on the beads. However, with direct split-and-pool barcoding of fixed cells or nuclei, incomplete barcode assemblies remain on the target molecules. Indeed, when considering mRNA sequencing as an example, the majority of unique transcripts never undergo complete barcoding and are therefore lost in the final sequencing data. Losses due to split-and-pool barcode assembly inefficiencies can result in test failures and hinder certain applications, such as single-organism whole-genome sequencing.

[0094] Figure 19 illustrates a specific implementation of the method described herein, which enables split-and-pool barcoding of nucleic acids within microcapsules. Eukaryotic or prokaryotic cells are encapsulated in semi-permeable droplets (microcapsules) so that there is an average of no more than one cell per microcapsule (1). The cells are then lysed, and the nucleic acids (DNA or RNA) undergo multi-step processing, such as one or more of the following: buffer exchange to remove undesired lysate components; fragmentation; A-tailing; adapter ligation; removal of undesired nucleic acid species by DNase or RNase treatment; reverse transcription; and template switching (2). Nucleic acid pre-processing typically includes amplification to compensate for inefficiencies during subsequent split-and-pool barcode synthesis. For copy-counting applications, such as RNAseq, target molecules are often tagged with a UMI prior to amplification. Steps 1 and 2 are also generalizable to other nucleic acid-containing particles, such as, but not limited to, viruses, organelles, extracellular vesicles (EVs), or liposomal vectors. The amplified nucleic acids ready for barcoding are split (3) and pooled (4) in a microwell plate. Typically, at least two split-and-pool cycles are performed (5). After the barcodes are incorporated, at least some of the nucleic acids in a given microcapsule have the same barcode, which is different from the barcodes attached to nucleic acids in at least some other microcapsules. During sequencing (6), the barcode sequences are used to sort reads by their microcapsule of origin.

[0095] The barcode technology disclosed herein exhibits, in some cases, remarkably high integration efficiency. For example, after three rounds of barcode addition, the technology disclosed herein exhibits a proportion of target molecules irretrievably lost of 50%, 40%, 30%, 20%, 10% or less, or less than 10%. As seen in Figure 7, in many cases, the percentage of unique transcripts irretrievably lost is, in some cases, 3.5%, 2%, 1.5%, 0.3%, 0.2% or less, or in many cases, less than 0.1%.

[0096] Similarly, the barcoding techniques disclosed herein facilitate nucleic acid sorting and, in some cases, facilitate substantial genome coverage of genomes sequenced from homogeneous or heterogeneous samples. Barcoding of distributed nucleic acids in heterogeneous samples may, in some cases, result in 10% or less mixed sample reads, such as 10, 9, 8, 7, 6, 5, 4, 3, or less than 3% mixed sample. In some cases, substantial genome coverage is achieved on genomes extracted from distributed cells in homogeneous or heterogeneous samples, such as at least 50%, 60%, 70%, 75%, or up to about 80% genome coverage.

[0097] Thus, in certain aspects, a method for preparing a plurality of nucleic acids for sequencing (see, e.g., Examples 9 and 12) comprises: (a) generating a plurality of microcapsules containing biological entities, wherein the microcapsules are in an aqueous environment; the plurality of microcapsules contain, on average, no more than one biological entity per microcapsule; and each biological entity carries at least one nucleic acid molecule; (b) after part (a), contacting the intact microcapsules with release conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to amplification conditions that generate nucleic acid amplicons in the intact microcapsules; (d) after part (c), (i) dividing intact microcapsules into separate compartments, each compartment containing more than one intact microcapsule; (ii) exposing the intact microcapsules in each compartment to barcode polynucleotide binding conditions that cause the barcode polynucleotide species bound to the nucleic acid in each microcapsule in a particular compartment to bind to the nucleic acid in the microcapsules, such that the barcode polynucleotide species bound to the nucleic acid in each microcapsule in a particular compartment differs from the barcode polynucleotide species bound to the nucleic acid in microcapsules in other compartments; and (iii) pooling the intact microcapsules from the compartments; and (e) repeating (d) at least once to produce barcoded nucleic acids in the intact microcapsules. After pooling in part (iii), the microcapsules are often exposed to wash conditions that remove unincorporated barcoded oligonucleotides; sometimes the wash conditions inhibit further enzymatic addition of barcoded oligonucleotides (e.g., the wash buffer may contain EDTA).

[0098] In certain implementations, (i) each microcapsule comprises a shell surrounding a core; (ii) each microcapsule comprises a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core; (iii) the microcapsule shell sometimes comprises a polysaccharide and is glycosidase degradable; (iv) the shell allows the passage of primers, enzymes, and assay reagents and prevents nucleic acids from escaping the microcapsule and being released from the biological entity; or (v) a combination of two or more of (i), (ii), (iii), and (iv). The microcapsules produced in part (a) are sometimes microcapsules described herein that comprise a core surrounded by a shell, where the shell is a hydrogel comprising a first polymer; the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; molecules of the cross-linking moiety of the first polymer are cross-linked in the hydrogel; and the core comprises a second polymer that does not comprise the cross-linking moiety of the first polymer and that comprises a polysaccharide that does not comprise a hydrophilic / hydrophobic modifying moiety.

[0099] In certain implementations, the plurality of microcapsules produced in part (a) includes microcapsules that do not contain a biological entity and microcapsules that contain a biological entity. Of the microcapsules that contain a biological entity, the majority of microcapsules generally contain a single biological entity. Of the total microcapsules in the population, sometimes about 1% to about 37% contain a single biological entity, and in certain instances, about 10% to about 30% contain a single biological entity. Of the microcapsules in the population that contain a biological entity, sometimes about 58% to about 99.5% of the microcapsules contain a single biological entity, and in certain instances, about 77% to about 95% of the microcapsules contain a single biological entity.

[0100] In certain instances, part (d) is repeated a number of times in part (e) until a predetermined number of barcode polynucleotide species are attached to the nucleic acid in the microcapsule. The predetermined number of barcode species attached is sometimes about 1 to about 6 barcode species attached to the nucleic acid in the microcapsule, and sometimes about 2 to about 5 barcode species attached to the nucleic acid in the microcapsule. In certain implementations, the method includes, after part (b), exposing the intact microcapsules to washing conditions. The washing conditions may include contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. The washing conditions sometimes include contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of the amplification conditions present in the microcapsules. In certain examples, the aqueous solution includes a buffer. In certain implementations, the method includes tagging the nucleic acids in the intact microcapsules with a molecular beacon polynucleotide (MIP) after part (b) but before part (c). See, e.g., Example 9. The MIP is from about 4 contiguous nucleotides to about 50 contiguous nucleotides in length.

[0101] In certain examples, the method includes exposing the nucleic acid in the intact microcapsules to fragmentation conditions before part (c) or after part (b). The fragmentation conditions sometimes result in nucleic acid fragments of from about 100 base pairs (bp) to about 100 kilobase pairs (kbp) in length, or from about 100 bp to about 10 kbp in length. The fragmentation conditions sometimes include exposing the nucleic acid in the intact microcapsules to a nuclease, a chemical agent that generates hydroxyl radicals, and / or ultrasound. In certain implementations, the amplification conditions include contacting the intact microcapsules with a DNA polymerase, an RNA polymerase, or a combination thereof. In certain examples, the method includes exposing the nucleic acid released in part (b) to reverse transcription conditions prior to part (c). The reverse transcription conditions often include contacting the nucleic acid with a reverse transcriptase enzyme.

[0102] In certain implementations, the microcapsules in part (d) are distributed into wells of a plate. The plate sometimes comprises a 96-well plate or a 384-well plate. Each well often contains a different barcode polynucleotide, and the barcode polynucleotide in each well is often about 4 contiguous nucleotides to about 100 contiguous nucleotides in length, or about 6 contiguous nucleotides to about 18 contiguous nucleotides in length, or about 6 contiguous nucleotides to about 12 contiguous nucleotides in length. Each barcode polynucleotide sometimes comprises a molecular identifier polynucleotide (MIP), and sometimes each barcode polynucleotide comprises a polymerase chain reaction (PCR) adapter polynucleotide. The barcode polynucleotide binding conditions are sometimes the same as the MIP binding conditions, and the barcode polynucleotide binding conditions sometimes include exposing the nucleic acid in the intact microcapsules to a plurality of barcode polynucleotides under ligation, primer extension with a DNA or RNA polymerase, Gibson assembly, and / or template switching conditions. In certain implementations, the method includes, after part (e), generating released barcoded nucleic acids by exposing the intact microcapsules to microcapsule-degrading conditions that release the barcoded nucleic acids. The microcapsule-degrading conditions often include a glycosidase, as described herein.

[0103] In certain examples, the method includes producing purified barcoded nucleic acids by exposing the released barcoded nucleic acids to purification conditions. The purification conditions sometimes are or include a phase extraction purification process, such as, but not limited to, magnetic bead purification (e.g., AMPure purification) or spin column purification. When using magnetic bead purification, for example, 0.4x, 0.5x, 0.6x, 0.7x, 0.8x, 0.9x, or 1x AMPure XP bead purification may be selected. The purification conditions sometimes are or include a chemical purification process, such as, but not limited to, ethanol precipitation and / or phenol-chloroform extraction. In certain implementations, the method includes contacting the nucleic acid with library preparation conditions. The library preparation conditions sometimes include contacting the nucleic acid with an adaptor under adaptor incorporation conditions. In certain examples, the method includes sequencing the released barcoded nucleic acid and / or the purified barcoded nucleic acid.

[0104] In certain instances, in part (d), the nucleic acid encapsulated by the microcapsules is not fixed. The nucleic acid is often not fixed to a solid support, often not fixed to the microcapsules, and often not fixed to any other matrix. In certain implementations, fixed biological entities (e.g., cells fixed with a cross-linking fixative such as formaldehyde or a coagulating agent such as methanol and ethanol) can be encapsulated in microcapsules, rehydrated (e.g., applicable to MeOH fixation), or the cross-links reversed (e.g., applicable to formaldehyde fixation), and dissolved, and the no longer fixed nucleic acid can then be processed according to the methods described herein.

[0105] Figure 6 shows an example of a split-and-pool barcoding method applicable to nucleic acids in microcapsules. Biological entities, such as eukaryotic or prokaryotic cells, are encapsulated in semi-permeable compartments (i.e., microcapsules) (#1), with the majority of microcapsules containing one or zero cells. Next, the cells are lysed (#2), and the nucleic acids (DNA or RNA) undergo multistep processing, including buffer exchange to remove undesired lysate components, fragmentation, A-tailing, adapter ligation, removal of undesired nucleic acid species by DNase or RNase treatment, reverse transcription, and template switching. The core nucleic acid processing step prior to barcoding is amplification (#3), which compensates for inefficiencies during subsequent split-and-pool barcode synthesis. For copy-counting applications, such as RNAseq, target molecules are tagged with unique molecular identifiers (UMIs) before amplification. Steps 1 and 2 are generalizable to other nucleic acid-containing particles, such as viruses, organelles, extracellular vesicles (EVs), or liposomal vectors. The amplified nucleic acids ready for barcoding undergo split-and-pool barcoding in a microwell plate (#4). After barcoding, all nucleic acids in a given microcapsule have the same barcode, and the barcode attached to a nucleic acid in one microcapsule is different from the barcode attached to a nucleic acid in another microcapsule. The barcoded material is pooled by enzymatic microcapsule shell hydrolysis (#5) before continuing with further sequencing library preparation (#6).

[0106] As addressed above, a central step in the method illustrated in Figure 6 is the amplification of nucleic acids within microcapsules prior to split-and-pool barcoding. Without amplification, each molecule that fails to have a complete assembled barcode is irretrievably lost. Figure 7 illustrates how the percentage of molecules that are irretrievably lost in the three-step barcode assembly depends on the efficiency of barcode addition, and how amplification mitigates that loss.

[0107] Figure 7 shows the percentage of unique transcripts irrecoverably lost after three rounds of barcode extension. Percentages below 5% are highlighted in darker shades of gray. The first row ("0") represents a scenario in which transcripts are not amplified before barcoding. Considering the relatively high 95% efficiency of each barcoding step, without amplification before barcoding, approximately 86% of transcripts have complete barcodes, but 14% are lost (top right corner of the table). If the efficiency of each barcoding step is 50%, only 12.5% ​​of transcripts have complete barcodes, and 87.5% of unique transcripts are lost. Amplification significantly mitigates the irrecoverable loss of unique transcripts. If a given unique transcript is amplified before barcoding, some (or even most) of its copies may be lost due to incomplete barcoding, but as long as at least one copy has a complete barcode, no unique transcripts will be lost. For example, for a relatively low 30% efficiency of each barcoding step and 7 PCR preamplification cycles, the percentage of unique transcripts irrecoverably lost is 3%, whereas without amplification it is 97.3%.

[0108] Microcapsule split-and-pool barcoding can be used, in certain applications, for eukaryotic single-cell RNAseq (scRNAseq; Example 9) or microbial cell scDNAseq (see, e.g., Example 12). For scRNAseq, UMI tagging is required before amplification to obtain quantitative gene expression data, and amplification is performed using PCR. A specific workflow for scRNAseq is illustrated in FIG. 8A, and a specific workflow for scDNAseq is illustrated in FIG. 8B. For the microbial scDNAseq workflow illustrated in FIG. 8B, UMI tagging is not performed, and multiple displacement amplification (MDA) is used for DNA amplification.

[0109] Figures 8A and 8B illustrate a comparison of specific microcapsule split-and-pool barcoding workflows for eukaryotic single-cell RNAseq (scRNAseq) (Figure 8A) and microbial single-cell DNAseq (scDNAseq) (Figure 8B). Figure 8A shows nucleic acids modified with a UMI before amplification, a requirement for quantitative scRNAseq. The UMI is introduced during the reverse transcription (RT) step (#1). RT can be performed as a single-tube reaction (without barcoding). Alternatively, a first cellular barcode can be introduced in addition to the UMI during RT, in which case RT is performed using microcapsules divided into wells of a multiwell plate. The resulting UMI-tagged cDNA is then amplified by PCR (#2), and cellular barcodes are assembled on the transcripts by split-and-pool barcoding (#3). An essential step in further library preparation (#4) for sequencing (#5) is enrichment of fully assembled barcodes by PCR using a single primer targeting a primer annealing site present only on molecules successfully modified by the final barcode. Figure 8B illustrates that for microbial DNA sequencing, UMIs are not used, and total cellular DNA is amplified by multiple displacement amplification (MDA) (#1), resulting in highly branched products that are fragmented and / or debranched (#2) before split-and-pool barcoding (#3). Further steps (#4 and #5) are similar to those shown in Figure 8A.

[0110] Figures 9A and 9B illustrate examples of the final Illumina sequencing library structures obtained after microcapsule split-and-pool barcoding of eukaryotic whole transcriptomes (Figure 9A, see e.g., Example 9) and MDA-amplified whole cellular DNA (Figure 9B, see e.g., Example 12). "SPASp5" refers to the Illumina sequencing primer annealing site at the p5 end, and "SPASp7" refers to the Illumina sequencing primer annealing site at the p7 end. The p5, p7, SPASp7, and SPASp5 sequences are based on the Illumina TruSeq library design. W, X, Y, and Z refer to the cellular barcodes introduced during the first, second, third, and fourth rounds of split-and-pooling, respectively. Figure 9A illustrates that a PCR adapter is introduced between the UMI and the cellular barcode, as in the case of mRNA barcoding, which requires UMI tagging prior to amplification. To avoid unnecessary sequencing cycles on the adapter sequence, the sequence between the cell barcode and the UMI is used as SPASp7 (which itself is not sequenced during the Illumina instrument run). Read index 1 is set to 20 cycles and reveals cell barcode portions X, Y, and Z. If a cell barcode (W) is also introduced during RT, it is revealed by read 2 along with the UMI. Transcript sequencing is revealed by read 1. Figure 9B illustrates that UMI tagging is not performed, as in the case of whole-cell DNA sequencing amplified by MDA, and read 2 is used to reveal the complete cell barcode (W, X, Y, and Z portions).

[0111] Figure 10 shows a schematic diagram for oligonucleotide sequencing detailing the assembly of barcodes when cellular DNA amplification is performed by MDA followed by split-and-pool barcoding in microcapsules. Post-barcoding PCR is performed to enrich for DNA fragments with successfully added final barcodes (Z) and introduce adapters for sequencing on an Illumina instrument.

[0112] Figure 11 shows a schematic diagram for oligonucleotide sequencing detailing the assembly of barcodes when cDNA amplification followed by split-and-pool barcoding in microcapsules is performed. Adapters for pre-barcoding PCR are introduced during reverse transcription upstream of the UMI. Post-barcoding PCR is performed to enrich DNA fragments with successfully added final barcode (Z) and introduce adapters for sequencing on Illumina instruments. The workflow detailed here is for 3'-biased scRNAseq. For 5'-biased scRNAseq, assembly is similar except that the PCR1 adapter, UMI, and optional barcode W are introduced using TSO instead of the RT primer. Barcodes Z and X are 5-mers, while barcodes Y and W are 6-mers (Figure 11). By including a 2-nucleotide linker between the barcodes, the combined barcode ZYX is 20 nt long, the longest index read possible by any Illumina sequencing platform. Leveraging index reads to reveal barcode structure allows for more cycle-efficient sequencing because sequencing cycles are not wasted on the adapter sequence between barcodes X and W (Figure 9B). Five-mers (barcodes Z and X) are selected to meet the following criteria: i) 40% ≤ %GC ≤ 60%; ii) palindromic barcodes, i.e., not a sequence that is its own reverse complement; iii) a minimum pairwise Hamming distance of 2 between any pair of barcodes X (or Z). Six-mers (barcodes Y and W) are selected to meet the following criteria: i) %GC = 50%; ii) palindromic barcodes, i.e., not a sequence that is its own reverse complement; iii) a minimum pairwise Hamming distance of 2 between any pair of barcodes Y (or W); iv) for barcode Y, a melting temperature (Tm) close to or higher than that of barcode "CGGTTA," a low-Tm barcode identified as suitable for barcoding applications in small sample barcoding samples. The specific barcode sequences used in Example 9 are as follows:バーコードW:AGTGTG、ATGCAC、ATACGC、CGATCA、GCGATA、ATTGCC、GTTTGC、ATGCTG、CACGTA、TCGATG、CGACAT、TGT CGT、TCAGCT、CGCATT、GCAGAT、TGATGC。バーコードGGAG、GGAGT、GAAAC、CAGTA、GTTAG、ACTAG、AAGCA、CTACT、AGACT、GAAGG、GCTTC、TGACG、CTATC、GTGCA、TACGG 、AAGAC、ACATG、CAACA、CTCAG、TAGTC、ACTCA、AGCGT、GGCTA、GATCG、CAAGT、ACCTA、TCTCG、CAATG、CGTTA、TCC CA、CATGA、TTTCC、TTGGG、AGTAC、GCGTT、GACCA、ACAGT、CAGAG、TGGAT、AACTC、TTGAC、TAACC、CTGTG、CCAAT、 GGTCA、GCTCT、AGTCG、TCGAG、AACGA、TGTTC、ACACC、CCTAA、GACTT、GAACT、TGTGA、ATGCT、CACAA、CTAGG、CATT C、TCACT、CGGTT、TAGCT、CGTCT、TCCTG、GTGTC、CGAAC、GCAGA、GTCGA、TCGGT、TTCTC、TCCAT、GGCAT、ATACG、GT GGT、TTCCG、AACAG、GCCAA、AGAGG、CACCT、GAGTG、CCTTG、GATGT、AAGGG、CTTCA、GTATG、GAGAT、TGCAG、AATCC。バーコードY:AGTGTG、ATGCAC、ATACGC、TCGGAA、CGATCA、GCCAAT、GCGATA、GCAAGA、ATTGCC、CCACAA、GTTTGC、CACAAC、AAGCCA、ATGCTG、AACACC、CCAACA、CACGTA、TCGATG、CGACAT、TGTCGT、CGCTAA、TCAGCT、CGCATT、GCAGAT、TGATGC、ATCAGC、GCATTG、AAGGCT、ACGGTT、CGTCAA、TGCTGA、TCGAAC、AGGTGT、ATCGCT、CAACCA、TCAACG、TCGACA、GGTTGT、GCTTCA、TAACCG、ACCCAT、TGCAAG、TGTGGA、TTGCAG、ACCGTA、TTGCTC、AACGGT、CATTGC、AACGAC、ACGACT、TCGTTC、AAGTGC、TTGGCA、TGCGTA、TTCCCA、CGATGT、GAAGCT、TCTCGA、CATTCG、AGCAGA、TCGTGT、TGTTCG、ACGTAC、AAAGCG、ATCCGA、CTGTGT、TACGTC、ATTCGG、TTGTGC、TTGTCG、ACTTCG、TCGCTT、TCCGTT、ACAGCA、AGCATC、ACAGTG、AGCGAA、GCTGAA、GTCGAT、GCAACT、AGGCAA、ATCACG、ACTGCT、CAGCTT、AGCTCA、ACGATC、AAGCTC、TGACAC、AGGCTT、TGCACA、TAGCGT、ACCACA、ACTTGC、TCTGCA、CATGCA、ACTCGT。Barcode Z: CCATA, AGATC, TTCGT, TGGTA, TCAAC, ATGGC, CTGAT, AGGAG, GGAGT, GAAAC, CAGTA, GTTAG, ACTAG, AAGCA, CTACT, AGACT, GAAGG, GCTTC, TGACG, CTATC, GTGCA, TACGG, AAGAC, ACATG, CAACA, TAGTC, ACTCA, AGCGT, GGCTA, GATCG, CAAGT, ACCTA, TCTCG, CAATG, CGTTA, TCCCA, CATGA, TTTCC, TTGGG, AGTAC, GCGTT, GACCA, ACAGT, CAGAG, TGGAT, AACTC, TTGAC, TA ACC, CTGTG, CCAAT, GGTCA, GCTCT, AGTCG, TCGAG, AACGA, TACAC, TGTTC, ACACC, CCTAA, GACTT, GAACT, TGTGA, ATGCT, CACAA, CTAGG, CATTC, TCACT, CGGTT, TAGCT, CGTCT, TCCTG, GTGT C, CGAAC, GCAGA, GTCGA, TCGGT, TTCTC, CTGGA, TCCAT, ATACG, GTGGT, TTCCG, AACAG, GCCAA, AGAGG, CACCT, GAGTG, CCTTG, GTCAC, GATGT, AAGGG, CTTCA, GTATG, GAGAT, TGCAG, AATCC.

[0113] Droplet barcoding method Methods are provided in which microcapsules containing encapsulated nucleic acids derived from biological entities are mixed in droplets with particles to which barcode polynucleotides are attached, and barcoded nucleic acids derived from the microcapsules in the droplets (see, e.g., Example 10).

[0114] An advantage of the core-shell microcapsule-based methods described herein is their ability to utilize a variety of biological entities and biological molecule processing steps, some of which are incompatible with other types of methods. For example, the possibility of using "compromise-free" lysis conditions is an advantage over droplet-based methods. Droplet-based methods generally use mild lysis conditions, enzymatic reactions occur simultaneously, and workarounds include complex droplet fusion techniques that are not easily adaptable. In split-and-pool barcoding protocols, cells act as compartments and must be permeabilized before barcoding. Various permeabilization techniques have been described for different cell types, and it is unclear whether a universal method is possible. Microcapsules allow the use of virtually any chemical cell lysis technique, including proteases, high concentrations of detergents such as SDS, and alkaline pH. Heat and / or sonication can be used (microcapsules survive thermal cycling during PCR). Lysis can be performed in one step or as a series of independent steps. Additionally, the ability to amplify nucleic acids released from biological entities prior to barcoding significantly reduces the effects of target sequence loss that detrimentally affect other methods.

[0115] Another advantage of the core-shell microcapsule-based method described herein over conventional droplet barcoding of cells is that microcapsule loading in droplets can be synchronized with droplet generation so that every droplet is loaded with a microcapsule. Microcapsule and barcoded particle loading can be synchronized so that every droplet contains one microcapsule and one barcoded bead (Figures 13A-13B). Although a small fraction of microcapsules contain nucleic acid (Figure 13A), the problem of empty microcapsules can be overcome by sorting only microcapsules that contain nucleic acid (i.e., productive microcapsules). Microcapsules are flow cytometry-compatible; for example, productive microcapsules can be fluorescently labeled with a DNA-staining dye, enabling flow cytometric enrichment of productive microcapsules. When using a microcapsule suspension depleted of empty, non-productive microcapsules for barcoding in droplets, all or many droplets are productive (Figure 13B). Considering that typical regimens for cell barcoding in droplets result in 90% of droplets containing no cells, pre-sorting of core-shell microcapsules allows for a 10-fold higher barcoding throughput for a given time period and reagent amount. Empty, non-productive microcapsules can introduce different types of background (e.g., by-products from primers in scRNAseq applications, by-products from surrounding RNA present in all droplets), and background signals that can confound sequencing analysis can also be reduced by 10-fold by depleting empty, non-productive microcapsules.

[0116] Figures 13A and 13B illustrate enhancement over Poissonian cell barcoding using empty microcapsule depletion. Figure 13A illustrates barcoding of unsorted microcapsules. Microcapsules behave similarly to hydrogel beads in microfluidic channels, and loading of microcapsules into droplets can be synchronized with the droplet generation rate. As a result, one-to-one loading of barcoded particles and microcapsules can be achieved. However, encapsulation of cells into microcapsules is a random process governed by a Poisson distribution. A typical approach is to ensure that less than 5% of non-empty microcapsules have two or more cells (in other words, P(X>1) / P(X>0) is less than or equal to 5%; where X is the number of cells in the microcapsule). When operating under this approach, approximately 90% of microcapsules are typically empty, and therefore, 90% of barcoded droplets are non-productive. Figure 13B illustrates barcoding of sorted microcapsules.

[0117] Figures 14A and 14B compare non-limiting examples of methods involving pre-sorting based on the presence of a target nucleic acid sequence. For comparison, Figure 14A illustrates a strategy using cell fixation and permeabilization without the use of microcapsules. After fixing and permeabilizing the cells (1), a fluorescent probe complementary to the target sequence of interest is annealed, and unannealed probe is washed away (2). Fluorescent cells are then enriched for use with flow cytometry. Figure 14B illustrates a microcapsule-based method. After encapsulating the cells in microcapsules (1), the cells are lysed (2), and genetic material is optionally amplified (3), which is simultaneously translated into fluorescent signal amplification after probe annealing in the next step. A probe for the target sequence of interest is then annealed (4), and fluorescent microcapsules are selected for use with flow cytometry.

[0118] Barcoding methods based on core-shell microcapsules are particularly useful for single-cell microbial genome sequencing. While droplet-based, highly efficient single-cell RNA and DNA sequencing can be applied to animal cells, they have not generally been applied to single-microbial DNA or RNA sequencing. A technical limitation is the need to apply harsh lysis conditions (proteases, detergents, alkaline pH treatments), which preclude subsequent molecular biology steps in the same droplet. While several droplet-based single-microbial sequencing methods have been demonstrated, they rely on technically challenging, sophisticated droplet manipulations. In such manipulations, reagents are added via droplet fusion, which essentially limits the selection of lysis strategies that can be used. Alternatively, agarose hydrogel techniques have also been demonstrated and used in single-microbial sequencing methods. Microorganisms are embedded in agarose hydrogels, which enable multi-step processing by displacing existing buffers. However, when using hydrogel beads, more than half of the genomic material from a single bacterial cell is likely lost due to the bacteria being located close to the edge of the hydrogel during its formation. Also, the workflow generally relies on dispensing a single hydrogel into a multi-well plate, which requires specialized cell sorting equipment, making it more complicated and less efficient. Methods based on core-shell microcapsules allow, for example, the efficient retention of nucleic acids from a single microorganism within the microcapsules.

[0119] Thus, in certain aspects, there is provided a method for preparing a plurality of nucleic acids for sequencing, comprising: (a) generating a plurality of microcapsules containing biological entities, wherein the microcapsules are in an aqueous environment; the plurality of microcapsules contain, on average, no more than one biological entity per microcapsule; and each biological entity carries at least one nucleic acid molecule; (b) after part (a), contacting the intact microcapsules with releasing conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to nucleic acid processing conditions that produce processed nucleic acids in the intact microcapsules; and (d) after part (c), separating each intact microcapsule from the biological entities. (e) optionally, after or during part (d), exposing the droplets to microcapsule degradation conditions that release nucleic acids contained within the microcapsules into the interior of the droplets; and (f) after part (d) or after part (e), generating barcoded nucleic acids in the droplets by exposing the droplets to barcode polynucleotide incorporation conditions that bind the barcode polynucleotides to the nucleic acids in the droplets. In part (f), the barcode polynucleotide is sometimes bound to the nucleic acid in the microcapsules if part (e) is not performed before part (f), or the barcode polynucleotide is sometimes bound to the nucleic acid in the droplets if part (e) is performed before part (f).

[0120] In certain implementations, the method includes exposing the nucleic acid released from the biological entity after part (b) to nucleic acid processing conditions. Any suitable nucleic acid processing conditions can be used, and in certain examples, the nucleic acid processing conditions include exposing the nucleic acid to reverse transcription conditions and / or amplification conditions that generate nucleic acid amplicons. The nucleic acid processing conditions sometimes include exposing the nucleic acid to oligonucleotide probe annealing conditions that anneal one or more oligonucleotide probes to the nucleic acid.

[0121] Certain implementations include exposing the microcapsules to selection conditions prior to part (d) that select for microcapsules containing released and / or processed nucleic acids. Certain microcapsules may not contain processed nucleic acids because they were never loaded with a biological entity (i.e., they did not encapsulate a biological entity). Any suitable selection conditions can be used, and in certain implementations, the selection conditions may include (i) fluorescence-activated microcapsule sorting, in which the nucleic acids within the microcapsules are stained with a non-specific DNA dye or a sequence-specific probe, and the stained microcapsules can be sorted by flow cytometry techniques, and (ii) electrophoretic separation of microcapsules containing nucleic acids.

[0122] In certain implementations, (i) each microcapsule comprises a shell surrounding a core; (ii) each microcapsule comprises a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core; (iii) the microcapsule shell sometimes comprises a polysaccharide and is glycosidase degradable; (iv) the shell allows the passage of primers, enzymes, and assay reagents and prevents nucleic acids from escaping the microcapsule and being released from the biological entity; or (v) a combination of two or more of (i), (ii), (iii), and (iv). The microcapsules produced in part (a) are sometimes microcapsules described herein that comprise a core surrounded by a shell, where the shell is a hydrogel comprising a first polymer; the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; molecules of the cross-linking moiety of the first polymer are cross-linked in the hydrogel; and the core comprises a second polymer that does not comprise the cross-linking moiety of the first polymer and that comprises a polysaccharide that does not comprise a hydrophilic / hydrophobic modifying moiety.

[0123] In certain implementations, the plurality of microcapsules produced in part (a) includes microcapsules that do not contain a biological entity and microcapsules that contain a biological entity. Of the microcapsules that contain a biological entity, the majority of microcapsules generally contain a single biological entity. Of the total microcapsules in the population, sometimes about 1% to about 37% contain a single biological entity, and in certain instances, about 10% to about 30% contain a single biological entity. Of the microcapsules in the population that contain a biological entity, sometimes about 58% to about 99.5% of the microcapsules contain a single biological entity, and in certain instances, about 77% to about 95% of the microcapsules contain a single biological entity.

[0124] In certain examples, the barcode polynucleotide species bound to the nucleic acid in part (f) are from about 10 contiguous nucleotides to about 100 contiguous nucleotides in length, or from about 16 contiguous nucleotides to about 90 contiguous nucleotides in length. In certain implementations, part (f) is repeated any number of times until a predetermined number of barcode polynucleotide species are bound to the nucleic acid in the droplet. Part (f) is sometimes repeated about 1 to about 5 times, and part (f) is sometimes repeated about 1 to about 3 times. When part (f) is repeated, the barcode polynucleotide added each time is sometimes about 4 contiguous nucleotides to about 100 contiguous nucleotides in length, or about 6 contiguous nucleotides to about 18 contiguous nucleotides in length, or about 6 contiguous nucleotides to about 12 contiguous nucleotides in length. The final length of the barcode polynucleotide species attached to the nucleic acid after repeated barcode addition is sometimes about 10 contiguous nucleotides to about 100 contiguous nucleotides in length, or about 16 contiguous nucleotides to about 90 contiguous nucleotides in length.

[0125] Barcode polynucleotide binding conditions are sometimes the same as MIP binding conditions (i.e., ligation, primer extension by DNA or RNA polymerase, Gibson assembly, and / or template switching conditions). After single-step barcode polynucleotide addition, or after barcoding-addition iterations, each barcode polynucleotide species bound to a nucleic acid sometimes comprises a molecular identifier polynucleotide (MIP), and sometimes each barcode polynucleotide species bound to a nucleic acid comprises a polymerase chain reaction (PCR) adapter polynucleotide. Certain implementations include exposing the intact microcapsules to washing conditions after part (b). The washing conditions may include contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. The washing conditions sometimes include contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of the amplification conditions present in the microcapsules. In certain examples, the aqueous solution includes a buffer.

[0126] Certain implementations include tagging the nucleic acids in the intact microcapsules with a molecular beacon polynucleotide (MIP) after part (b), before part (c), and / or as part of part (c), where the MIP is sometimes from about 4 contiguous nucleotides to about 50 contiguous nucleotides in length. In certain examples, the method includes exposing the nucleic acid in the intact microcapsules to fragmentation conditions prior to, as part of, and / or after part (c). The fragmentation conditions sometimes result in nucleic acid fragments of from about 100 base pairs (bp) to about 100 kilobase pairs (kbp) in length, or from about 100 bp to about 10 kbp in length. The fragmentation conditions sometimes include exposing the nucleic acid in the intact microcapsules to a nuclease, a chemical agent that generates hydroxyl radicals, and / or ultrasound.

[0127] In certain implementations, the amplification conditions include contacting the intact microcapsules with a DNA polymerase, an RNA polymerase, or a combination thereof. In certain examples, the method includes exposing the nucleic acid released in part (b) to reverse transcription conditions. Reverse transcription conditions generally include contacting the nucleic acid with a reverse transcriptase enzyme. In certain implementations, part (e) is not performed and the method includes, after part (f), generating released barcoded nucleic acids by exposing the intact microcapsules to microcapsule-degrading conditions that release the barcoded nucleic acids. The microcapsule-degrading conditions often include a glycosidase, as described herein. In certain implementations, the microcapsules are hydrolyzed within the droplets, and the hydrolyzed microcapsule contents are released inside the droplets. In such implementations, the nucleic acid contents can be barcoded within the droplets. After barcoding, the droplets are combined and the nucleic acids can be processed, for example, for sequencing (e.g., subjected to library preparation), starting with purification (addressed later in this specification).

[0128] In certain implementations, the microcapsules are not hydrolyzed within the droplets and remain intact within the droplets. In such implementations, the encapsulated nucleic acids can be barcoded within the core of the microcapsules by barcoded oligonucleotides that freely diffuse through the shell. After barcoding, the droplets can be merged, and the microcapsules are then in the same suspension (e.g., aqueous suspension). The nucleic acids can then be processed, with or without release from the microcapsules (i.e., with or without microcapsule hydrolysis), for example, starting with purification (discussed later in this specification), followed by sequencing (e.g., library preparation).

[0129] In certain examples, the method includes producing a purified barcoded nucleic acid by exposing the barcoded nucleic acid to purification conditions. The purification conditions sometimes are or include a phase extraction purification process, such as, but not limited to, magnetic bead purification (e.g., AMPure purification) or spin column purification. When using magnetic bead purification, for example, 0.4x, 0.5x, 0.6x, 0.7x, 0.8x, 0.9x, or 1x AMPure XP bead purification may be selected. The purification conditions sometimes are or include a chemical purification process, such as, but not limited to, ethanol precipitation and / or phenol-chloroform extraction. In certain implementations, the method includes exposing the nucleic acid to library preparation conditions. The library preparation conditions sometimes include contacting the nucleic acid with an adaptor under adaptor incorporation conditions. In certain examples, the method includes sequencing the released barcoded nucleic acid and / or the purified barcoded nucleic acid.

[0130] In certain implementations, the droplet generation conditions include an inlet for the continuous phase; an inlet for the first aqueous fluid containing the first polymer; an inlet for the second aqueous fluid containing the second polymer; a microchannel where the first and second aqueous fluids mix; a flow focusing junction where the continuous phase meets the first aqueous fluid, or the second aqueous fluid, or the first and second aqueous fluids; a channel where droplet generation occurs; and a water-in-oil droplet collection outlet. In certain examples, the continuous phase is a carrier oil. The droplet generation conditions are sometimes provided in part by the fluidic device described herein.

[0131] kit In certain aspects, a kit is provided that includes a first polymer and a second polymer described herein. The kit may include any suitable number of separate containers, and in certain implementations, the first polymer and the second polymer are each in a separate container. The first polymer and the second polymer are each independently in a liquid or solid form (e.g., a hydrogel form, a dry powder). The kit may also include a microfluidic device. The kit may also include a carrier oil with or without a surfactant. The kit may also include additional reagents, such as one or more of a buffer-containing solution for washing (rinsing) the microcapsules, a cross-linking initiator for conjugating the cross-linking moieties in the first polymer, and a demulsifier (e.g., perfluorooctanol). The kit may also include additional consumables, such as microfluidic consumables such as tubing, syringes, needles, etc. The kit may or may not include additional devices, such as a light-emitting device for light illumination and initiation of conjugation of the cross-linking moieties in the first polymer. The kit may include one or more of RNA or DNA amplification enzymes (e.g., reverse transcriptases and polymerase chain reaction enzymes), nucleoside triphosphates or analogs thereof, primers, buffers, etc. The kit may include a molecular beacon polynucleotide (MIP) in any suitable form (e.g., dry, liquid, or substrate-bound). The kit may include a microcapsule degradation reagent, such as an enzyme that degrades the microcapsule shell, such as a glycosylase.

[0132] The kit may include instructions for carrying out a manufacturing process or method using the microcapsules described herein. The kit may include instructions for generating the microcapsules described herein (e.g., instructions for generating water-in-oil droplets containing a first polymer and a second polymer), or may include instructions for using the microcapsules to amplify contained nucleic acids. The instructions and / or specifications may be in tangible form (e.g., paper, etc.) or electronic form (e.g., a computer-readable file on a tangible medium (e.g., compact disc), etc.), and may be included in a kit insert. The kit may also include a written description of an internet location providing such instructions or specifications. Consistent with the above disclosure, the kits may include reagents for microcapsule assembly, microcapsule reagent release, sequential reactions performed on the contents of the microcapsules, ligation, barcoding, or other microcapsule reagents.

[0133] Thus, provided are kits comprising a first polymer and a second polymer, wherein the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety, and the second polymer comprises a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise a hydrophilic / hydrophobic modifying moiety. The kit may also include instructions for using the first polymer and the second polymer. The instructions are sometimes for producing microcapsules according to a process described herein, and sometimes for producing microcapsules in a composition described herein. The instructions are sometimes for using microcapsules according to a method described herein. In certain implementations, kits are provided that include reagents, and optionally microcapsules, for performing the methods described herein, and may include instructions for performing the methods described herein. Consistent with the disclosure herein, kits for the synthesis or use of any of the compositions disclosed herein or for performing any of the methods herein are included as part of this disclosure.

[0134] Drawing Overview Looking at the drawing, the following can be seen: Figure 1 shows a schematic of the microcapsule production and analysis workflow. Droplet production begins with the encapsulation of a core / shell polymer and a biological entity in an oil emulsion. The shell polymer accumulates at the edge of the droplet, while the core polymer mixture and the encapsulated biological entity, such as an analyte, accumulate in the center. Without being bound by theory, the shell and core polymer undergo liquid-liquid phase separation. In the oil carrier, the more hydrophobic shell polymer is attracted to the outside of the emulsion droplet. The droplets are then cross-linked, causing the shell polymer to form a shell hydrogel. The polymerized microparticles are redistributed into an aqueous solution, which facilitates the exchange of buffers and reagents, some of which are mutually incompatible, necessary for carrying out the various biological entity processing steps. After analyte processing, biocompatible release of the biological entity or analyte reaction products occurs without damage to the microcapsule contents, facilitating downstream analysis.

[0135] Figures 2A-E show diagrams depicting the microencapsulation of biological entities. Droplet formation begins with a mixture of core and shell polymers and the biological entity as aqueous droplets in oil, as seen in Figures 2A and 2B. Phase separation results in droplets composed of the core polymer mixture in oil and an outer shell polymer mixture encapsulating the biological entity in a population of droplets, as seen in Figure 2C. Polymerization of the shell polymer mixture forms an outer shell hydrogel, as seen in Figures 2D and 2E. Once the shell is polymerized, the microcapsules can be removed from their oil carrier and redistributed into an aqueous solution, for example, to facilitate the delivery and removal of reagents from the microcapsule core. Figure 2E shows a magnified view of the microcapsule, demonstrating the uniform shell thickness that facilitates reagent exchange.

[0136] In Figure 3, the chemical synthesis scheme for Dex-MAB can be seen. Methacryloyl (MA) and butyryl (B) are added to the dextran (Dex) scaffold in proportion to their initial concentrations. GMA - glycidyl methacrylate, GB - glycidyl butyrate. In FIG. 4, the HNMR analysis of the synthesis product of the synthetic route of FIG. 3 is seen.

[0137] Figure 5 shows a workflow facilitated by the microcapsule technology herein. Biological entities such as cells, organelles, virus particles, or other discrete units, or even free-floating nucleic acids, are compartmentalized. The sample then undergoes a series of processing steps, some of which may be mutually incompatible if performed simultaneously on the sample (e.g., lysis, DNase treatment, reverse transcription, ligation, and end-tagging). Individual nucleic acids are then ligated, carrying information about the common biological entity from which the co-ligated molecules originated upon release of the microcapsule contents into an aqueous environment. The ligated nucleic acid products are sequenced so that reads derived from single molecules can be correlated with the single biological entity from which they originated. This process relies on the ability to wash away mutually incompatible reagents and buffers to facilitate repeated reactions in a single microcapsule while retaining the nucleic acid of interest within the microcapsule core. The microcapsules undergo shell hydrolysis, and the released contents are subjected to library preparation and sequencing.

[0138] Figure 6 shows a split-and-pool workflow facilitated by the microcapsule technology herein. Biological entities such as cells, organelles, virus particles, or other discrete units, or even free-floating nucleic acids, are compartmentalized. The sample then undergoes a series of processing steps, including lysis, washing, nucleic acid processing, and split-and-pool barcoding of nucleic acids within SPCs. Importantly, nucleic acids can be amplified without losing compartmentalization prior to barcoding. Such amplification mitigates the inefficiencies of barcoding. This process relies on the ability to wash away mutually incompatible reagents and buffers to facilitate repeated reactions within a single microcapsule. The microcapsules undergo shell hydrolysis, and the released contents are subjected to library preparation and sequencing.

[0139] Figure 7 illustrates a model for the efficiency of the labeling process performed using the technology herein. Compartmentalized samples are subjected to 0–10 PCR cycles before barcoding with barcodes having addition efficiencies of 10–95%. This model assumes 100% PCR efficiency, i.e., input doubles with every cycle. After three rounds of addition, the percentage of unique transcripts irrecoverably lost was calculated. For highly efficient barcode addition, it is observed that most transcripts can be recovered even without PCR amplification before barcoding, as indicated by the low percentage of irrecoverably lost transcripts in the upper right corner of the figure. For less efficient barcode addition, a high barcoding success rate is achieved by performing a small number of PCR cycles before barcoding, as indicated by the low percentage of irrecoverably lost transcripts in the lower left corner of the figure. This figure demonstrates that the number of unique transcripts irrecoverably lost can be minimized for a wide range of barcode and PCR amplification regimens using the microcapsule technology disclosed herein.

[0140] Figures 8A and 8B show workflows for eukaryotic cell scRNAseq and microbial cell scDNAseq, respectively. Both workflows include a nucleic acid amplification step prior to barcoding. In Figure 8A, lysis and cleanup are followed by reverse transcription including UMI tagging, followed by PCR amplification, split-and-pool barcoding, library preparation, and sequencing. In Figure 8B, lysis and cleanup are followed by MDA amplification, fragmentation and / or debranching of MDA products, split-and-pool barcoding, library preparation including enrichment for complete barcodes, and sequencing. Both of these workflows, and variants of either workflow, rely on the ability to efficiently wash away or replace reaction conditions to perform repetitive reactions on a common microcapsule, as well as the ability to efficiently and gently release microcapsule contents to enable downstream sequencing.

[0141] Figures 9A and 9B present exemplary Illumina library configurations. SPASp5 and SPASp7 represent sequencing primer annealing at the p5 and p7 ends, respectively. For scDNAseq (Figure 9A), a traditional paired-end sequencing regimen is required, and Illumina indexing may be used. For scRNAseq (Figure 9B), one of the index reads (i7 read, 20 bases long) is used to reveal part of the cell barcode sequence. Figure 10 presents an exemplary barcoding step, nucleotide sequence, and reagents for scDNAseq applications. Barcoding must be performed using single-cell compartmentalization retained within the SPC. Library preparation steps downstream of barcoding can be performed as bulk reactions after release of the encapsulated nucleic acids from the SPC. Figure 11 presents an exemplary barcoding step, nucleotide sequence, and reagents for scRNAseq applications. Barcoding must be performed using single-cell compartments retained within the SPC. Library preparation steps downstream of barcoding can be performed as bulk reactions after release of the encapsulated nucleic acids from the SPC.

[0142] Figure 12 lists the sequence of steps for scRNAseq applications, including mutually incompatible steps, performed in some workflows disclosed herein or facilitated by the technology herein, including cell encapsulation, lysis, reverse transcription, cDNA enrichment PCR, proteinase K treatment, USER treatment, split-and-pool barcoding, library preparation, and sequencing, which in some cases are performed after biocompatible release of the microcapsule contents.

[0143] Figures 13A and 13B show the loading of SPCs and barcoded beads into compartments for barcoding of nucleic acids encapsulated in microcapsules / SPCs. Barcoded beads can be repeatedly removed and replaced to facilitate multiple rounds of barcoding and increase the microcapsule-specific uniqueness of the final nucleic acid barcoding pattern for a particular set of microcapsule contents. For single-cell sequencing applications, cells are encapsulated in SPCs using a typical microfluidic regimen, in which many SPCs are acellular and only a portion (typically less than 10%) of the SPCs need to contain cells to avoid multiple cells entering the same SPC. During barcoding in droplets containing barcoded beads, many droplets are non-productive because they contain empty SPCs (Figure 13A). This inefficiency can be overcome by pre-sorting SPCs containing the desired cells at every step between SPC generation and barcoding (Figure 13B).

[0144] Figures 14A and 14B show alternative approaches for nucleic acid detection. In Figure 14A, cells are permeabilized and subjected to nucleic acid detection. The signal is a function of the number of nucleic acid copies in the original cell. In Figure 14B, cells are compartmentalized, lysed, and subjected to nucleic acid amplification prior to detection, such that the nucleic acids available for detection and the subsequent signal are substantially amplified compared to the signal arising from the nucleic acid population of the original cell. This facilitates isolation of the intracellular contents of cells carrying the target nucleic acid.

[0145] Figures 15A and 15B show the protocol and results for determining microcapsule nucleic acid size retention for compositions DexMAB5-45 and DexMAB10-90. The results demonstrate that multiple compositions are suitable for microcapsule formation and that the nucleic acid size retention threshold can be modulated by selecting a suitable microcapsule shell composition. Figures 16 and 17 show microcapsule populations before and after dextranase treatment of the core polymer. The backbone polymer of the shell is Ficoll, which is resistant to dextranase. The hydrogel shell and microcapsule size are notably uniform for the population shown, but are approximately 15% smaller after treatment.

[0146] Figure 18 presents a workflow for preparing nucleic acids for sequencing. Cells are compartmentalized, lysed, washed, and processed from the readout, e.g., they undergo in-capsule sequencing library preparation, DNA labeling, or restriction endonuclease treatment. The microcapsules are then loaded onto a sequencing instrument, such as a flow cell, and the microcapsule contents are released onto the instrument. The position on the instrument can be used to reflect the microcapsule of origin. High-molecular-weight (HMW) DNA preparation for analysis benefits from the protection that microcapsules provide against mechanical fragmentation during handling. 19-20 illustrate exemplary workflows compatible with the technology herein, including those for ligation, barcoding, and sequencing and isolation of heavy and light chain amplicon concatemers.

[0147] Figure 21 presents a schematic diagram of long-read sequencing library preparation of concatemers formed within microcapsules. Cells are compartmentalized and lysed, subjected to targeted reverse transcription and BCR enrichment, followed by USER processing, ligation, and exonuclease treatment. Ligated molecules were subjected to MDA, T7 debranching, and then library preparation and nanopore sequencing. This workflow involves multiple mutually incompatible reaction steps that are efficiently performed due to the ability to wash away and replace the reaction environment within the microcapsules and efficiently recover reaction products for downstream processing, such as nanopore sequencing.

[0148] Figure 22 shows the workflow and specific nucleotide sequences for heavy and light chain ligation with USER treatment and addition of uracil bases to generate sticky ends for ligation. The ligated chains can then be sequenced to determine the heavy / light chain combination for a given cell of origin. In Figure 23, detection of MDA amplified nucleic acid is seen, as indicated by fluorescence in the DNA-containing microcapsules. Figure 24 presents the UMI / ligation workflow and the "1 UMI set = 1 cell" principle. Samples are compartmentalized in microcapsules, UMI-tagged, and subjected to amplification, ligation, SPC shell hydrolysis, library preparation, and sequencing. Reads sharing a common UMI are unambiguously assigned to a common microcapsule of origin.

[0149] Figure 25 presents a tagging workflow compatible with the technology herein. Microparticles containing cells or other nucleic acids are compartmentalized, lysed, washed, and subjected to amplification and UMI tagging of a target panel. The UMI-tagged amplicons are ligated, after which the microcapsules are hydrolyzed to release the contents, which undergo library preparation and then long-read sequencing. Figure 26 provides a schematic diagram of an exemplary workflow for target amplification, UMI tagging, and ligation. Multiple targets containing DNA of interest are amplified using a panel of primers for multiplex PCR (#1). The number of cycles ranges from 2 to 10. The resulting amplicons are tagged with UMIs (#2) using Gibson assembly and a duplex DNA oligonucleotide with a bridge-UMI-GSfw or bridge-UMI-GSrev structure (where "GSfw" and "GSrev" are PCR1 primer sequences, and "bridge" serves as an adapter for single-primer PCR2 (#3) and as an overlap sequence between amplicons that are ligated in the subsequent step (#4)). "GSfw" refers to the gene-specific forward primer, and "GSrev" refers to the gene-specific reverse primer.

[0150] Figures 27A-27B provide expected results based on two in silico simulations of the workflow described in Figures 24-26 and the "1 UMI set = 1 cell" principle. To enable successful graph-based demultiplexing of reads with shared UMIs, as shown in Figure 27A, the number of reads and / or concatemer length must be sufficient for the selected number of cells, genomic targets, and PCR1 amplification cycles. For example, increasing the number of PCR1 cycles from 5 (Figure 27A) to 10 (Figure 27B) while holding other parameters constant results in incomplete demultiplexing of the data and the presence of "orphan" reads that do not share a UMI with any other reads. Simulations similar to these can be used to determine in advance the sequencing depth required for the "1 UMI set = 1 cell" principle to work well and prevent "orphan" reads.

[0151] Figure 28 shows the workflow for USER-mediated ligation of bacterial amplicons. In Figure 29, a more detailed implementation of the workflow in Figure 28 is seen, resulting in targeted linkage of AmpR, 16S, and GFP loci from a single source. The choice of locus for amplification is arbitrary, as this approach can be used to link a wide number of target loci from a single source. Figure 30 shows the coverage for a sample of 100 reads identified as containing all three of the loci identified in Figure 29. This figure demonstrates that the expected concatemers of the desired order can be efficiently obtained using the approach elucidated in Figures 28 and 29.

[0152] Figure 31 shows the split-pool synthesis workflow for scDNAseq, including encapsulation and lysis, MDA, T7 debranching, and end preparation, split-and-pool labeling, followed by release, library preparation, and sequencing. This approach relies on the ability to efficiently interchange reagents and buffer conditions to perform mutually incompatible reactions on a common microcapsule volume. Figure 32 presents successful results obtained from using the techniques of Figures 8A, 11, and 12. This table is generated as part of the STARsolo pipeline for scRNAseq read mapping and demultiplexing. Figure 33 presents a graphical representation of the results from the techniques in Figures 8A, 11, and 12, demonstrating the ability to separate the results of reads in pooled sequencing reactions. Human gene counts are presented on the Y-axis, labeled from 0 to 1200 in intervals of 200, while mouse gene counts are presented on the X-axis, labeled from 0 to 4000 in intervals of 1000. Each dot represents a barcode, and therefore a cell. Cell barcodes containing both human and mouse counts are presented off-axis. Reads associated with a given barcode map exclusively to either the mouse or human genome, as indicated by their position on the X- or Y-axis, respectively. The few instances of mixed-breed mouse and human barcodes are shown in black and map close to the original, indicating their relative rarity.

[0153] Figure 34 presents another graphical representation of the success of the approach of Figures 8A, 11, and 12. The data is presented as a histogram of barcodes, where barcodes are binned by the fraction of reads that map to the human genome out of all reads that map to the combined human-mouse reference genome. Barcode counts are presented on the y-axis ranging from 0 to 3000 in intervals of 500, and the fraction of human counts is presented on the x-axis from 0 to 1. It can be seen that the majority of barcodes had either 0% or 100% human count reads.

[0154] Figure 35 presents another graphical representation of the success of the methods in Figures 8A, 11, and 12. An unbiased 2D representation of the high-dimensional scRNAseq data was obtained using UMAP (Uniform Manifold Approximation and Projection for Dimension Reduction). UMAP1 and UMAP2 are arbitrary axis names. Barcodes containing only human counts cluster in the upper right, while barcodes containing only mouse counts cluster in the lower left. No mixed barcodes are found in the data. FIG. 36 shows DNA stained images of microcapsule-encapsulated genomic amplified DNA and an intermediate control of the procedure of FIG. Figure 37 depicts the barcoding specificity for encapsulated nucleic acids of the approach in Figure 31. Nearly 94% of the reads mapped to high abundance, representing microcapsules containing cells.

[0155] Figure 38 presents results from a mixed-species experiment using the approach of Figure 31. E. coli read counts are shown on the y-axis, ranging from 0 to 600,000 in intervals of 100,000. B. subtilis read counts are shown on the x-axis, ranging from 0 to 400,000 in intervals of 100,000. In this plot, every dot is a barcode, and its position on the x- and y-axes depends on the number of reads carrying that barcode and their unique mapping to the B. subtilis or E. coli reference genome, respectively. The majority of barcodes are seen to have reads that are exclusively assigned to one or the other of the bacterial genomes. Off-axis mixed-species barcodes are relatively rare, indicating that cross-contamination of microcapsule-entrapped nucleic acids is not occurring and that the barcoding approach can efficiently map barcoded reads to their compartmentalized cells of origin.

[0156] Figure 39 shows the scattering of barcodes from the approach of Figure 31 on a plot of coverage percentage versus depth. Coverage is defined as the percentage of the reference genome that is encompassed at least once. Depth is defined as the average number of bases in the sequencing data per base in the reference genome. Coverage percentage is presented on the y-axis from 0 to 100% in 20% intervals. The x-axis presents coverage depth from 0 to 8. This graph shows that for both the E. coli and B. subtilis genomes, high coverage for a given depth is achieved using an approach previously proven to accurately sort these genomes by their microcapsule of origin (Figure 38). Figure 40 presents a workflow for efficient genome amplification and barcoding in droplets using barcoded beads, followed by whole genome or targeted sequencing.

[0157] Figures 41A-41E show experimental results from the application of the method detailed in Figure 40 for whole microbial genome sequencing. Figure 41A shows a single amplified genome (SAG) stained with a DNA-binding fluorescent dye (Cyto9). Figure 41B shows an electropherogram of fragmented SAG DNA before barcoding. Figure 41C shows co-encapsulation of fragmented SAG-containing microcapsules with barcoded beads. Barcoded beads were delivered through (i), ligation reagents through (ii), and microcapsules through (iii). Figure 41D shows an electropherogram of the final DNA library loaded onto an Illumina MiSeq sequencer. Figure 41E shows the number of reads mapping to the E. coli and B. subtilis genomes for each barcode. Microcapsules carrying E. coli and B. subtilis SAGs were mixed in approximately equal ratios before barcoding.

[0158] Figures 42A-42D show the results of bacterial lysis optimization. Dots in the scatter plots represent individual barcodes (e.g., cells). Breadth is defined as the percentage of the reference E. coli genome that is encompassed at least once. Depth is defined as the average number of bases in the sequencing data per base in the reference genome. Both units of measure were obtained from the BAM file after aligning the sequencing data to the E. coli reference genome using STARsolo. The solid line represents the maximum expected breadth for a given depth. The experimental procedure was as described below, with MDA performed for 1 hour and modifications to the lysis conditions. Figure 43 depicts the results as a bright field microscope image of the SPC suspension in aqueous buffer after polymerization. Formulation 4 was used (5% TEMED in the core phase, 5% APS in the shell phase; detailed in Example 11). Figure 44 shows the results of sonication on microcapsules. Some intact microcapsules and large debris are observed after sonication at 20% amplitude. The reaction products are available for downstream analysis.

[0159] Figure 45 shows the results of sonication on microcapsules. Intact microcapsules and no large debris are observed after sonication at 40% amplitude. The reaction products are available for downstream analysis. Figure 46 shows the results of sonication on microcapsules. Intact microcapsules and no small debris are observed after sonication at 80% amplitude. The reaction products are available for downstream analysis. Figure 47 presents an analysis of the effect of sonication on reaction products. Agarose gel electrophoresis showed that the MDA products within SPC were fragmented by sonication, with the level of fragmentation dependent on the sonication amplitude, with some full-length MDA products and a length distribution of 3000-800 base pair fragments observed after sonication at 20% amplitude (Figure 47, lane 1). A length distribution of 1200-700 base pair fragments was observed after sonication at 40% amplitude (Figure 47, lane 2). A length distribution of 800-600 base pair fragments was observed after sonication at 80% amplitude (Figure 47, lane 3). These results indicate that sonication can serve as a technique for fragmenting nucleic acids contained in microcapsules, with or without concomitant release of capsule contents, instead of enzymatic shell degradation.

[0160] Figure 48 shows successful microcapsule formation using methacryloyl-arabinoxylan (AxylMA10) as the shell polymer and under varying starting material composition. SPCs were formed using both dextran 500k (average molecular weight 500 kDa) and dextran 2M (average molecular weight 2 MDa) as the core polymer. The figure depicts bright-field microscopy images of SPCs based on AxylMA10 shells at several stages of their production using dextrans of two different average molecular weights as the core polymer. The scale bar is 200 μm. Figure 49 presents fluorescence microscopy images of SPCs with (left) or without (center and right) biotin modification of the shell. The center and right images are the same field of view at two different exposure times. FITC-avidin stains capsules with biotin-modified shells but not those without biotin modification.

[0161] Figure 50 shows fluorescence microscopy images of SPC with (left) and without (right) biotin modification of the shell stained with FITC-biotin via an avidin bridge. Capsules with biotinylated shells bind to FITC-biotin via an avidin bridge. Figure 51 presents the appearance and enzymatic dissolution of SPC with a shell based on 2-hydroxyethyl cellulose (HEC). The scale bar in the microscopic images is 100 μm. The figure shows that SPC can be formed using a shell based on methacryloyl-modified 2-hydroxyethyl cellulose. As can be seen on the right side of the figure, such SPC can be dissolved by enzymatic shell digestion with cellulase.

[0162] Figure 52 depicts a bright field microscopy image of an SPC formed using a shell polymer modified with acryloyl crosslinking moieties. The scale bar is 100 μm. The characteristic shell-core topology is observed. Figure 53 shows electrophoretic analysis of microcapsule content retention for two shell polymers. The ladder is a General 1 kb Plus DNA ladder. The Rg-dsDNA radius of gyration was calculated as described by Leonaviciene et al. As shown in Figure 53, dsDNA fragments of 300 bp or greater (radius of gyration approximately 25 nm) are retained within the SPC for the two shell polymers tested and cannot be removed from the SPC by washing. Visual evaluation of the agarose gel clearly suggests that the SPC shell based on the DexMAB545 polymer is permeable to 200 bp fragments (radius of gyration approximately 17 nm). By comparison, DexMAB1090 is less permeable, as the 200 bp fragment is better retained compared to DexMAB545.

[0163] Figure 54 presents bright-field microscopy images of SPC with shell patterns using 2-3 μm magnetic beads. Left: Capsules in 1x PBS immediately after the creation and disruption of the water-in-oil emulsion. Right: Capsules after 10 washes, including vigorous vortexing to remove beads from the shell. The depletion of the number of magnetic beads in the shell can be assessed after this procedure. Removal of particles from the shell results in pores or holes at least as large as the particles being removed. Figure 55 shows that SPCs can be generated using the DexMAC21090 polymer, which uses acetyl groups as the hydrophilic / hydrophobic modifying moiety.

[0164] Figure 56 shows the formation of an emulsion followed by the formation of capsules with diameters less than 20 μm. Figure 57 shows the formation of capsules with diameters less than 20 μm. Figure 58 shows the formation of emulsions followed by the formation of capsules with diameters greater than 100 μm. Figure 59 shows the formation of capsules with diameters greater than 100 μm. Figure 60 shows the formation of an emulsion according to triple co-flow aqueous phase encapsulation. Brightfield microscope images of core solutions 1 and 2 (top right and bottom right, respectively) are shown creating stable flows of the required ratio with the shell solution (far right). Particle encapsulation can be observed within the droplets (left).

[0165] Figure 61 presents a bright-field microscopy image montage of a single pre-SPC droplet traveling along a microfluidic channel immediately after formation in a triple parallel flow chip; note the four dark particles changing position. The vertical scale bar is 50 μm. The elapsed time is 25 ms from start to finish. Figure 62 shows a bright-field microscope image of an aqueous suspension of SPC produced using the triple parallel-flow chip. SPC with a diameter of approximately 54 μm is formed. Note that dark particles are embedded within the capsules. This indicates that the solution destined for the core of the two separated capsules (Figure 60) did not interfere with capsule formation. In this way, sample components can be efficiently separated prior to the capsule production step.

[0166] Figure 63 shows that SPCs are successfully formed when various dextrans with average molecular weights ranging from 10 kDa to 2 MDa are used as core polymers. A characteristic shell-core topology is observed. Figure 64 shows that SPCs are successfully formed when using a blend of two shell-forming polymers, DexMAB1090 and DexAB50100. A characteristic shell-core topology is observed. Numbered Embodiments The present disclosure is further elucidated by the following enumeration of numbered embodiments, where some numbered embodiments refer to previous embodiments, and does not exclude a numbered embodiment from being dependent on another or multiple other embodiments, such that any numbered embodiment herein is intended to be dependent on any other numbered embodiment herein. A partial list of numbered embodiments includes:

[0167] 1. A process for producing a composition comprising a plurality of microcapsules, comprising: (a) a first polymer comprising dextran (i) modified with conjugated methacryloyl cross-linking moieties and (ii) modified with conjugated butyryl moieties; a second polymer comprising dextran not modified with conjugated methacryloyl cross-linking moieties and not modified with conjugated butyryl moieties; a first aqueous solution and / or a second aqueous solution comprising a biological entity; and a monodisperse oil solution containing the first polymer, the second polymer, and the biological entity. A process comprising: emulsifying (i) a first aqueous solution comprising a first polymer and (ii) a second aqueous solution comprising a second polymer in oil in a droplet generating device, wherein aqueous droplets are generated; an aqueous two-phase system is formed within the water-in-oil droplets in which the liquid core is completely surrounded by a liquid shell and the biological species is preferentially distributed in the liquid core; and (b) forming a hydrogel shell surrounding the core in a plurality of microcapsules by exposing the microcapsules to crosslinking conditions that conjugate at least a portion of the methacryloyl moieties in the first polymer. A1. A composition comprising a plurality of microcapsules, each comprising a core surrounded by a shell, wherein the shell is a hydrogel comprising a first polymer; the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; molecules of the cross-linking moiety of the first polymer are cross-linked in the hydrogel; and the core comprises a second polymer comprising a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise a hydrophilic / hydrophobic modifying moiety. A1.1. The composition of embodiment A1, wherein the microcapsules or portions thereof are glycosidase-degradable. A2. The composition of embodiment A1 or A1.1, wherein the first polymer is the majority component of the shell and the second polymer is the majority component of the core. A3. The composition of embodiment A1, A1.1, or A2, wherein the first polymer and the second polymer comprise different polysaccharides. A4. The composition of embodiment A1, A1.1, or A2, wherein the first polymer and the second polymer comprise the same polysaccharide.A5. The composition of any one of embodiments A1-A4, wherein the polysaccharide of the first polymer, or the first polymer and the second polymer, is a neutrally charged, non-ionic polysaccharide. A6. The composition of embodiment A5, wherein the polysaccharide comprises monomers linked by glycosidic bonds. A7. The composition of embodiment A6, wherein the polysaccharide is a glucan. A8. The composition of embodiment A6 or A7, wherein the polysaccharide comprises pentose and / or hexose monomers. A9. The composition of embodiment A6 or A7, wherein the polysaccharide comprises glucose and / or fructose monomers. A10. The composition of any one of embodiments A5-A9, wherein the polysaccharide is naturally occurring. A10.1. The composition of embodiment A10, wherein the polysaccharide is selected from dextran and cellulose. A10.2. The composition of embodiment A10, wherein the polysaccharide is dextran. A11. The composition of any one of embodiments A5-A9, wherein the polysaccharide is not naturally occurring. A11.1. The composition of embodiment A11, wherein the polysaccharide is Ficoll. A12. The composition of any one of embodiments A5 to A11.1, wherein the polysaccharide has a molecular mass of about 5,000 g / mol to about 50,000,000 g / mol. A13. The composition of embodiment A12, wherein the polysaccharide has a molecular mass of about 50,000 g / mol to about 2,000,000 g / mol. A14. The composition of embodiment A13, wherein the polysaccharide has a molecular mass of about 500,000 g / mol. A15. The composition of any one of embodiments A1 to A14, wherein the first polymer comprises one type of cross-linking moiety. A16. The composition of embodiment A15, wherein the first polymer comprises two or more types of cross-linking moieties. A17. The composition of any one of embodiments A1 to A16, wherein the one or more cross-linking moieties are selected from photoactivated, chemically activated, or thermally activated cross-linking moieties. A18. The composition of any one of embodiments A1-A17, wherein one or more bridging moieties are independently selected from an acryloyl group or a substituted acryloyl group. A19. The composition of embodiment A18, wherein one or more bridging moieties are independently selected from acryloyl, or methacryloyl, or acryloyl and methacryloyl. A20. The composition of any one of embodiments A1-A19, wherein the second polymer does not comprise a bridging moiety.A21. The composition of any one of embodiments A1-A20, wherein the second polymer is not crosslinked. A22. The composition of any one of embodiments A1-A21, wherein the first polymer comprises a hydrophilic / hydrophobic modifying moiety. A23. The composition of embodiment A22, wherein the hydrophilic / hydrophobic modifying moiety modifies the water solubility of the first polymer. A24. The composition of embodiment A22 or A23, wherein the first polymer comprises one type of hydrophilic / hydrophobic modifying moiety. A25. The composition of embodiment A24, wherein the first polymer comprises two or more types of hydrophilic / hydrophobic modifying moieties. A26. The composition of any one of embodiments A22-A25, wherein the hydrophilic / hydrophobic modifying moiety comprises a fatty acyl group. A27. The composition of embodiment A26, wherein the fatty acid is a C2-C8 fatty acid. A28. The composition of embodiment A27, wherein the hydrophilic / hydrophobic modifying moiety comprises a butyryl group. A29. The composition of any one of embodiments A1-A28, wherein the second polymer does not comprise a hydrophilic / hydrophobic modifying moiety that modifies the first polymer. A30. The composition of any one of embodiments A1-A20, wherein a crosslinking moiety, or a hydrophilic / hydrophobic modifying moiety, or a crosslinking moiety and a hydrophilic / hydrophobic modifying moiety are covalently attached to the polymer backbone of the first polymer. A31. The composition of any one of embodiments A1-A30, wherein the first polymer backbone comprises a monomer, and the molar ratio of (i) the crosslinking moiety to (ii) the first polymer monomer is from about 0.01 to about 2.0. A31.1. The composition of any one of embodiments A1-A31, wherein the first polymer backbone comprises a monomer, and the molar ratio of (i) the crosslinking moiety to (ii) the first polymer monomer is about 0.01 or greater. The composition of any one of embodiments A1-A31, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) crosslinking moiety to (ii) first polymer monomer is about 0.20 or less. A31.3 The composition of any one of embodiments A1-A31, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) crosslinking moiety to (ii) first polymer monomer is about 0.01 to about 0.20. A32 The composition of any one of embodiments A22-A31.3, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) hydrophilic / hydrophobic modifying moiety to (ii) first polymer monomer is about 0.05 to about 1.0.A32.1 The composition of any one of embodiments A22-A31.3, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) hydrophilic / hydrophobic modifiers to (ii) first polymer monomer is about 0.10 or greater. A32.2 The composition of any one of embodiments A22-A31.3, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) hydrophilic / hydrophobic modifiers to (ii) first polymer monomer is about 0.80 or less. A32.3 The composition of any one of embodiments A22-A31.3, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) hydrophilic / hydrophobic modifiers to (ii) first polymer monomer is about 0.20 to about 0.80. A32.4. The composition of any one of embodiments A22-A31.3, wherein the first polymer backbone comprises a monomer and the molar ratio of (i) the hydrophilic / hydrophobic modifying moiety to (ii) the first polymer monomer is from about 0.25 to about 0.65. A33. The composition of any one of embodiments A1-A32.4, wherein the polysaccharide of the first polymer is modified with a bridging moiety and a hydrophilic / hydrophobic modifying moiety, wherein the bridging moiety is methacryloyl and the hydrophilic / hydrophobic modifying moiety is butyryl. A34. The composition of any one of embodiments A1-A33, wherein the first polymer comprises a detectable label. A34.1. The composition of embodiment A34, wherein the detectable label comprises a fluorophore or a dye. A35. The composition of any one of embodiments A1-A34.1, wherein the first polymer comprises a binding partner moiety to which a binding partner counterpart moiety can be bound. A36. The composition of embodiment A35, wherein the binding partner moiety is biotin and the binding partner counterpart moiety is avidin, or the binding partner counterpart moiety is biotin and the binding partner moiety is avidin. A37. The composition of any one of embodiments A33-A36, wherein the detectable label and / or binding partner moiety is covalently attached to the first polymer backbone. A38. The composition of any one of embodiments A1-A37, wherein the microcapsules remain intact for 2 hours or more at 37°C in the pH range of about 2 to about 12.A39. The composition of any one of embodiments A1-A38, wherein the microcapsules remain intact under polymerase chain reaction thermal cycling conditions. A40. The composition of any one of embodiments A1-A39, wherein the microcapsules are microspheroids. A41. The composition of embodiment A40, wherein the microcapsules are defined by a diameter of from about 1 micrometer to about 10,000 micrometers. A42. The composition of embodiment A41, wherein the diameter is from about 10 micrometers to about 100 micrometers. A43. The composition of any one of embodiments A40-A42, wherein the diameter of the microcapsules varies by a coefficient of variation of about 30% or less. A44. The composition of any one of embodiments A1-A43, wherein the circularity of the microcapsules in the composition is from about 0.8 to about 1.0. A45. The composition of any one of embodiments A1-A44, wherein the concentricity of the microcapsules in the composition is about 75% or greater. A46. The composition of any one of embodiments A1 to A45, wherein the microcapsule shell comprises pores of about 0.1 nanometers to about 500 nanometers. A47. The composition of any one of embodiments A1 to A46, wherein the microcapsule shell comprises pores of about 10 nanometers to about 50 nanometers. A48. The composition of any one of embodiments A1 to A47, wherein the microcapsule shell comprises pores, and the microcapsules retain nucleic acids of about 100 base pairs or more in size. A49. The composition of any one of embodiments A1 to A48, wherein the microcapsule shell comprises pores, and the microcapsules retain nucleic acids of about 500 base pairs or more in size. A50. The composition of any one of embodiments A1 to A49, wherein the microcapsule shell comprises pores, and the microcapsules retain nucleic acids of about 1,000 base pairs or more in size. A51. The composition of any one of embodiments A1 to A50, wherein the microcapsules or portions thereof are glycosidase degradable at a pH of about 3 to about 11 and at a temperature of about 80°C or less. A52. The composition of any one of embodiments A1-A51, wherein the microcapsules or portions thereof are glycosidase degradable at a pH of about 6 to about 8 and at a temperature of about 40°C or less. A53. The composition of any one of embodiments A1-A52, wherein the glycosidase is selected from dextranase and cellulase. A54. The composition of any one of embodiments A1-A53, provided that the microcapsules do not contain an intermediate layer between the shell and the core. A55. The composition of any one of embodiments A1-A53, provided that there is no intermediate layer between the shell and the core, the intermediate layer containing a polymer different from the first polymer and the second polymer. A56. The composition of any one of embodiments A1-A53, wherein the polymer of the microcapsule consists of the first polymer and the second polymer. A57. The composition of any one of embodiments A1-A53, wherein there is no layer on the outside of the microcapsule shell. A58. The composition of any one of embodiments A1 to A53, wherein the microcapsules are lipid-free and organic solvent-free. A59. The composition of any one of embodiments A1 to A58, wherein the composition is a liquid composition. A60. The composition of embodiment A59, wherein the composition is an aqueous liquid composition.A61. The composition of any one of embodiments A1-A58, wherein the composition is a solid composition. A62. The composition of embodiment A61, wherein the solid comprises a hydrogel. A63. The composition of any one of embodiments A1-A62, comprising a biological entity encapsulated within a microcapsule core. A64. The composition of embodiment A63, wherein the biological entity is selected from eukaryotic cells, prokaryotic cells, unicellular organisms, multicellular organisms, microorganisms, bacteria, archaea, fungi, plants, viruses, organelles, liposome vectors, extracellular vesicles, nucleic acids, proteins, organic molecules, and biomolecules. A65. A method comprising contacting a composition of any one of embodiments A1-A64 with a glycosidase under enzymatic microcapsule degradation conditions. A66. The method of embodiment A65, wherein the glycosidase is capable of enzymatically degrading the polysaccharide in the first polymer and the polysaccharide in the second polymer. A67. The method of embodiment A66, wherein the polysaccharide in the first polymer is the same as the polysaccharide in the second polymer. A68. The method of any one of embodiments A65-A67, wherein at least the shells of the majority of the microcapsules are enzymatically degraded by a glycosidase. A69. The method of any one of embodiments A65-A68, wherein the enzymatic microcapsule degradation conditions are a pH of about 3 to about 11 and a temperature of about 80°C or less. A70. The method of any one of embodiments A65-A68, wherein the enzymatic microcapsule degradation conditions are a pH of about 6 to about 8 and a temperature of about 40°C or less. A71. The method of any one of embodiments A65-A70, wherein the glycosidase is dextranase. A72. The method of any one of embodiments A65-A70, wherein the glycosidase is cellulase. A73. A method comprising exposing the composition of any one of embodiments A1-A64 to washing conditions that reduce the concentration of and / or remove components encapsulated in the microcapsules. A74. The method of embodiment A73, wherein the microcapsules contain nucleic acids; and after the microcapsules are exposed to nucleic acid processing conditions, the microcapsules are exposed to washing conditions.A75. The method of embodiment A74, wherein the nucleic acid processing conditions are selected from one or more of cell lysis conditions, nucleic acid fragmentation conditions, reverse transcription conditions, ligation conditions, MIP incorporation conditions, amplification conditions, barcode incorporation conditions, and sequencing adapter incorporation conditions. B1. A process for producing a composition comprising a plurality of microcapsules, the process comprising: (a) emulsifying in a droplet generating device (i) a first aqueous solution comprising a first polymer and (ii) a second aqueous solution comprising a second polymer in oil, wherein the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety; the second polymer comprises a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise the hydrophilic / hydrophobic modifying moiety; the first aqueous solution and / or the second aqueous solution comprises a biological entity; monodisperse water-in-oil droplets are generated containing the first polymer, the second polymer, and the biological entity; an aqueous two-phase system is formed within the water-in-oil droplets in which the liquid core is completely surrounded by the liquid shell and the biological species is preferentially distributed in the liquid core; and (b) exposing the microcapsules to cross-linking conditions that conjugate the cross-linking moieties in the first polymer, thereby forming a hydrogel shell surrounding the core in the plurality of microcapsules. B2. The process of embodiment B1, wherein the contacting in (a) comprises contacting the first and second aqueous solutions with a third aqueous solution, and the third aqueous solution is contained in a water-in-oil droplet. B3. The process of embodiment B2, wherein the first aqueous solution, the second aqueous solution, the third aqueous solution, or a combination thereof independently comprises a reagent and / or a biological entity. B4. The process of embodiment B3, wherein the reagent is selected from a buffer, a nucleotide, a detection agent, an amino acid, an enzyme, a ligase, a polymerase, a transposase, and an antibody. B5. The process of embodiment B3 or B4, wherein the biological entity is selected from one or more of a eukaryotic cell, a prokaryotic cell, a unicellular organism, a multicellular organism, a microorganism, a bacterium, an archaea, a fungus, a plant, a virus, an organelle, a liposome vector, an extracellular vesicle, a nucleic acid, a protein, an organic molecule, and a biomolecule.B6. The process of any one of embodiments B1-B5, wherein the water-in-oil droplets are generated by a microfluidic device. B7. The process of embodiment B6, wherein the microfluidic device comprises a capillary assembly. B8. The process of embodiment B6 or B7, wherein the microfluidic device is a microfluidic chip. B9. The process of any one of embodiments B6-B8, wherein the microfluidic device comprises a channel having a cross-sectional width of from about 20 micrometers to about 100 micrometers. B10. The process of any one of embodiments B1-B9, wherein the water-in-oil droplets are generated by injecting a first aqueous solution, a second aqueous solution, optionally a third aqueous solution, and an oil through a flow focusing junction. B11. The process of any one of embodiments B1-B10, wherein the oil comprises a surfactant. B12. The process of embodiment B11, wherein the carrier oil comprises a fluorinated fluid and a fluorosurfactant. B13. The process of any one of embodiments B1-B12, wherein the water-in-oil droplets are collected in the form of an emulsion. B14. The process of embodiment B13, wherein the emulsion is collected outside the microfluidic device. B15. The process of any one of embodiments B1-B14, comprising separating the microcapsules from the oil into the aqueous solution after part (a) or after part (b). B16. The process of embodiment B15, wherein separating comprises demulsifying. B17. The process of embodiment B16, comprising contacting the water-in-oil droplets with perfluorooctanol. B18. The process of any one of embodiments B1-B17, wherein the first polymer is the majority component of the shell and the second polymer is the majority component of the core.B19. A process for producing a composition comprising a plurality of microcapsules, the process comprising: (a) contacting (i) a first aqueous solution comprising the first polymer, (ii) a second aqueous solution comprising the second polymer, and (iii) oil under droplet-forming conditions such that: (a) a first polymer comprises a polysaccharide modified with conjugated cross-linking moieties and optionally modified with hydrophilic / hydrophobic modifying moieties; and (b) cross-linking the cross-linking moieties in the first polymer to form a hydrogel shell surrounding the core in a plurality of microcapsules encapsulating a biological entity; and (c) disrupting the water-in-oil droplets, releasing the microcapsules encapsulating the biological entity into an aqueous solution. B20. The process of any one of embodiments B1-B19, provided that the water-in-oil droplets and microcapsules are not atomized. B21. A composition comprising a plurality of microcapsules, obtainable by the process of any one of embodiments B1-B20. B22. The composition of any one of embodiments A1-A64, obtainable by the process of any one of embodiments B1-B20. C1. A method for preparing a plurality of nucleic acids for sequencing, the method comprising: (a) generating a plurality of microcapsules containing biological entities, wherein the microcapsules are suspended in an aqueous environment; each biological entity containing at least one nucleic acid molecule; (b) after part (a), contacting the intact microcapsules with release conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to nucleic acid amplification conditions that generate amplicons corresponding to target portions of the released nucleic acids in the intact microcapsules; and (d) after part (c), generating one or more concatemers within certain intact microcapsules by exposing the intact microcapsules to ligation conditions that join the plurality of amplicons end-to-end within the intact microcapsules.C1.1 The method of embodiment C1, wherein the microcapsules comprise a shell surrounding a core. C1.2 The method of embodiment C1 or C1.1, wherein the microcapsules comprise a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core, respectively. C1.3 The method of embodiment C1.2, wherein the microcapsule shell comprises a polysaccharide and is glycosidase-degradable. C1.4 The shell allows passage of primers, enzymes, and assay reagents and prevents nucleic acids from escaping the microcapsule and being released from the biological entity. The method of any one of embodiments C1.1, C1.2, or C1.3. C1.5. The method of any one of embodiments C1, C1.1, C1.2, C1.3, and C1.4, wherein the plurality of microcapsules includes microcapsules that do not contain a biological entity and microcapsules that contain a biological entity; and of the microcapsules that contain a biological entity, a majority of the microcapsules contain a single biological entity. C2. The method of any one of embodiments C1, C1.1, C1.2, C1.3, C1.4, and C1.5, comprising, after part (d), exposing the intact microcapsules to microcapsule-disrupting conditions that release concatemers from the microcapsules. C3. The method of any one of embodiments C1, C1.1, C1.2, C1.3, C1.4, C1.5, and C2, wherein parts (b), (c), and (d) are carried out in a single vessel, or parts (b), (c), (d) and the release in embodiment C2 are carried out in a single vessel. C4. The method of any one of embodiments C1-C3, comprising placing the microcapsules or portions thereof into a sequencing device and then releasing the concatemers from the microcapsules in the sequencing device. C5. The method of any one of embodiments C1-C3, comprising releasing the concatemers from the microcapsules and then placing the concatemers or portions thereof, or processed products thereof, into a sequencing device. C5.1. The method of embodiment C4 or C5, comprising contacting the nucleic acid with library preparation conditions. C5.2. The method of embodiment C5, wherein the library preparation conditions comprise contacting the nucleic acid with an adaptor under adaptor incorporation conditions. C5.3. The method of embodiment C5.2, wherein the adaptor comprises a tether, motor, or hairpin. C6. The method of any one of embodiments C4-C5.3, comprising sequencing the concatemers. C7. The method of embodiment C6, wherein sequencing generates reads greater than 1,000 base pairs in length, each read corresponding to a nucleic acid derived from a single biological entity.C8. The method of any one of embodiments C1-C7, comprising amplifying and / or reverse transcribing nucleic acids released from the biological entities in the intact microcapsules after part (b) and before part (c). C9. The method of any one of embodiments C1-C8, comprising tagging the nucleic acids released in part (b) or tagging nucleic acids amplified and / or reverse transcribed from the nucleic acids released in part (b) before part (c) with MIPs derived from a plurality of different MIPs, wherein the concatemers in one microcapsule comprise a set of MIPs that differs from the set of MIPs in the other microcapsules. C9.1. The method of any one of embodiments C1-C8, wherein the amplification conditions of part (c) incorporate MIPs derived from a plurality of different MIPs into each amplicon, wherein the amplicon in one microcapsule comprises a set of MIPs that differs from the set of MIPs in the other microcapsules. C9.2. The method of embodiment C9 or C9.1, wherein sequencing generates reads that each contain one or more MIPs and a portion of the genome sequence, and individual reads that share one or more MIPs are attributed to a single biological entity. C10. The method of any one of embodiments C1-C9.2, wherein the biological entities in the plurality of microcapsules are from a group of no more than about 10 million biological entities. C11. The method of any one of embodiments C1-C10, wherein the biological entities in the microcapsules are independently selected from eukaryotic cells, prokaryotic cells, unicellular organisms, multicellular organisms, microorganisms, algae, protozoa, bacteria, archaea, fungi, plants, viruses, organelles, liposomal vectors, and extracellular vesicles. C12. The method of embodiment C11, wherein the organelle is a mitochondria or chloroplast. C13. The method of embodiment C11, wherein the biological entity is an antibody-producing cell and the nucleic acid targeting moieties released into the intact microcapsules in part (c) are heavy chain variable (VH) domain and light chain variable (VL) domain targeting moieties. C13.1. The method of embodiment C13, wherein the antibody-producing cell is a B cell or a hybridoma. C14. The method of embodiment C11, wherein the biological entity is a prokaryotic cell.C15. The method of embodiment C14, wherein the prokaryotic cell is a Gram-positive bacterium, a Gram-negative bacterium, or an Archaea. C16. The method of embodiment C11, wherein the biological entity is a yeast cell. C17. The method of any one of embodiments C1 to C16, comprising, after part (b), exposing the intact microcapsules to washing conditions. C17.1. The method of embodiment C17, wherein the washing conditions comprise contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. C18. The method of embodiment C17.1, wherein the washing conditions comprise contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of the amplification conditions present in the microcapsules. C19. The method of embodiment C17.1 or C18, wherein the aqueous solution comprises a buffer. C20. The method of any one of embodiments C1-C19, comprising, after part (b) and before part (c), purifying one or more of: (i) the nucleic acid released into the intact microcapsules, (ii) the nucleic acid amplified before part (c), and (iii) the amplicon produced in part (c). C21. The method of any one of embodiments C1-C20, wherein the amplification conditions or other amplification of part (c) comprise contacting the nucleic acid in the microcapsules with a DNA polymerase, an RNA polymerase, a reverse transcriptase, or a combination thereof. C22. The method of any one of embodiments C1-C21, wherein the microcapsule is a microcapsule of any one of embodiments A1-A64, B21, and B22. C23. The method of any one of embodiments C1-C22, with the proviso that particles comprising barcode nucleic acids are not contacted with the microcapsules. C24. The method of any one of embodiments C1-C23, with the proviso that the biological entity and the nucleic acid of the biological entity are not immobilized on a solid support or in a matrix and are not contacted with a barcode polynucleotide. C25. The method of any one of embodiments C1-C24, with the proviso that the nucleic acid is not exposed to precipitation conditions that produce precipitated nucleic acids. C26. The method of embodiment C25, with the proviso that the nucleic acid is not exposed to rehydration conditions that rehydrate precipitated nucleic acids.D1. A method for preparing a plurality of nucleic acids for sequencing, comprising: (a) generating a plurality of microcapsules containing biological entities, wherein the microcapsules are in an aqueous environment; the plurality of microcapsules contain, on average, no more than one biological entity per microcapsule; and each biological entity carries at least one nucleic acid molecule; (b) after part (a), contacting the intact microcapsules with release conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to amplification conditions that generate nucleic acid amplicons in the intact microcapsules; (d) after part (c), (i) amplifying the nucleic acid amplicons in each compartment to produce at least one nucleic acid molecule. (ii) exposing the intact microcapsules in each compartment to barcode polynucleotide binding conditions that cause the barcode polynucleotide species bound to the nucleic acid in each microcapsule in a particular compartment to bind to the nucleic acid in the microcapsules, such that the barcode polynucleotide species bound to the nucleic acid in each microcapsule in the particular compartment differs from the barcode polynucleotide species bound to the nucleic acid in microcapsules in the other compartments; and (iii) pooling the intact microcapsules from the compartments; and repeating (e) and (d) at least once to produce barcoded nucleic acids in the intact microcapsules. D2. The method of embodiment D1, wherein the microcapsules comprise a shell surrounding a core. D3. The method of embodiment D1 or D2, wherein the microcapsules each comprise a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core. D3.1. The method of embodiment D3, wherein the microcapsule shell comprises a polysaccharide and is glycosidase degradable. D4. The method of embodiment D2, D3 or D3.1, wherein the shell allows passage of primers, enzymes and assay reagents and prevents nucleic acids from escaping the microcapsules and being released from the biological entity.D5. The method of any one of embodiments D1-D4, wherein the plurality of microcapsules includes microcapsules that do not contain a biological entity and microcapsules that contain a biological entity; and of the microcapsules that contain a biological entity, a majority of the microcapsules contain a single biological entity. D6. The method of any one of embodiments D1-D5, wherein part (d) is repeated several times in part (e) until a predetermined number of barcode polynucleotide species are bound to nucleic acids in the microcapsules. D7. The method of any one of embodiments D1-D6, comprising exposing the intact microcapsules to wash conditions after part (b). D8. The method of embodiment D7, wherein the wash conditions comprise contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. D9. The method of embodiment D7, wherein the wash conditions comprise contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of amplification and / or reverse transcription present in the microcapsules. D10. The method of embodiment D7 or D8, wherein the aqueous solution comprises a buffer. D11. The method of any one of embodiments D1-D10, wherein after part (b) but before part (c), the nucleic acid in the intact microcapsules is tagged with a molecular beacon polynucleotide (MIP). D11.1. The method of embodiment D11, wherein the MIP is from about 4 contiguous nucleotides to about 50 contiguous nucleotides in length. D12. The method of any one of embodiments D1-D11.1, wherein before part (c) or after part (c), the nucleic acid in the intact microcapsules is exposed to fragmentation conditions. D13. The method of embodiment D13, wherein the fragmentation conditions result in nucleic acid fragments from about 100 base pairs (bp) to about 100 kilobase pairs (kbp) in length. D14. The method of embodiment D13, wherein the fragments are from about 100 bp to about 10 kbp in length. D15. The method of any one of embodiments D12-D14, wherein the fragmentation conditions comprise exposing the nucleic acid in the intact microcapsules to a nuclease, a chemical agent that generates hydroxyl radicals, and / or ultrasound.D16. The method of any one of embodiments D1-D15, wherein the amplification conditions comprise contacting the intact microcapsules with a DNA polymerase, an RNA polymerase, or a combination thereof. D16.1. The method of any one of embodiments D1-D16, comprising exposing the nucleic acids released in part (b) to reverse transcription conditions prior to part (c). D16.2. The method of embodiment D16.1, wherein the reverse transcription conditions comprise contacting the nucleic acids with a reverse transcriptase. D17. The method of any one of embodiments D1-D16.2, wherein the microcapsules in part (d) are dispensed into wells of a plate. D18. The method of embodiment D17, wherein the plate is a 96-well plate or a 384-well plate. D19. The method of embodiment D17 or D18, wherein each well contains a different barcode polynucleotide. D20. The barcode polynucleotide in each well is. The method of any one of embodiments D17-D19, wherein the barcode polynucleotides in each well are from about 4 contiguous nucleotides to about 100 contiguous nucleotides in length. D21. The method of any one of embodiments D17-D19, wherein the barcode polynucleotides in each well are from about 6 contiguous nucleotides to about 18 contiguous nucleotides in length. D22. The method of any one of embodiments D1-D21, wherein each barcode polynucleotide comprises a molecular identifier polynucleotide (MIP). D23. The method of any one of embodiments D1-D22, wherein each barcode polynucleotide comprises a polymerase chain reaction (PCR) adapter polynucleotide. D24. The method of any one of embodiments D1-D23, comprising, after part (e), generating released barcoded nucleic acids by exposing intact microcapsules to microcapsule degradation conditions that release the barcoded nucleic acids. D25. The method of embodiment D24, wherein the microcapsule degradation conditions comprise a glycosidase. D26. The method of embodiment D24 or D25, wherein the released barcoded nucleic acids are exposed to purification conditions to produce purified barcoded nucleic acids. D27. The method of any one of embodiments D1-D26, comprising contacting the nucleic acids with library preparation conditions. D28. The method of embodiment D27, wherein the library preparation conditions comprise contacting the nucleic acids with adapters under adapter incorporation conditions. D29. The method of any one of embodiments D24-D28, comprising sequencing the released barcoded nucleic acids and / or purified barcoded nucleic acids. D30. The method of any one of embodiments D1-D29, provided that in part (d), the nucleic acids encapsulated by the microcapsules are not immobilized. D31. The method of any one of embodiments D1-D30, wherein the microcapsules are those of any one of embodiments A1-A64, B21 and B22.E1. A method for preparing a plurality of nucleic acids for sequencing, comprising: (a) generating a plurality of microcapsules containing biological entities, wherein the microcapsules are in an aqueous environment; the plurality of microcapsules contain, on average, no more than one biological entity per microcapsule; and each biological entity carries at least one nucleic acid molecule; (b) after part (a), contacting the intact microcapsules with releasing conditions that release nucleic acids from the biological entities within the intact microcapsules; (c) after part (b), exposing the intact microcapsules to nucleic acid processing conditions that produce processed nucleic acids in the intact microcapsules; (d) after part (c), (e) optionally, after or during part (d), exposing the droplets to microcapsule degradation conditions that release nucleic acids contained within the microcapsules into the interior of the droplets; and (f) after part (d) or after part (e), generating barcoded nucleic acids in the droplets by exposing the droplets to barcode polynucleotide incorporation conditions that bind the barcode polynucleotides to the nucleic acids in the droplets. E1.1. The method of embodiment E1, comprising exposing the nucleic acid released from the biological entity after part (b) to nucleic acid processing conditions. E2. The method of embodiment E1 or E1.1, wherein the nucleic acid processing conditions comprise exposing the nucleic acid to reverse transcription conditions and / or amplification conditions that generate amplicons of the nucleic acid. E3. The method of embodiment E1, E1.1 or E2, wherein the nucleic acid processing conditions comprise exposing the nucleic acid to oligonucleotide probe annealing conditions that anneal one or more oligonucleotide probes to the nucleic acid. E4. The method of any one of embodiments E1-E3, comprising, prior to part (d), exposing the microcapsules to selection conditions that select for microcapsules containing released and / or processed nucleic acid.E5. The method of any one of embodiments E1-E4, wherein the microcapsules comprise a shell surrounding a core. E6. The method of any one of embodiments E1-E5, wherein the microcapsules each comprise a cross-linked, porous, semi-permeable shell surrounding a liquid or semi-liquid core. E6.1. The method of embodiment E6, wherein the microcapsule shell comprises a polysaccharide and is glycosidase degradable. E7. The method of embodiment E5, E6, or E6.1, wherein the shell allows passage of primers, enzymes, and assay reagents and prevents nucleic acids from escaping the microcapsule and being released from the biological entity. E8. The method of any one of embodiments E1-E7, wherein the plurality of microcapsules comprises microcapsules that do not contain a biological entity and microcapsules that contain a biological entity; and of the microcapsules that contain a biological entity, a majority of the microcapsules contain a single biological entity. E9. The method of any one of embodiments E1-E8, wherein in part (f), the barcode polynucleotide species bound to the nucleic acid is from about 10 contiguous nucleotides to about 100 contiguous nucleotides in length. E9.1. The method of embodiment E9, wherein in part (f), the barcode polynucleotide species bound to the nucleic acid are from about 16 contiguous nucleotides to about 90 contiguous nucleotides in length. E9.2. The method of any one of embodiments E1-E8, wherein part (f) is repeated a number of times until a predetermined number of barcode polynucleotide species are bound to the nucleic acid in the droplet. E9.3. The method of embodiment E9.2, wherein part (f) is repeated from about 1 to about 5 times. E9.4. The method of embodiment E9.3, wherein part (f) is repeated from about 1 to about 3 times. E9.5. The method of any one of embodiments E9.2-E9.4, wherein the total length of the barcode polynucleotide species bound to the nucleic acid is from about 10 contiguous nucleotides to about 100 contiguous nucleotides in length. E9.6. The method of embodiment E9.5, wherein the total length of the barcode polynucleotide species bound to the nucleic acid is from about 16 contiguous nucleotides to about 90 contiguous nucleotides in length. E10. The method of any one of embodiments E1 to E9.6, comprising, after part (b), exposing the intact microcapsules to washing conditions.E11. The method of embodiment E10, wherein the washing conditions comprise contacting the intact microcapsules with an aqueous solution that alters the internal composition of the microcapsules. E12. The method of embodiment E10, wherein the washing conditions comprise contacting the intact microcapsules with an aqueous solution that removes or reduces the amount of inhibitors of amplification and / or reverse transcription present in the microcapsules. E13. The method of embodiment E11 or E12, wherein the aqueous solution comprises a buffer. E14. The method of any one of embodiments E1-E13, wherein after part (b), before part (c), and / or as part of part (c), the nucleic acids in the intact microcapsules are tagged with a molecular beacon polynucleotide (MIP). E14.1. The method of embodiment E14, wherein the MIP is from about 4 contiguous nucleotides to about 50 contiguous nucleotides in length. E15. The method of any one of embodiments E1-E14.1, wherein the nucleic acid in the intact microcapsules is exposed to fragmentation conditions prior to, as part of, and / or after part (c). E16. The method of embodiment E15, wherein the fragmentation conditions result in nucleic acid fragments of from about 100 base pairs (bp) to about 100 kilobase pairs (kbp) in length. E17. The method of embodiment E16, wherein the fragments are from about 100 bp to about 10 kbp in length. E18. The method of any one of embodiments E15-E17, wherein the fragmentation conditions comprise exposing the nucleic acid in the intact microcapsules to a nuclease, a chemical agent that generates hydroxyl radicals, and / or ultrasound. E19. The method of any one of embodiments E2-E18, wherein the amplification conditions comprise contacting the intact microcapsules with a DNA polymerase, an RNA polymerase, or a combination thereof. The method of any one of embodiments E1-E19, wherein the nucleic acid processing conditions comprise exposing the nucleic acid released in part (b) to reverse transcription conditions. E19.2. The method of embodiment E19.1, wherein the reverse transcription conditions comprise contacting the nucleic acid with a reverse transcriptase. E20. The method of any one of embodiments E1-E19.2, wherein each barcode polynucleotide is from about 10 contiguous nucleotides to about 100 contiguous nucleotides in length.The method of embodiment E20, wherein each barcode polynucleotide is between about 16 contiguous nucleotides and about 90 contiguous nucleotides in length. E22. Each barcode polynucleotide comprises a molecular identifier polynucleotide (MIP). The method of any one of embodiments E1-E21. E23. The method of any one of embodiments E1-E22, wherein each barcode polynucleotide comprises a polymerase chain reaction (PCR) adapter polynucleotide. E24. The method of any one of embodiments E1-E23, wherein part (e) is not performed and, after part (f), comprises generating released barcoded nucleic acids by exposing the intact microcapsules to microcapsule degradation conditions that release the barcoded nucleic acids. E25. The method of any one of embodiments E1-E24, wherein the microcapsule degradation conditions comprise contacting the microcapsules with a glycosidase. E26. The method of any one of embodiments E1-E25, comprising separating the barcoded nucleic acids from the droplets. E27. The method of embodiment E26, comprising generating purified barcoded nucleic acids by exposing the barcoded nucleic acids to purification conditions. E28. The method of any one of embodiments D1-D27, comprising contacting the nucleic acids with library preparation conditions. E29. The method of embodiment E28, wherein the library preparation conditions comprise contacting the nucleic acid with an adaptor under adaptor incorporation conditions. E30. The method of any one of embodiments E26-E29, comprising sequencing the barcoded nucleic acid and / or purified barcoded nucleic acid. E31. The method of any one of embodiments E1-E30, wherein the microcapsules are microcapsules of any one of embodiments A1-A64, B21 and B22. E32. The method of any one of embodiments E1-E31, wherein the droplet generation conditions comprise an inlet for a continuous phase; an inlet for a first aqueous fluid comprising a first polymer; an inlet for a second aqueous fluid comprising a second polymer; a microchannel where the first and second aqueous fluids mix; a flow focusing junction where the continuous phase meets the first aqueous fluid, or the second aqueous fluid, or the first and second aqueous fluids; a channel where droplet generation occurs; and a water-in-oil droplet collection outlet. E33. The method of embodiment E32, wherein the continuous phase is a carrier oil.F1. A kit comprising a first polymer and a second polymer, wherein the first polymer comprises a polysaccharide modified with a conjugated cross-linking moiety, optionally modified with a conjugated hydrophilic / hydrophobic modifying moiety, and the second polymer comprises a polysaccharide that does not comprise the cross-linking moiety of the first polymer and does not comprise a hydrophilic / hydrophobic modifying moiety. F2. The kit of embodiment F1, comprising instructions for using the first polymer and the second polymer. F3. The kit of embodiment F2, wherein the instructions are for producing microcapsules according to the process of any one of embodiments B1-B22. F4. The kit of embodiment F2 or F3, wherein the instructions are for producing microcapsules in the composition of any one of embodiments A1-A64. F5. The kit of any one of embodiments F2-F4, wherein the instructions are for using microcapsules according to the method of any one of embodiments A65-A75, C1-C26, D1-D31, or E1-E33. F6. A kit comprising reagents for carrying out the method of any one of embodiments A65-A75, C1-C26, D1-D31, or E1-E33, and optionally microcapsules. F7. A kit of embodiment F6, comprising instructions for carrying out the method of any one of embodiments A65-A75, C1-C26, D1-D31, or E1-E33. Amendments to any preceding embodiment, such as suggested embodiments: 1. A method for carrying out a multi-step reaction, comprising containing a substrate in a microcapsule; contacting the substrate with a first reagent in the microcapsule to carry out a first reaction step; displacing the first reagent with a second reagent in the microcapsule to carry out a second reaction step; and releasing the reacted substrate from the microcapsules. 2. The method of any preceding embodiment, such as embodiment 1, wherein the substrate comprises a biomaterial. 3. The method of any preceding embodiment, such as embodiment 1, wherein the substrate comprises cells. 4. The method of any preceding embodiment, such as embodiment 1, wherein the substrate comprises cellular contents. 5. The method of any preceding embodiment, such as embodiment 1, wherein the substrate comprises a protein. 6. The method of any preceding embodiment, such as embodiment 1, wherein the substrate comprises a nucleic acid.7. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a hydrophilic shell. 8. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a porous shell. 9. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise an aqueous core. 10. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a degradable shell. 11. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a polymer. 12. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a carbohydrate. 13. The method of any of the preceding embodiments, such as embodiment 1, wherein the microcapsules comprise a polysaccharide. 14. The method of any of the preceding embodiments, such as embodiment 13, wherein the polysaccharide is cross-linked. 15. The method of any of the preceding embodiments, such as embodiment 10, wherein the degradable shell is enzymatically degradable. 16. The method of any of the preceding embodiments, such as embodiment 10, wherein the degradable shell is degradable under biological conditions. 17. The method of any preceding embodiment, such as embodiment 16, wherein the biological conditions comprise at least one of a temperature in the range of 4°C to 65°C, a pH in the range of 5 to 9, or 6 to 8, or 3 to 11. 18. The method of any preceding embodiment, such as embodiment 1, wherein the first reagent comprises a cell lysis reagent. 19. The method of any preceding embodiment, such as embodiment 1, wherein the first reagent comprises a protein denaturant. 20. The method of any preceding embodiment, such as embodiment 1, wherein the first reagent disrupts protein secondary structure. 21. The method of any preceding embodiment, such as embodiment 1, wherein the first reagent comprises a reverse transcriptase. 22. The method of any preceding embodiment, such as embodiment 1, wherein the second reagent comprises a reverse transcriptase. 23. The method of any preceding embodiment, such as embodiment 1, wherein the second reagent comprises a DNA polymerase. 24. The second reagent comprises a nucleic acid oligomer. The method of any preceding embodiment, such as embodiment 1. 25. The method of any preceding embodiment, such as embodiment 1, wherein the second reagent comprises a ligase. 26. The method of any preceding embodiment, such as embodiment 1, wherein the second reagent comprises an antibody. 27. The method of any preceding embodiment, such as embodiment 1, wherein the first reaction step and the second reaction step are incompatible. 28. The method of any preceding embodiment, such as embodiment 27, wherein the conditions required for the first reaction step do not include the performance of the second reaction step. 29. The method of any preceding embodiment, such as embodiment 1, wherein the replacement does not change the microcapsule volume. 30. The method of any preceding embodiment, such as embodiment 9, wherein the replacement does not change the microcapsule volume. 31. The method of any preceding embodiment, such as embodiment 1, wherein the replacement comprises washing the microcapsules under conditions such that the first reagent diffuses out of the microcapsules. 32. The method of any preceding embodiment, such as embodiment 1, wherein the replacement comprises washing the microcapsules under conditions such that the second reagent diffuses into the microcapsules. 33. The method of any preceding embodiment, such as embodiment 1, wherein the releasing of the reacted substrate comprises melting the microcapsules. 34. The method of any preceding embodiment, such as embodiment 1, wherein the releasing of the reacted substrate comprises dissolving the microcapsules. 35. The method of any preceding embodiment, such as embodiment 1, wherein the releasing of the reacted substrate comprises enzymatically digesting the microcapsules. 36. The method of any preceding embodiment, such as embodiment 1, comprising performing a sequencing reaction using the reacted substrate as a template following the release. 37. The method of any preceding embodiment, such as embodiment 1, comprising incubating the reacted substrate. 38. The method of any preceding embodiment, such as embodiment 1, comprising performing any one or more of lysis, protease treatment, DNase treatment, RNase treatment, reverse transcription, ligation, USER uracil degradation, barcoding, ligation, antibody binding, or any other suitable reaction described herein or contemplated in the art for nucleic acid, protein, or other analyte reactions.39. A method for producing a population of microcapsules having a uniform minimum wall thickness, comprising: providing a mixture of monomers, wherein the mixture comprises a hydrophilic monomer and a hydrophobic monomer; suspending an emulsion of droplets of the mixture in a hydrophobic carrier; and polymerizing the hydrophobic monomer. 40. The method of any preceding embodiment, such as embodiment 39, wherein the mixture of monomers comprises a hydrophilic monomer and a hydrophobic monomer sharing a common monomer core structure. 41. The method of any preceding embodiment, such as embodiment 40, wherein the common monomer core structure comprises a sugar. 42. The method of any preceding embodiment, such as embodiment 40, wherein the hydrophobic monomer comprises a conjugated cross-linking moiety. 43. The method of any preceding embodiment, such as embodiment 40, wherein the hydrophobic monomer comprises a conjugated hydrophilic / hydrophobic modifying moiety. 44. The method of any preceding embodiment, such as embodiment 39, wherein the hydrophobic monomer comprises a hydrophobic modification to the hydrophilic monomer core structure. 45. The method of any preceding embodiment, such as embodiment 39, wherein polymerization of the hydrophobic monomer comprises cross-linking. 46. ​​The method of any preceding embodiment, such as embodiment 39, producing a population with at least 50% concentricity. 47. The method of any preceding embodiment, such as embodiment 39, producing a population with at least 60% concentricity. 48. The method of any preceding embodiment, such as embodiment 39, producing a population with at least 75% concentricity. 49. The method of any preceding embodiment, such as embodiment 39, producing a population with at least 90% concentricity. 50. The method of any preceding embodiment, such as embodiment 39, producing a population with a circularity of at least 0.8. 51. The method of any preceding embodiment, such as embodiment 39, producing a population with a circularity of at least 0.9. 52. The method of any preceding embodiment, such as embodiment 39, producing a population with a diameter of between 10 micrometers and 100 micrometers. 53. The method of any preceding embodiment, such as embodiment 39, producing a population with a diameter of between 1 micrometers and 1000 micrometers.54. The method of any preceding embodiment, such as embodiment 39, producing a population having diameters that vary by a coefficient of variation of 30% or less. 55. A method of modulating microcapsule porosity, comprising modulating microcapsule precursor component concentrations. 56. The method of any preceding embodiment, such as embodiment 55, comprising selecting a polymer with desired porosity characteristics, or introducing and removing microparticles of desired pore size, or altering the surface chemistry to provide a charge that affects the porosity of the microcapsule, particularly for charged sets of particles, such as a negative charge to reduce porosity for negatively charged molecules such as nucleic acids. 57. The method of any preceding embodiment, such as embodiment 55, wherein the microcapsule shell comprises pores of about 0.1 nanometers to about 500 nanometers. 58. The method of any preceding embodiment, such as embodiment 55, wherein the microcapsule shell comprises pores of about 10 nanometers to about 50 nanometers. 59. The method of any preceding embodiment, such as embodiment 55, wherein the microcapsule shell comprises pores, and the microcapsules retain nucleic acids of a size of about 100 base pairs or greater. 60. The method of any preceding embodiment, such as embodiment 55, wherein the shell of the microcapsule comprises pores, and the microcapsules retain nucleic acids of about 500 base pairs or greater in size. 61. The method of any preceding embodiment, such as embodiment 55, wherein the shell of the microcapsule comprises pores, and the microcapsules retain nucleic acids of about 1,000 base pairs or greater in size. 62. A method of labeling a nucleic acid population, comprising encapsulating a nucleic acid population in microcapsules; amplifying the nucleic acid population; contacting the nucleic acid population with a first barcode under conditions that allow binding of copies of the first barcode to the nucleic acid population; removing unbound copies of the first barcode from the microcapsules; contacting the nucleic acid population with a second barcode under conditions that allow binding of copies of the second barcode to the nucleic acid population; and releasing the nucleic acid population from the microcapsules. 63. The method of any preceding embodiment, such as embodiment 62, wherein the nucleic acid population comprises nucleic acid transcripts. 64. The method of any preceding embodiment, such as embodiment 62, wherein the nucleic acid population comprises cDNA molecules.65. The method of any preceding embodiment, such as embodiment 62, wherein the population of nucleic acids comprises genomic nucleic acid molecules. 66. The method of any preceding embodiment, such as embodiment 64, wherein the cDNA molecules are reverse transcribed from mRNA templates within the microcapsules. 67. The method of any preceding embodiment, such as embodiment 62, wherein the microcapsules are subjected to cell lysis conditions prior to amplification. 68. The method of any preceding embodiment, such as embodiment 62, wherein the microcapsules are subjected to reverse transcription conditions prior to amplification. 69. The method of any preceding embodiment, such as embodiment 62, wherein the microcapsules are subjected to DNase conditions prior to amplification. 70. The method of any preceding embodiment, such as embodiment 62, wherein the microcapsules are subjected to RNase conditions prior to amplification. 71. The method of any preceding embodiment, such as embodiment 62, wherein the amplification comprises at least one PCR cycle. 72. The method of any preceding embodiment, such as embodiment 62, wherein the amplification comprises at least two PCR cycles. 73. The method of any preceding embodiment, such as embodiment 62, wherein the amplification comprises at least three PCR cycles. 74. The method of any preceding embodiment, such as embodiment 62, wherein the amplification comprises at least 5 PCR cycles. 75. The method of any preceding embodiment, such as embodiment 62, wherein the amplification comprises at least 10 PCR cycles. 76. The method of any preceding embodiment, such as embodiment 62, wherein the conditions allowing binding comprise ligation conditions. 77. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit an efficiency of single barcode addition of at least 10%. 78. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit an efficiency of single barcode addition of at least 50%. 79. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit an efficiency of single barcode addition of at least 60%. 80. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit an efficiency of single barcode addition of at least 70%. 81. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit an efficiency of single barcode addition of at least 80%.82. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit a single barcode addition efficiency of at least 90%. 83. The method of any preceding embodiment, such as embodiment 76, wherein the conditions exhibit a single barcode addition efficiency of at least 95%. 84. The method of any preceding embodiment, such as embodiment 62, wherein the nucleic acid population is tagged with both the first barcode and the second barcode with at least a 50% success rate. 85. The method of any preceding embodiment, such as embodiment 62, wherein the nucleic acid population is tagged with both the first barcode and the second barcode with at least a 90% success rate. 86. The method of any preceding embodiment, such as embodiment 62, wherein the nucleic acid population is tagged with both the first barcode and the second barcode with at least a 99% success rate.

[0168] The present disclosure is further elucidated by the following additional numbered embodiments: 1. A method for performing a series of reactions in a fixed microfluidic volume, the method comprising: encapsulating the microfluidic volume in a droplet; performing a first reaction in the fixed microfluidic volume using a first reagent; exchanging the first reagent for a second reagent; and performing a second reaction in the fixed microfluidic volume using the second reagent. 2. The method of embodiment 1, wherein the droplet comprises a semi-permeable shell. 3. The method of embodiment 2, wherein exchanging the first reagent for the second reagent comprises transporting the first reagent and the second reagent through the semi-permeable shell. 4. A method for performing a series of reactions in a droplet without diluting the droplet, the method comprising: performing a first reaction in the droplet; exchanging the first reagent for a second reagent; and performing a second reaction in the droplet using the second reagent. 5. The method of embodiment 4, wherein exchanging the first reagent for the second reagent comprises removing a substantial portion of the first reagent. 6. The method of embodiment 4 or 5, wherein the addition of the second reagent does not involve diluting the droplet. 7. The method of embodiment 4 or 5, wherein the addition of the second reagent does not involve substantially changing the volume of the droplet. [Example]

[0169] The present disclosure is further elucidated by the examples provided below. The examples illustrate the breadth of the scope of the present disclosure and the possession of the disclosure herein. The elements of the examples are expanded in accordance with the scope of the present disclosure in demonstrating the increased breadth of implementation. They are further limited to some, but not all, embodiments of the above disclosure and the entire disclosure.

[0170] Example 1 Dextran modification with butyryl and methacryloyl moieties This example describes the chemical synthesis of dextran modified with methacryloyl and butyryl moieties (DexMAB) for use as a shell-forming polymer in microcapsules (Figure 1A). DexMAB and dextran form an aqueous two-phase system (ATPS) required for microcapsule formation. The methacryloyl moieties allow for controlled shell polymerization after encapsulation and before release of the microcapsules from the continuous oil phase. Without being bound by theory, both the methacryloyl and butyryl moieties are expected to contribute to the formation of the ATPS by altering the solubility of the modified dextran compared to the unmodified dextran used as the core phase. The level of substitution is defined as the molar ratio of the modifying moiety to glucose units (Figure 3). For example, DexMAB-10-90 means that during the reaction setup, the concentrations of glycidyl methacrylate (GMA) and R-(-)-glycidyl butyrate (GB) were such that a ratio of methacryloyl:glucose units of 0.1 (or 10%) and a ratio of butyryl:glucose units of 0.9 (or 90%) were achieved. Since there are three hydroxyl groups that can be modified per glucose unit, the maximum total degree of substitution, given this definition, is 300%.

[0171] As a specific example, the synthesis of DexMAB-10-90 is described. HNMR analysis of the product indicated actual degrees of substitution of 6% and 57% with methacryloyl and butyryl moieties, respectively ( FIG. 4 ). Other degrees of substitution can be achieved by varying the molar equivalents of GB and GMA. FIGS. 3 and 4 illustrate dextran substitution with butyryl and methacryloyl moieties. Figure 3 shows the expected dextran substitution products under alkaline conditions. See, e.g., van Dijk-Wolthuis et al., Macromolecules 30(11):3411-3 (1997); and Reis et al., J. Organic Chemistry 74(10):3750-7 (2009). Figure 4 shows the H NMR spectrum of DexMAB.

[0172] Table 1 below lists the materials used for the synthesis of methacryloyl and butyryl substituted dextrans. [Table 1]

[0173] DMSO was placed in a round-bottom flask equipped with a magnetic stirrer and sparged with argon for 10 minutes. Dextran 500K was dissolved in 1-gram portions in DMSO. Once dissolved, DMAP was added to the reaction mixture, sparged with argon for 10 minutes, and mixed until dissolved. In a separate vial, GMA and GB were mixed with twice the volume of DMSO in the ratio specified in Table 1, and the mixture was transferred to the main reaction mixture. The mixture was then capped with a glass stopper and allowed to stir for 48 hours. The reaction was quenched with equimolar 1 M HCl relative to the base to neutralize the DMAP. The reaction mixture was then dialyzed against deionized water for 3 days, with the water replaced every 3–4 hours during the working period. After dialysis, the product was lyophilized to yield a highly electrostatically stable white or slightly yellowish powder. The product was analyzed by NMR to determine the observed degree of substitution.

[0174] The H-NMR analysis involved the following steps: a) Spectra were zoomed from 0 to 10 ppm and ±5000 arbitrary intensity units. b) The spectrum was aligned with the residual water signal and assigned to 4.79 ppm when recorded in D2O. c) Proton integral S of the anomer in the range of 4.9-5.05 ppm 4.9-5.05 was normalized to 1 to represent 100% of the sample (1H). d) Proton integral of the methacryloyl moiety S 6.26 and S 5.77 were calculated to be 6.26 ppm and 5.77 ppm, respectively. e) Methyl group integral of methacryloyl moiety S 1.94 was calculated at 1.94 ppm (3H). f) As a sanity check, 6.26 :S 5.77 :S 1.94 However, it was confirmed that the ratio was equal to 1:1:3. g) End group integral S of the butyryl moiety 0.92 was calculated at 0.92 ppm (3H). h) Degree of substitution with methacryloyl moiety (DS MA ) to DS MA =S 1.94 * (1 / S 4.9-5.05 ) * It was calculated as (1 / 3). i) Degree of substitution with butyryl moiety (DS Bu ) to DS Bu =S 0.92 * (1 / S 4.9-5.05 ) * It was calculated as (1 / 3).

[0175] Example 2 Microcapsule generation This example describes the microfluidic generation of microcapsules of various diameters, from 42 to 88 μm, in 1x PBS. The generation of smaller and larger microcapsules is described in separate examples. The selection of flow rate and channel geometry dictates the microcapsule size achieved. For example, the generation of microcapsules with a radius of approximately 42 μm is detailed. Table 2 summarizes the results of testing 15 different combinations of microfluidic chip geometries and reagent injection flow rates. The specific shell and core polymers used in this example are DexMAB-10-90 and dextran (MW 500k), but the experimental steps are the same for different polymer combinations.

[0176] Figures 2A-2E illustrate the generation of microcapsules. Figure 2A is a schematic diagram of the microfluidic device used for microcapsule generation, along with inlets for specific core solutions, shell solutions, and droplet-stabilizing oils. Figure 2B is a photograph of the droplet generation process, highlighting the region of the microfluidic chip designated by the dashed rectangle in Figure 2A. The arrows indicate the direction of flow. Figure 2C is a photograph of the resulting water-in-oil emulsion. Figure 2D is a photograph of the same microcapsules shown in Figure 2C after transfer into 1x PBS. Figure 2E is a close-up of an 85-micrometer diameter microcapsule with a clearly visible shell and core. Table 2 below is a size chart for microcapsules based on the DexMAB-10-90 shell polymer. The "Chip" column provides the catalog number of the microfluidic chip at Droplet Genomics. Microcapsule diameters are given in water-in-oil emulsion and aqueous buffer (1x PBS). Depending on the aqueous buffer used, the microcapsules swell to varying degrees compared to the diameter of the droplets before breaking the emulsion.

[0177] [Table 2]

[0178] Table 3 below provides information on the materials used. [Table 3]

[0179] The shell solution (10% w / w DexMAB-10-90, 0.2% w / w LAP, 1x PBS) and core solution (10% w / w Dextran 500K, 1x PBS) were co-encapsulated using a parallel flow microfluidic device (20 micrometer height, 20 micrometer nozzle) (Figures 2A and 2B) on a syringe pump-based instrument (Droplet Genomics, Onyx). The flow rates for the shell solution, core solution, and droplet-stabilizing oil (DSO) were 35, 35, and 350 μl / h, respectively. The resulting emulsion was collected in a 1.5 ml tube for 30 min, after which it was exposed to 405 nm light for 30 s (Droplet Genomics, catalog no. DG-BRD-405). Microscopic images of the water-in-oil emulsion were taken for diameter measurements (Figure 2C, Table 2). Next, excess DSO was removed from the bottom of the tube, and 300 μl of 1× PBS containing 0.1% Pluronic-F68 and 300 μl of 20% v / v PFO in HFE7500 were added to break the emulsion. The resulting aqueous upper layer containing the microcapsules was transferred to a fresh tube and then washed three times in 1× PBS containing 0.1% Pluronic-F68. Washing consisted of concentrating the microcapsules at the bottom of the tube by centrifugation at 1000 g for 1 minute, followed by removal of the supernatant and addition of fresh buffer. Microscopic images of the microcapsules in 1× PBS loaded into a hemocytometer were taken for diameter measurements (Figures 2D and 2E, Table 2).

[0180] Example 3 Assessment of shell permeability by polymerase chain reaction (PCR) This example describes a procedure for determining the minimum PCR amplicon size retained by a given microcapsule shell polymer. Two polymer compositions, DEXMAB-5-45 and DEXMAB-10-90, were evaluated. For these shell polymers, the minimum amplicon sizes robustly retained within the microcapsules were determined from microscopic images: 1000 bp and 500 bp, respectively. Figures 15A and 15B show the experimental procedure for determining the retained amplicon size within the microcapsules. Figure 15A shows a schematic diagram of the evaluation. Bacterial cells were encapsulated in microcapsules so that there was an average of one cell or less per microcapsule (1). After lysis and washing (2), the same microcapsule suspension was distributed into six PCR reactions (3). Each PCR produced an amplicon of a different, defined size. Figure 15B provides imaging results showing the microcapsules after PCR. Rows represent two different shell polymers. Each column represents a different amplicon size. The microcapsules were approximately 50 μm in diameter. The same imaging conditions (microscope, magnification, illumination, exposure time) were used for all images in a given row. Dashed rectangles highlight images showing amplicon retention. The retention thresholds were 1000 bp and 500 bp for DexMAB-5-45 and DexMAB-10-90, respectively. Amplicon sizes smaller than the retention threshold resulted in a significant increase in the fraction of fluorescent microcapsules. By selecting polymeric reagents, among other things, for microcapsule synthesis, one skilled in the art can modulate the porosity of the microcapsules. It can be seen that DexMAB-10-90 exhibited autofluorescence in the green channel.

[0181] In addition to the list of materials for microcapsule production provided in Example 2, the reagents listed in Table 4 were used. [Table 4]

[0182] E. coli cells were encapsulated into microcapsules so that there was an average of less than one cell per microcapsule. The shell solution consisted of 10% w / w DexMAB-5-45 or DexMAB-10-90; 0.2% w / v lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) (Sigma-Aldrich, 900889-1G); and 1x PBS. The core solution consisted of 10% w / w Dextran 500k, 1x PBS, and E. coli cells. Microcapsules were produced on a microfluidic chip with a 40-μm-high and 40-μm-wide nozzle using flow rates of 50, 50, and 300 μl / h for the core solution, shell solution, and droplet-stabilizing oil, respectively.

[0183] The collected emulsion was exposed to 405 nm light for 30 seconds to induce shell polymerization. 300 μl of wash buffer (10 mM Tris-HCl (pH 7.5), 0.1% Triton X-100) and 300 μl of 20% PFO in HFE7500 were added per 100 μl of emulsion to release the microcapsules into the aqueous phase. The oil (bottom) phase was removed, and the microcapsules were washed twice in wash buffer. Washing was performed by centrifuging the microcapsules at 1000 g for 1 minute and removing the supernatant. Cell lysis was performed by incubating the microcapsules in 50 U / μl lysozyme (Lucigen, R1804M), 0.2 mg / ml proteinase K, 0.1% Triton X-100, 1 mM EDTA, 10 mM Tris-HCl (pH 7.5) for 30 minutes at 37° C., then 30 minutes at 50° C. After lysis, the microcapsules were washed five times in wash buffer.

[0184] Six PCR reactions containing different sets of primers were prepared. Each reaction consisted of 20 μl of filled microcapsules (i.e., most of the supernatant was removed), 2.5 μl of nuclease-free water, 2.5 μl of primers (10 μM each), and 25 μl of 2x PCR Master Mix (Thermo Scientific, K9021). One universal reverse primer targeting the OmpA gene and six different forward primers were used to obtain amplicons of various sizes ranging from 100 to 1000 bp. The sequences are provided in Table 5.

[0185] [Table 5] The PCR temperature program was 95°C for 3 minutes; (95°C for 30 seconds, 52°C for 30 seconds, 72°C for 1 minute) x 30; 72°C for 5 minutes; +4°C hold. After PCR, 5 μl of 50 μM SYTO9 dye was added to 50 μl of PCR mix. The microcapsules were then washed five times with wash buffer and imaged using a fluorescent microscope.

[0186] Example 4 Shell polymer characterization This example describes the characterization of newly synthesized shell polymers (as described in Example 1), including microcapsule formation assays (see, e.g., Example 2), dextranase release tests, and PCR amplicon retention tests (see, e.g., Example 3). Microcapsule formation is the first prerequisite for a given core and shell polymer pair. Controllable shell polymer collapse allows for the release of microcapsule contents as needed, and in the case of dextran-based polymers, can be achieved by dextranase or other backbone polysaccharide-specific enzyme treatment. In the case of dextran-based shells, substitution of more than 20% with methacryloyl moieties was observed to prevent dextranase digestion (Table 6). However, as exemplified by the polymer DexMAB-25-75 (see abbreviations described below), pretreatment of the capsules with alkaline conditions subsequently renders them susceptible to dextranase digestion (Table 6). A likely explanation is alkaline hydrolysis of the ester bond, where the modifying moiety is attached to the polysaccharide backbone (Figure 3), making the backbone more accessible to enzymatic hydrolysis. Importantly, alkaline treatment alone did not change the appearance of the SPC under bright-field microscopy or reduce the volume of the SPC in the tube. While on-demand release of microcapsule contents under mild enzymatic conditions is desirable, shell polymers that do not meet this criterion are still useful, for example, for digital microcapsule analysis. For shells based on different polymers, dextranase can be used to digest the unmodified dextran used as the core polymer. The resulting glucose monomers and oligomers can be washed away from the microcapsules, which may be desirable in certain applications. Microcapsules based on Ficoll shells undergo a 15% reduction in diameter after dextranase treatment to digest the core (Figures 16 and 17).

[0187] Table 6 provides a summary of the results characterizing the degree of substitution of several dextran (Dex), hydroxyethylcellulose (HEC), ficoll (Fic), and arabinoxylan (Axyl) with methacryloyl (MA), acryloyl (A), butyryl (B), acetyl (C2), and biotin (Bio), or combinations thereof. The polymer name (column 1) encodes the target degree of substitution during the reaction setup. The level of substitution is defined as the molar ratio of the modified moiety to glucose units. For example, DexMAB-10-90 means that during the reaction setup, the concentrations of GMA and GB were such as to achieve a ratio of 0.1 (or 10%) of methacryloyl:glucose units and a ratio of 0.9 (or 90%) of butyryl:glucose units. Column 2 provides the actual degree of substitution as determined by NMR (column 2). Columns 3 and 4 provide non-limiting examples of shell and core polymer concentrations that enable robust microcapsule formation. In the case of the DexMA-20 polymer, aqueous phase separation could not be achieved using 10% w / w core polymer and 10% w / w shell polymer, resulting in beads rather than microcapsule formation. Column 5 summarizes whether cross-linked shell polymers can be hydrolyzed using relatively mild enzymatic conditions, including a 5-minute enzymatic treatment at room temperature. Dextranase, an invertase for Ficoll-based shells, was used for Dex-based shells. FicMAB-10-90 was resistant to invertase treatment. For shell compositions resistant to mild hydrolysis, column 6 provides alternative, more harsh dextranase digestion conditions that, when determined, were confirmed to degrade the cross-linked shell polymer gel. Column 7 provides the minimum size of robustly retained PCR amplicons for each shell polymer.

[0188] [Table 6-1] [Table 6-2]

[0189] Figures 16 and 17 illustrate Ficoll shell-based microcapsules in 1x PBS before and after dextranase treatment, respectively. Microcapsule formation was tested by encapsulating shell (modified dextran) and core (dextran) polymers using a microfluidic chip with a 40 μm high and 40 μm wide nozzle. Polymer concentrations could be varied anywhere from 1 to 15% w / w, with a typical working range of 5 to 10% w / w. Achieving the lowest working concentration is desirable to reduce viscosity and maximize flow rate and emulsion generation rate. Upon shell polymerization by exposure to 405 nm light (Droplet Genomics, catalog number DG-BRD-405), microcapsules were washed and microscopic images were taken. Successfully formed microcapsules were characterized by a discernible shell (Figure 2E).

[0190] Dextranase release was tested at room temperature by mixing 8 μl of loaded microcapsules in 1×PBS with 2 μl of dextranase (Sigma-Aldrich, catalog no. D0443-50ML) diluted 100-fold with 1×PBS. For soluble dextran-based shell polymers with less than 20% methacryloyl substitution, microcapsule disintegration occurred in less than 5 minutes. For Ficoll-based compositions, 20 μL of loaded microcapsules were subjected to 40 μL of invertase (Sigma-Aldrich, catalog no. i4504, 100 mg / mL, approximately 450 U / mg enzyme activity) in 3 M acetate buffer (pH 5.2) at 37° C. for 3 hours or at 45° C. overnight. Neither of these conditions resulted in microcapsule degradation.

[0191] PCR amplicon retention was tested as detailed in Example 3. It was also shown that four bacterial strains and two mammalian cell lines could grow in core-shell microcapsules (e.g., in DexMAB250 or DexMAB1090). It was also confirmed that dextranase treatment did not affect cell viability. As a specific example, single mammalian cell-derived colonies were expanded in microcapsules, microcapsules encapsulating individual cells were placed into separate wells by serial dilution, the microcapsules in the wells were degraded with dextranase, and microcolonies derived from the wells were further expanded in full-scale cell cultures.

[0192] Example 5 Degradable microcapsules for high molecular weight (HMW) DNA isolation This example describes a method for using microcapsules to process high molecular weight (HMW) DNA. a) Selective permeability of the microcapsule shell, which retains HMW DNA but allows buffer exchange and diffusion of enzymes and lysate components; b) enzymatic degradability of the shell under mild conditions that prevent DNA hydrolysis or denaturation; c) Processing of the core-shell microcapsule suspension as a typical aqueous solution using standard liquid handling equipment such as pipettes, reaction tubes, and multi-well plates; and d) HMW DNA entrapped within the microcapsules is protected by the microcapsule shell from mechanical shearing during pipetting; Use.

[0193] Eukaryotic or prokaryotic cells are encapsulated in microcapsules. Lysis is performed to release HMW DNA from the cells, and lysate components are washed away by buffer exchange. The HMW DNA contained in the microcapsules is then subjected to further processing, which may include restriction endonuclease digestion, fragmentation, DNA end repair, A-tailing, adapter ligation, and / or probe annealing, depending on the readout technology used. Examples of such techniques include long-read sequencing (LRS; e.g., Oxford Nanopore), optical mapping, and restriction pattern analysis by pulsed-field gel electrophoresis. Only after loading the processed DNA onto an instrument (e.g., a sequencing flow cell, an optical mapping chip, or a pulsed-field gel electrophoresis (PFGE) gel) is it released from the microcapsules by enzymatic hydrolysis of the shell. Such a workflow facilitates handling of unstable and viscous HMW DNA solutions, avoids time-consuming DNA precipitation and rehydration steps, and is amenable to automation.

[0194] Figure 18 illustrates a specific workflow for the isolation and processing of HMW DNA within microcapsules for readout techniques of long DNA molecules. Cells are compartmentalized within the microcapsules (1), such that most microcapsules contain at least one cell. The cells are lysed to release the DNA (2), and washes are performed to remove lysate components. The HMW DNA is then processed using a readout method-specific protocol (3). Examples include library preparation for long-read sequencing, DNA labeling for optical mapping, and restriction digestion for fragment analysis. The processed DNA, ready for analysis, is loaded onto the readout instrument while still within the microcapsules (4), only after which it is released by enzymatic hydrolysis of the shell.

[0195] In certain implementations, E. coli cells are encapsulated in microcapsules to achieve an average of five or more cells per microcapsule. Water-in-oil droplet formation, shell polymerization, and microcapsule release into the aqueous phase procedures are performed as described in the previous examples. E. coli cells are lysed using a ready-to-use lysis reagent from a commercial supplier (e.g., ThermoFisher Scientific, catalog number K0721) or an in-house method that may include SDS, proteinase K, lysozyme, and / or RNAse A treatment and elevated temperature. In one method, lysis is performed by incubating microcapsules containing bacteria in 10 mM Tris-HCl 7.5, 0.1% v / v Triton X-100, 1 mM EDTA, 50 U / μl lysozyme, and 100 μg / ml RNAse A at 37°C for 30 minutes, followed by the addition of 200 μg / ml proteinase K and 1% (w / v) SDS and incubation at 50°C for 30 minutes. After lysis, perform 5-10 washes in wash buffer (10 mM Tris-HCl (pH 7.5), 0.1% Triton X-100). During the washes, collect the microcapsules at the bottom of the tube by centrifugation (e.g., 1000 g for 1 min). Further processing depends on the choice of readout technique.

[0196] For use with Oxford Nanopore sequencing, an example of LRS, the HMW DNA within the microcapsules can be further processed using sequencing library preparation reagents recommended by the manufacturer (e.g., Ligation Sequencing Kit, Oxford Nanopore, catalog number SQK-LSK109), and as addressed later in this specification (e.g., Example 6), the purification step can be replaced with buffer exchange of the microcapsule suspension using magnetic beads. Prior to library preparation, fragmentation of the genomic DNA into smaller fragments, on the order of 100 kilobases, can be performed. After library preparation, the microcapsules are loaded directly onto a Flongle or MinION flow cell, followed by the addition of a glycosidase specific for the shell polymer used to release the DNA from the microcapsules (e.g., dextranase for modified dextran shell polymers).

[0197] For optical DNA mapping, which can be performed using the Bionano Genomics Saphyr instrument, for example, the HMW DNA contained in the microcapsules is labeled using a reagent kit recommended by the manufacturer (e.g., Bionano Prep Direct Label and Stain (DLS) Protocol, Bionano Genomics, catalog number 80005), replacing the membrane-based purification step with microcapsule washing. The labeled DNA is released from the microcapsules by glycosidase treatment after loading the microcapsules onto the Saphyr chip flow cell.

[0198] For restriction fragment analysis using pulsed-field gel electrophoresis (PFGE), the HMW DNA contained in the microcapsules is digested using a restriction enzyme that produces a characteristic restriction profile, such as NotI. After the microcapsules are loaded into the wells of an agarose gel, a glycosidase enzyme is added to the same well. Both the microcapsule suspension and the enzyme solution are premixed with glycerol to facilitate loading into the wells. PFGE is performed using standard parameters used for bacterial typing.

[0199] Example 6 Single-cell B-cell receptor (BCR) nucleic acid sequencing using microcapsules This example describes the application of nucleic acid ligation within microcapsules to recover nucleic acids encoding natural pairs of B cell receptor (BCR) heavy and light chains. Figure 20 details a method that begins with the compartmentalization of antibody-producing cells in microcapsules, with most microcapsules containing one or zero cells. The cells are then lysed, and BCR gene transcripts are enriched using reverse transcription and targeted PCR. The use of microcapsules allows for buffer exchange between individual steps, enabling optimal reaction conditions. The resulting amplicons of heavy and light chain cDNA are then ligated into long DNA molecules, for example, using ligation or Gibson assembly. From that step, concatemers from multiple microcapsules can be fused by enzymatic hydrolysis of the shells and further retrieved by sequencing library preparation and sequencing. Because this method requires a read length greater than 1000 bp and can benefit from a read length greater than 10,000 bp, long-read sequencing technologies are commonly used (e.g., Oxford Nanopore, PacBio).

[0200] The central steps of this method are the physical binding of target molecules within a given microcapsule into concatemers and obtaining sequencing reads that span at least some of the concatemer units. There are several different approaches for performing the steps between encapsulation in microcapsules and ligation. There are also several different approaches for performing steps after concatemer formation. For example, release of concatemers from microcapsules can be performed immediately after ligation (as illustrated in Figure 20), after sequencing library preparation, or after loading the microcapsules into a sequencing component (e.g., a Nanopore flow cell cartridge).

[0201] Figure 20 illustrates a general method for sequencing BCR heavy and light chain pairs, enabled by microcapsules and long-read sequencing. Antibody-producing cells are compartmentalized in microcapsules (#1) and then lysed (#2), retaining the nucleic acids within the microcapsules. Next, reverse transcription (RT) of the entire polyadenylated transcriptome is performed (#3). Alternatively, gene-specific primers can be used in the RT step. Heavy and light chain cDNAs are enriched in two rounds of semi-nested PCR (#4). The resulting amplicons within the microcapsules are then linked by ligation or Gibson assembly. Buffer exchange is performed between each step performed within the microcapsules (#2–#6). Concatemers from individual microcapsules are pooled by enzymatic hydrolysis of the microcapsule shell, and further library preparation is performed using protocols specific to the long-read sequencing technology being used (#7). Notably, all or part of the sequencing library preparation, including sequencing technology adapter ligation, can still be performed using DNA within the SPC. In this scenario, the purification step, typically using magnetic beads or columns, is replaced with the SPC wash. The information within a given sequencing read originates from the same microcapsule, and therefore the same cell. Heavy and light chain sequences present in the same read represent natural pairs.

[0202] Figure 21 outlines a specific experiment involving the mixing of two mouse hybridoma cell lines. To avoid duplication of different cell lines caused by random cell encapsulation into SPCs during formation, 9e10 (ATCC® CRL-1729) and TNF-alpha (Sigma Aldrich 92030603) cells were encapsulated separately into SPCs. The resulting SPCs were then mixed in equal ratios before further processing. Using such a strategy, trans-cell line heavy and light chain pairing can only be explained by nucleic acid diffusion between SPCs. All further steps were performed as single-tube reactions. Cells were lysed, and heavy and light chain amplicons were enriched by gene-specific RT along with template switching and two PCR reactions. Proteinase K treatment was performed to remove DNA polymerase molecules that remained bound to the amplicon ends, preventing efficient USER (uracil-specific excision reagent) for the creation of sticky ends for efficient subsequent amplicon joining by ligation. As detailed in Figure 22, the sticky DNA ends resulting from digestion only allow the formation of circular ligation products when both heavy and light chain fragments are present in the concatemer. Linear ligation products were removed by exonuclease treatment, and the circular ligation products were amplified by multiple displacement amplification (MDA). The amplification step is crucial for generating sufficient material for Nanopore sequencing. Debranching was then performed using T7 endonuclease, and the resulting linear fragments were retrieved by the Nanopore library while still in SPC. Material from SPC was released by dextranase treatment before loading onto the Nanopore flow cell.

[0203] Figure 22 depicts the ligation of heavy and light chain amplicons for single-cell BCR sequencing and long-read sequencing using SPC. After gene-specific RT and two rounds of enrichment PCR, amplicons with uracil bases at the 5' end are generated. A uracil-specific excision reagent (USER) is used to generate a single nucleotide gap at the position of the uracil residue, followed by dissociation of the resulting 5-mer, creating a 6-base 3' overhang for sticky-end ligation. Due to the sticky-end design, the formation of a concatemer containing both heavy and light chain amplicons is a prerequisite for circular product formation. The linear ligation product is removed by exonuclease treatment, while the circular product serves as a template for subsequent MDA. Further details of the experimental procedures used in the workflow are presented in Figures 20, 21 and 22.

[0204] Encapsulation. Cells from 9E10 mice (ATCC® CRL-1729) secreting anti-cMyc antibodies and M357-101-4 mice (Sigma Aldrich 92030603) secreting anti-TNF-α antibodies were separately seeded into 25 cm culture flasks with 5 mL of complete medium (45 mL of RPMI-1640 (Gibco, 21875034), 5 mL of 100% FBS (Gibco, 15250061), 0.5 mL of 100× GlutaMax (Thermo Scientific, 35050038), and 0.5 mL of 10,000 U / mL penicillin-streptomycin (Gibco, 15140148)) and incubated at 37°C for 3 days. The culture medium was discarded, and the cells were washed with 5 mL of 1× PBS (Invitrogen, AM9625). The cells were then incubated with 1 mL of 1x TrypLE (Thermo Scientific, 12563011) at 37°C for 3 minutes for detachment. When 90% or more of the cells had detached, 5 mL of fresh complete medium was added, and the cells were transferred to a 15 mL conical tube and centrifuged at 300 x g for 5 minutes. The supernatant was discarded, and the cells were washed with 10 mL of 1x PBS supplemented with 0.1% Pluronic F-68 (Gibco, 24040032) and centrifuged at 300 x g for 5 minutes. The cell pellet was then resuspended in 200 μL of 1x PBS. The total number and percent viability of cells were determined using an Invitrogen Countess Automated Cell Counter. Shell solution was prepared by mixing 100 μL of 20% w / w DexMAB1090 with 100 μL of nuclease-free water. The core solution was prepared by mixing 100 μL of 20% w / w dextran 500k, 25 μL of 4% LAP (Merck, 900889), 20 μL of 100 mM DTT (Sigma-Aldrich, 43816), 2 μL of 10% Pluronic F-68, and 53 μL of cells diluted in 1x PBS. The cell concentration aimed for an occupancy ratio of 0.1 in the SPC. 9E10 and TNFα were encapsulated separately.Approximately 200 μL of the working solution was added to two different 1 mL syringes backfilled with approximately 300 μL of HFE-7500 (3M, Novec 7500), and 1 mL of 0.25% DSO (Droplet Genomics, DG-DSO-20) was added to another 1 mL syringe. SPC was generated in a CF-60 microfluidic device (Droplet Genomics) at flow rates of 100 μL / h, 100 μL / h, and 700 μL / h for the shell, core, and DSO, respectively. The shell was polymerized by placing the collected emulsion tube in a 405 nm LED device (Droplet Genomics) and exposing the emulsion to light for 30 seconds. After removing excess oil, the emulsion was broken using 20% ​​PFO (Fluorochem, 007128) in HFE7500. Cell lysis. SPC were washed three times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Pluronic F-68 (Gibco, 24040032)). The washed SPC containing 9E10 and TNFα were pooled together to obtain approximately 200 μL of SPC. SPC were then suspended in 1 mL of lysis buffer (Fisher Scientific, K0731) supplemented with 80 μL of 1 M DTT (Sigma-Aldrich, 43816-10ML), incubated at room temperature for 1 minute, and centrifuged at 1000 × g for 1 minute. This step was repeated twice. The SPCs were then washed five times with 1 mL of washing buffer containing proteinase K (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 1 mM EDTA (Invitrogen, 15575-038), 0.1% Triton x-100 (Sigma-Aldrich, T8787-100ML), and proteinase K (Thermo Scientific, K0731)) and incubated at room temperature for 1 minute, with the first incubation held for 10 minutes. To remove the proteinase K, the SPCs were then washed ten times with 1 mL of washing buffer containing EDTA (10 mM Tris-HCl pH 7.5, 0.1% Triton x-100, 1 mM EDTA). The SPCs were then washed three times with 0.5 mL of wash buffer containing RiboLock (10 mM Tris-HCl pH 7.5, 0.1% Triton x-100, 0.5 U / μL RiboLock (Fisher Scientific, EO0382)). 200 μL of the washed SPCs were then mixed with 429 μL of wash buffer containing RiboLock, 70 μL of 10×DNase I reaction buffer (Fisher Scientific, EN0521), and 1 μL of DNase I (Fisher Scientific, EN0521) and incubated at 37°C for 30 minutes. After incubation, 1 μL of 0.5 M EDTA was added per 100 μL of sample, and the mixture was incubated at 65°C for 10 minutes to inactivate the DNase I. The SPCs were then washed three times with 0.5 mL of wash buffer containing RiboLock.

[0205] Reverse transcription. Reverse transcription was performed by mixing 200 μL of SPC with 30 μL of nuclease-free water, 80 μL of 5× RT buffer (Fisher Scientific, EP0753), 20 μL of 10 mM dNTPs (Fisher Scientific, R0192), 20 μL of 20× RT_GS primer mix (primer sequences from Table 7, standard desalting, IDT, Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 (10× Genomics)), 20 μL of 20 μM RT_TSO (5′AAGCAGTGGTATCAACGCAGAGTACATrGrGrG, HPLC, IDT), 10 μL of 40 U / μL RiboLock (Fisher Scientific, EO0382), and 20 μL of 200 U / μL RT Maxima H Minus (Fisher Scientific, EP0753). The samples were mixed by vortexing, then placed in a thermal cycler and incubated at 50°C for 45 minutes, followed by inactivation at 85°C for 5 minutes. The SPCs were then washed three times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)). Table 7: 20x RT_GS Primer Mix. Primer sequences and molar ratios are those used for mouse BCR enrichment PCR1 as described in the Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 (10x Genomics).

[0206] [Table 7] Primer sequences and molar ratios are those used for mouse BCR enrichment PCR1 as described in the Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 (10x Genomics).

[0207] BCR enrichment PCR I and II. BCR enrichment PCR I was performed by mixing 190 μL of SPC with 26 μL of nuclease-free water, 24 μL of 20× BCR M1 primer mix (Table 8A, standard desalting, IDT; primer sequences are obtained from Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 (10x Genomics)), and 240 μL of 2× Q5 High-Fidelity Master Mix (NEB, M0492S). The sample was mixed by vortexing and then placed in a thermal cycler with the following parameters: 98°C for 45 seconds, 13 cycles of 98°C for 20 seconds, 67°C for 15 seconds, and 72°C for 15 seconds, with a final extension of 72°C for 1 minute. The SPC was then washed three times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)). BCR enrichment PCR II was performed by mixing 110 μL of SPC with 2.5 μL of nuclease-free water, 12.5 μL of 20× BCR_M2_U primer mix (Table 8A, standard desalting, IDT), and 125 μL of 2× KAPA HiFi HotStart Uracil+ReadyMix (Roche, 07959052001). The sample was mixed by vortexing and placed in a thermal cycler using the same parameters as BCR enrichment PCR I. The SPCs were then washed three times with washing buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)).

[0208] [Table 8] The primer sequences were modified from those used for mouse BCR enrichment PCR2 as described in the Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 (10x Genomics). The modification involves the addition of sequences for cohesive end ligation at the 5' end.

[0209] [Table 9] Electropherograms were used to confirm the identity and purity of the enriched BCR products amplified from 9E10 and TNFα. BCR light chain: approximately 550 bp. Heavy chain: approximately 600-670 bp. SPC samples were obtained after BCR enrichment PCR II, treated with dextranase to release the amplicons, and AMPure XP purified (0.8x) before loading onto an Agilent Bioanalyzer HS DNA chip.

[0210] Proteinase K treatment. After the PCR reaction, a 140 μL aliquot of SPC was taken and mixed with 3 μL of proteinase K (Thermo Scientific, EO0491) and 57 μL of nuclease-free water. The sample was mixed by vortexing and then placed in a thermal cycler. The mixture was incubated at 37°C for 30 minutes, followed by inactivation of the enzyme at 68°C for 10 minutes. The SPC was then washed five times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)). USER Enzyme Treatment. USER Reagent treatment was performed by mixing 100 μL of SPC with 79 μL of nuclease-free water, 20 μL of 10× rCutSmart Buffer (NEB, M5505L), and 1 μL of USER Reagent (NEB, M5505L). The sample was mixed by vortexing, then placed in a thermal cycler and incubated at 37°C for 15 minutes. The SPC was then washed five times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)).

[0211] Ligation. Ligation was performed by mixing 100 μL of SPC with 76 μL of nuclease-free water, 20 μL of 10× T4 DNA ligase buffer (Thermo Scientific, EL0012), and 4 μL of T4 DNA ligase 5 U / μL (Thermo Scientific, EL0012). The sample was mixed by vortexing and then placed in a thermal cycler and incubated at 22°C for 1 hour, followed by enzyme inactivation at 70°C for 5 minutes. The SPC was then washed three times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)).

[0212] Electropherograms were used to confirm the formation of ligated BCR heavy and light chain products. Exonuclease treatment. Exonuclease treatment was performed by mixing 80 μL of SPC with 88 μL of nuclease-free water, 20 μL of 10× NEB T7 Buffer 2 (NEB), 4 μL of Exonuclease I (Fisher Scientific, EN0582), 4 μL of Exonuclease III (Fisher Scientific, EN0191), and 4 μL of Lambda Exonuclease (Fisher Scientific, EN0562). The sample was mixed by vortexing and then placed in a thermal cycler and incubated at 22°C for 1 hour, followed by enzyme inactivation at 70°C for 5 minutes. The SPCs were then washed three times with washing buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)).

[0213] MDA was performed by mixing 40 μL of SPC with 26 μL of nuclease-free water, 10 μL of 10x EquiPhi29 buffer (Thermo Scientific, B39), 10 μL of dNTP mix (Thermo Scientific, R0192), 1 μL of 0.1 M DTT solution, 1 μL of 10% Triton X-100, 5 μL of Exo-Resistant Random Primer Mix (Thermo Scientific, SO181), 5 μL of 10 U / μL EquiPhi29 DNA polymerase (Thermo Scientific, A39391), and 2 μL of 0.1 U / μL pyrophosphatase (Thermo Scientific, EF0221). The sample was mixed by pipetting and then placed in a thermal cycler. The mixture was incubated at 45°C for 1 hour, followed by 65°C for 10 minutes to inactivate the enzyme. Fluorescence microscopy images of SPCs after MDA (Figure 23) showed the presence of DNA in some, but not all, SPCs, as expected. In Figure 23, BCR heavy and light chain concatemers amplified by MDA are seen within the SPCs. DNA was stained with SYTO9 green fluorescent nucleic acid stain and imaged using a fluorescence microscope equipped with a FITC filter (excitation 480 / 30, emission 535 / 40).

[0214] T7E1 debranching. The T7E1 debranching reaction was performed by mixing 20 μL of SPC with 14 μL of nuclease-free water, 4 μL of 10× NEBuffer 2 (NEB, B7002S), and 2 μL of 10 U / μL T7 endonuclease I (NEB, M0302L) and vortexing. The sample was then placed in a thermal cycler and incubated at 37°C for 2 hours. The sample was washed three times with wash buffer (10 mM Tris-HCl pH 7.5 (Invitrogen, 15575027), 0.1% Triton X-100 (Sigma-Aldrich, T8787)).

[0215] Library preparation and sequencing for Nanopore sequencing. Ready-to-sequence libraries were constructed based on the Ligation Sequencing Amplicon V14 protocol and using the Ligation Sequencing Kit V14 (Oxford Nanopore Technologies (ONT), SQK-LSK114) on 20 μL of SPC as input. After Nanopore adapter ligation, the SPC was dissolved by adding 1 μL of dextranase (Sigma-Aldrich, D0443) and nuclease-free water to achieve a total volume of 100 μL. AMPure purification (beads included in the SQK-LSK114 kit) was performed at a 0.5x ratio. 17 fmol of the prepared library was sequenced on an R10.4.1 flow cell, MinION (ONT). The conditions were 260 bps for accuracy selection. Reads were base-called using Guppy 6.3.8 in 260 bps SUP mode. After initial cleavage of the concatenated reads at the PCR primer sites, the resulting inserts were filtered by size >400 bp and mapped using Minimap2 with default parameters for ONT sequencing and the options --secondary=none--sam-hit only, discarding unmapped reads and secondary alignments.

[0216] Table 9 below summarizes the results of the experiment. Of all base-called reads, 3.6% of the reads mapped to the reference containing the expected TNF-alpha and 9e10 hybridoma cell line heavy and light chain sequences. Many reads (68%) were not mapped, and others did not pass length and quality filtering. Although a higher fraction of mapped reads would be desirable for practical application of the workflow, the 10,962 mapped reads showed a low level of mixed cell line concatemers (6.3%), with HL concatemers corresponding to natural pairs for TNF-alpha and 9e10 cells being 52.7% and 41%, respectively.

[0217] [Table 10]

[0218] Example 7 UMI-assisted demultiplexing of concatemers This example describes a variation of the ligation method in which all targets of interest derived from a single cell do not need to be part of the same concatemer to be successfully demultiplexed by the original cell. Here, targets derived from a single cell are tagged with a unique set of UMIs (one UMI per target). The UMIs are random sequences sampled from a pool of poly-N oligos, and the method is illustrated in Figures 24 and 25. Given a large enough pool of poly-N oligos (e.g., 100 * m * n (where m is the number of cells tested and n is the number of targets), each sample of UMI is essentially unique and constitutes a cellular "barcode." The UMI-tagged targets are then amplified (e.g., by PCR) and then linked. Concatameric reads originating from the same cell share one or more UMIs, but all information derived from a given read originates from the same cell. This demultiplexing approach is based on the "1 UMI set = 1 read" principle.

[0219] Figure 24 illustrates the "1 UMI set = 1 cell" principle. The steps shown here correspond to steps 4-5 in Figure 25. Nucleic acids (NAs) within individual microcapsules are tagged with unique molecular identifiers (UMIs), for example, by ligation or Gibson assembly. The UMI-tagged NAs are amplified and ligated within the microcapsules. The UMI-containing concatemers are then pooled into bulk solution, prepared for sequencing, and sequenced using standard protocols for long-read sequencing platforms. The resulting reads are demultiplexed by the shared UMI information within the long reads.

[0220] Figure 25 illustrates an example of a possible method for testing a given genomic target panel in a single cell using UMI tagging and ligation in microcapsules. For example, a cancer panel of 10 to 100 amplicons can be used. Cells of interest are first encapsulated in microcapsules so that the majority of cell-containing microcapsules contain a single cell. The cells are lysed, and PCR amplification is performed to enrich for target sequences in a multiplex PCR. The resulting amplicons are UMI-tagged using Gibson assembly, followed by further amplification and ligation. From there, material from all microcapsules is pooled by enzymatic shell hydrolysis, and further library preparation and long-range sequencing (e.g., Oxford Nanopore) are performed using standard protocols. Figure 26 further details one possible concatemer assembly strategy at the level of DNA sequence elements.

[0221] Figure 25 illustrates a workflow for multiplex PCR amplicon sequencing in single cells using target ligation within microcapsules. Cells or other nucleic acid (NA)-containing particles are encapsulated in microcapsules (#1) and then lysed (#2), retaining the nucleic acid within the microcapsules. Next, a limited number of PCR cycles (<10) are performed to amplify the target DNA sequence of interest (#3). The amplicons are UMI-tagged (#4) and further amplified (#5). The resulting UMI-tagged amplicons within the microcapsules are then joined by ligation or Gibson assembly (#6). Buffer exchange is performed between each step performed within the microcapsules (#2-#6). Concatemers from individual microcapsules are pooled by enzymatic hydrolysis of the microcapsule shell (#7), and further library preparation is performed using the recommended protocol for the long-read sequencing technology used (#8). Concatemer reads that share one or more UMIs are derived from the same cell. Figure 26 provides a schematic diagram of a specific workflow for target amplification, UMI tagging, and ligation. Multiple target...

Claims

1. 1. A composition comprising a plurality of microcapsules, each of which comprises a core surrounded by a shell, the shell is a hydrogel comprising a first polymer; the first polymer comprises a polysaccharide modified with conjugated cross-linking moieties and optionally modified with conjugated hydrophilic / hydrophobic modifying moieties; the molecules of the cross-linking portion of the first polymer are cross-linked in the hydrogel; A composition wherein the core comprises a second polymer comprising a polysaccharide that does not include the crosslinked portions of the first polymer and does not include hydrophilic / hydrophobic modifying portions.

2. The composition of claim 1 , wherein the first polymer is the majority of the shell and the second polymer is the majority of the core.

3. The composition of claim 1 or 2, wherein the first polymer and the second polymer comprise different polysaccharides.

4. The composition of claim 1 or 2, wherein the first polymer and the second polymer comprise the same polysaccharide.

5. The composition according to any one of claims 1 to 4, wherein the polysaccharide of the first polymer or the first polymer and the second polymer is a non-ionic polysaccharide with a neutral charge.

6. The composition of claim 5 , wherein the polysaccharide comprises monomers linked by glycosidic bonds.

7. The composition of claim 6 , wherein the polysaccharide is a glucan.

8. 8. The composition of claim 6 or 7, wherein the polysaccharide comprises pentose and / or hexose monomers.

9. 8. The composition of claim 6 or 7, wherein the polysaccharide comprises glucose and / or fructose monomers.

10. The composition according to any one of claims 5 to 9, wherein the polysaccharide is selected from dextran and cellulose.

11. The composition of any one of claims 5 to 9, wherein the polysaccharide is not naturally occurring.

12. The composition according to any one of claims 5 to 11, wherein the polysaccharide has a molecular mass of from about 5,000 g / mol to about 50,000,000 g / mol.

13. The composition of claim 12, wherein the polysaccharide has a molecular mass of from about 50,000 g / mol to about 2,000,000 g / mol.

14. The composition of claim 13, wherein the polysaccharide has a molecular mass of about 500,000 g / mol.

15. The composition of any one of claims 1 to 14, wherein the first polymer comprises one type of cross-linking moiety.

16. The composition of claim 15 , wherein the first polymer comprises two or more types of crosslinking moieties.

17. The composition of any one of claims 1 to 16, wherein the one or more cross-linking moieties are selected from photoactivated, chemically activated, or thermally activated cross-linking moieties.

18. The composition of any one of claims 1 to 17, wherein the one or more crosslinking moieties are independently selected from an acryloyl group or a substituted acryloyl group.

19. 20. The composition of claim 18, wherein the one or more crosslinking moieties are independently selected from acryloyl, or methacryloyl, or acryloyl and methacryloyl.

20. The composition of any one of claims 1 to 19, wherein the second polymer does not include a crosslinking moiety.

21. The composition of any one of claims 1 to 20, wherein the second polymer is not crosslinked.

22. The composition of any one of claims 1 to 21, wherein the first polymer comprises hydrophilic / hydrophobic modifying moieties.

23. 23. The composition of claim 22, wherein the hydrophilic / hydrophobic modifying moiety modifies the water solubility of the first polymer.

24. 24. The composition of claim 22 or 23, wherein the first polymer comprises one type of hydrophilic / hydrophobic modifying moiety.

25. 25. The composition of claim 24, wherein the first polymer comprises two or more types of hydrophilic / hydrophobic modifying moieties.

26. The composition of any one of claims 22 to 25, wherein the hydrophilic / hydrophobic modifying moiety comprises a fatty acyl group.

27. 27. The composition of claim 26, wherein the fatty acid is a C2-C8 fatty acid.

28. 28. The composition of claim 27, wherein the hydrophilic / hydrophobic modifying moiety comprises a butyryl group.

29. The composition of any one of claims 1 to 28, wherein the second polymer does not include a hydrophilic / hydrophobic modifying moiety that modifies the first polymer.

30. 21. The composition of any one of claims 1 to 20, wherein the cross-linking moiety, or the hydrophilic / hydrophobic modifying moiety, or the cross-linking moiety and the hydrophilic / hydrophobic modifying moiety, are covalently attached to the polymer backbone of the first polymer.

31. 31. The composition of any one of claims 1 to 30, wherein the backbone of the first polymer comprises a monomer, and the molar ratio of (i) the cross-linking moiety to (ii) the monomer of the first polymer is from about 0.01 to about 2.

0.

32. 32. The composition of any one of claims 22 to 31, wherein the backbone of the first polymer comprises monomers, and the molar ratio of (i) the hydrophilic / hydrophobic modifying moieties to (ii) the monomers of the first polymer is from about 0.05 to about 1.

0.

33. the polysaccharide of the first polymer is modified with a cross-linking moiety and also modified with a hydrophilic / hydrophobic modifying moiety; The crosslinking moiety is methacryloyl, The composition of any one of claims 1 to 32, wherein the hydrophilic / hydrophobic modifying moiety is butyryl.

34. The composition of any one of claims 1 to 33, wherein the first polymer comprises a detectable label.

35. The composition of any one of claims 1 to 34, wherein the first polymer comprises a binding partner moiety to which a binding partner counterpart moiety can bind.

36. 36. The composition of claim 35, wherein the binding partner moiety is biotin and the binding partner counterpart moiety is avidin, or the binding partner counterpart moiety is biotin and the binding partner moiety is avidin.

37. The composition of any one of claims 33 to 36, wherein the detectable label and / or binding partner moiety is covalently attached to the backbone of the first polymer.

38. 38. The composition of any one of claims 1 to 37, wherein the microcapsules remain intact in the pH range of about 2 to about 12 at 37°C for 2 hours or more.

39. A composition according to any one of claims 1 to 38, wherein the microcapsules remain intact under polymerase chain reaction thermal cycling conditions.

40. The composition according to any one of claims 1 to 39, wherein the microcapsules are microspheroids.

41. 41. The composition of claim 40, wherein the microcapsules are defined by a diameter of from about 1 micrometer to about 10,000 micrometers.

42. 42. The composition of claim 41, having a diameter of about 10 micrometers to about 100 micrometers.

43. A composition according to any one of claims 40 to 42, wherein the diameter of the microcapsules varies with a coefficient of variation of about 30% or less.

44. 44. The composition of any one of claims 1 to 43, wherein the circularity of the microcapsules in the composition is from about 0.8 to about 1.

0.

45. 45. The composition of any one of claims 1 to 44, wherein the concentricity of the microcapsules in the composition is about 75% or greater.

46. 46. ​​The composition of any one of claims 1 to 45, wherein the shell of the microcapsule comprises pores of from about 0.1 nanometers to about 500 nanometers.

47. The composition of any one of claims 1 to 46, wherein the shell of the microcapsule comprises pores of from about 10 nanometers to about 50 nanometers.

48. 48. The composition of any one of claims 1 to 47, wherein the shell of the microcapsule comprises pores, and the microcapsule retains nucleic acids of about 100 base pairs or greater in size.

49. 49. The composition of any one of claims 1 to 48, wherein the shell of the microcapsule comprises pores and the microcapsule retains a nucleic acid of about 500 base pairs or greater in size.

50. 50. The composition of any one of claims 1 to 49, wherein the shell of the microcapsule comprises pores, and the microcapsule retains a nucleic acid of about 1,000 base pairs or greater in size.

51. 51. The composition of any one of claims 1 to 50, wherein the microcapsule or a portion thereof is glycosidase degradable at a pH of about 3 to about 11 and at a temperature of about 80°C or less.

52. 52. The composition of any one of claims 1 to 51, wherein the microcapsule or a portion thereof is glycosidase degradable at a pH of about 6 to about 8 and at a temperature of about 40°C or less.

53. 53. The composition of any one of claims 1 to 52, wherein the glycosidase is selected from dextranase and cellulase.

54. A composition according to any one of claims 1 to 53, provided that the microcapsules do not contain an intermediate layer between the shell and the core.

55. The composition of any one of claims 1 to 53, provided that there is no intermediate layer between the shell and the core, the intermediate layer containing a polymer different from the first polymer and the second polymer.

56. The composition of any one of claims 1 to 53, wherein the polymer of the microcapsules consists of a first polymer and a second polymer.

57. A composition according to any one of claims 1 to 53, wherein there is no layer on the outside of the shell of the microcapsule.

58. A composition according to any one of claims 1 to 53, wherein the microcapsules are lipid-free and organic solvent-free.

59. The composition of any one of claims 1 to 58, which is a liquid composition.

60. 60. The composition of claim 59 which is an aqueous liquid composition.

61. The composition of any one of claims 1 to 58, which is a solid composition.

62. 62. The composition of claim 61, wherein the solid comprises a hydrogel.

63. A composition according to any one of claims 1 to 62, comprising a biological entity encapsulated within the core of a microcapsule.

64. 64. The composition of claim 63, wherein the biological entity is selected from a eukaryotic cell, a prokaryotic cell, a unicellular organism, a multicellular organism, a microorganism, a bacterium, an archaea, a fungus, a plant, a virus, an organelle, a liposomal vector, an extracellular vesicle, a nucleic acid, a protein, an organic molecule, and a biomolecule.